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1. General introduction 
1.1. Introduction 
Both asthma and Chronic Obstructive Pulmonary Disease (COPD) can be regarded 
as chronic, progressive disorders of the airways (1-5), with a prevalence of 10-20 per 
1,000 in The Netherlands and other countries in Europe (6,7). Asthma can occur in 
all age groups, although it is particularly a disease of the young. The most common 
symptoms of asthma are wheezing, dyspnoea, chest tightness, cough, and sputum 
production. Characteristic is a history of recurrent exacerbations (or attacks) often 
provoked by exogenous factors such as allergens, irritants, exercise, and virus infec-
tions. Nocturnal and early morning asthma symptoms are particularly characteristic 
(3,8). Bronchial hyperresponsiveness to nonspecific stimuli like cigarette smoke, fog, 
perfume, exercise and cold air is present and is a hallmark of asthma. Asthma is no-
wadays regarded as an inflammatory disorder of the airways in which many cells 
play a role, including mast cells and eosinophils (8-10). Inflammation of the airway 
wall is related to bronchial hyperresponsiveness and to variability of airway obstruc-
tion. 
COPD characteristically affects middle-aged and older patients. Patients with 
COPD mostly have dyspnoea which is often accompanied by cough, wheezing, spu-
tum, and recurrent respiratory infections (3). COPD comprises three disorders: em-
physema, peripheral airway disease and chronic bronchitis. Any individual patient 
may have one or more or all of these conditions, but the dominant feature in COPD is 
the permanent limitation of expiratory airflow. Nonspecific bronchial hyperrespon-
siveness can be present but is less common than in asthma (11). Long-term use of ci-
garettes is one of the principal identified causes of COPD. However, the above disor-
ders do not occur solely in cigarette smokers, nor does the majority of cigarette smo-
kers develop clinically manifest COPD (3). 
In the Netherlands, Orie et al. developed a hypothesis about the origin and devel-
opment of 'chronic non-specific lung disease (CNSLD)', which later became known 
as the 'Dutch hypothesis' (12). They proposed that a common genetic host factor pre-
disposes to bronchial hyperresponsiveness and allergy which in connection with ex-
posure to smoke, allergens and other environmental irritants may induce chronic air-
way obstruction. Defined in this way, 'asthma', 'asthmatic bronchitis', 'chronic bron-
chitis' or 'COPD' may have a comparable pathogenetic mechanism although the em-
phasis may be on different factors (12,13). The various views were recently dis-
cussed (13,14). So far, it is a hypothesis under study which has neither been refuted, 
nor proven. The pathogenetic mechanisms have only partly been revealed today. In 
this thesis, patients with asthma have been discriminated from those with COPD on 
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the basis of the standards for diagnosis of the American Thoracic Society (3). 
'Chronic bronchitis', 'chronic airflow limitation' and 'COPD' are used as synonyms 
in this thesis. 
In the treatment of asthma and COPD, two main classes of drugs can be identi­
fied: bronchodilators (beta-adrenergic agonists, anticholinergics or theophyllines) 
and anti-inflammatory drugs (corticosteroids, sodium cromoglycate or nedocromil) 
(3,10). Bronchodilators are believed to act primarily by reversing or inhibiting the 
contraction of airway smooth muscle, although they may have additional properties 
(10). Corticosteroids are anti-inflammatory drugs, of which the exact mechanisms of 
action are not fully understood. They probably inhibit and decrease inflammation on 
various levels. They are (possibly) important in preventing migration, activation and 
release of all kinds of mediators of inflammatory cells (8,10). 
There are indications for a world-wide increase in morbidity and mortality due to 
asthma and COPD in the last two decades (15-17), although differences exist be­
tween countries (18). This increase may not be present in the Netherlands (19). It is 
possible that continuous (mono)therapy with bronchodilators is to some extent re­
lated to this world-wide increase in morbidity and mortality (20). Data to support this 
concept come from several retrospective studies (21-24) and from two prospective 
ones (25,26). Following some earlier case control studies from New Zealand, Spitzer 
et al. investigated the relationship between the use of all kinds of bronchopulmonary 
medications and the risk of death or near-death episodes in asthma (24). An in­
creased, even dose-related risk was found, not only for the betaa-agonist fenoterol but 
also for the other beta2-agonists and theophyllines. No increased risk was found for 
the anti-inflammatory agents sodium cromoglycate and inhaled corticosteroids. In a 
prospective study of 89 stable asthmatics. Sears et al. found a poorer control of as­
thma during regular use of fenoterol for six months than during therapy on demand 
(26). In the two-year randomized controlled study of our own group, the effects of 
bronchodilators on the course of asthma and COPD was assessed in 223 patients se­
lected from general practice (25,27). Two important aspects of the treatment of as­
thma and COPD with bronchodilators alone were found: a) a relatively large group 
of patients had an unexpectedly rapid progression of asthma or COPD (in terms of 
annual decline in lung function and frequency of exacerbations), and b) continuous 
bronchodilator treatment as monotherapy was accompanied by a more rapid annual 
decline in lung function than treatment on demand. 
The main questions of our follow-up study in this group (and of this thesis) there­
fore are: 
1 ) How can we identify patients who have a rapid progression of asthma or COPD? 
2) Does treatment with inhaled corticosteroids decelerate this rapid progression of 
asthma or COPD in these patients? 
To answer the second question, a group of 56 patients with a relatively rapid progres­
sion of their disease during bronchodilator therapy alone was selected for two-year 
additional treatment with an inhaled corticosteroid (beclomethasone dipropionate 400 
μg, two times daily). 
It is possible that in the past too much emphasis was put on bronchodilator therapy 
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(alone) rather than on anti-inflammatory therapy with inhaled corticosteroids, sodium 
cromoglycate and nedocromil (10). Three recent reports on the treatment of asthma 
have proposed anti-inflammatory treatment with inhaled corticosteroids as an import-
ant, first-line therapy of asthma (8,10,28). Although there is ample evidence for the 
short-term efficacy of inhaled steroids in asthma, hardly any data are available of the 
effects during one or more years. In patients with COPD, there is controversy about 
the treatment with corticosteroids (29). Several short-term studies of some weeks to 
some months reported beneficial effects of corticosteroids in COPD (30-32), whereas 
others observed no significant effects (29,33-34). Two retrospective, uncontrolled 
studies during several years suggested that corticosteroids might slow down the de-
cline in lung function in COPD patients with moderately severe and severe airway 
obstruction (35,36). A preliminary report of a two-year prospective controlled study 
in 58 male patients with chronic airflow obstruction suggested that inhaled bu-
desonide was able to reduce the annual decline in lung function in these patients (37). 
Long-term studies with inhaled corticosteroids during several years are urgently 
needed in both patients with asthma and COPD in order to establish the place of in-
haled corticosteroids in the treatment of these diseases (8,38). 
In the past few years, two other long-term trials with inhaled corticosteroids have 
been carried out in the Netherlands, one in children with asthma, the other in adults 
with obstructive airway disease. The main results suggest beneficial effects of in-
haled corticosteroids on lung function, bronchial hyperresponsiveness, symptoms 
and exacerbations (39,40). 
The questions of our follow-up study are very much related to the early diagnosis 
and early treatment of patients with asthma or COPD in general practice. Underdiag-
nosis and undertreatment of asthma and COPD have been reported several times in 
general practice (41-44). Most patients with asthma or COPD in the Netherlands and 
other countries are treated in general practice (45,46), which stresses the importance 
of the subject. In general, it is the difficult task of the general practitioner to identify 
the patients at risk, which in the case of asthma and COPD implies detecting patients 
with a large decline in ventilatory function. These patients run the risk of early dis-
ability or death from chronic airway obstruction (1,47). The question is if the general 
practitioner can trace these patients in an early stage of their disease with diagnostic 
parameters like respiratory symptoms, physical signs of the chest and peak-flow rate 
(Chapter 4). Perhaps supplementary instruments like a FEVi meter are necessary in 
order to make a better assessment of airway obstruction and monitoring of the dis-
ease process possible. It is not clear whether the electronic spirometers available no-
wadays are reliable enough for use in general practice (48). An assessment of the re-
liability of the integrating Microspiro HI-298 flow meter is described in Chapter 2. 
The reversibility of airway obstruction as assessed by the increase in lung function 
after the administration of a bronchodilator is an important predictor of the course 
and prognosis of patients with asthma and COPD ( 1 ). However, it is unclear how re-
versibility is best expressed: as absolute increase, as a percentage of the initial lung 
function value or predicted lung function value, etc. (49). In Chapter 3, we have in-
vestigated which way of expressing reversibility is most reproducible and least de-
pendent on the prebronchodilator lung function. Another question is whether patients 
11 
with bronchial hyperresponsiveness should be identified by the general practitioner 
or not. It has been suggested that bronchial hyperresponsiveness to nonspecific 
stimuli is an important risk factor for the annual decline in lung function (2,4,50,51). 
However, it is also possible that bronchial hyperresponsiveness is not a 'cause' but a 
'consequence' of the loss in lung function (50). In Chapter 5, we tested the hypo-
thesis that bronchial hyperresponsiveness is a 'cause' of airway obstruction in asthma 
but a 'consequence' of airway obstruction in COPD. 
Early detection of patients at risk is only useful when early intervention is possible 
and effective. Corticosteroids may be the most effective therapy of asthma and 
COPD currently available. However, relatively little is known about the long-term ef-
fects of these drugs during one or more years (8,38). Do inhaled corticosteroids pre-
vent the loss of lung function during several years (52)? Once an excessive loss in 
lung function has occurred, an important therapeutic question is whether inhaled cor-
ticosteroids are able to restore the loss in lung function. The capacity of inhaled corti-
costeroids to decelerate the deterioration of asthma and COPD during bronchodilator 
therapy alone has been described in Chapters 6 and 7. We also analysed which pa-
tients with asthma or COPD in particular benefit from long-term treatment with in-
haled corticosteroids. This analysis is described in Chapter 8. Although the short-
term effects of steroids on objective parameters like lung function and bronchial 
hyperresponsiveness are well-known (particularly in asthma), no studies are known 
about the effects of inhaled corticosteroids on the subjective well-being (quality of 
life) of patients with asthma and COPD. We assessed the influence of an inhaled cor-
ticosteroid on quality of life in patients with asthma and COPD (Chapter 9). A prob-
lem for the long-term efficacy of inhaled corticosteroids is patient-compliance and 
inhaler technique (53). In contrast to bronchodilators, the prophylactic corticosteroids 
do not have a direct symptom-relieving effect (10). Therefore, patients may not no-
tice improvements in e.g. lung function, induced by corticosteroids. This may reduce 
patient compliance with the inhaled corticosteroids, particularly when used for sev-
eral years. Long-term patient compliance with and inhaler technique of an inhaled 
corticosteroid in asthma and COPD has been described in Chapter JO. Another very 
important question regarding the long-term treatment with inhaled corticosteroids 
concerns the possibility of stopping when patients are in a clinically stable phase of 
disease (54). The answer to this question has to do with fundamental aspects of ste-
roid action: do steroids merely suppress the disease temporarily or do they really 
'cure' asthma or COPD to some extent? If steroids are merely acting as suppressors, 
treatment with these medicines can not be discontinued. If long-term treatment with 
these drugs does 'cure' asthma or COPD to some extent, therapy with steroids can be 
interrupted. Chapter 11 describes the results of stopping treatment with inhaled corti-
costeroids in asthma and COPD. 
1.2. Aims of the thesis 
The aim of this thesis is to answer the following questions with respect to diagnosis 
and treatment of asthma or COPD: 
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Diagnosis 
a. Is the portable, integrating Microspiro HI-298 flow meter a reliable instrument for 
use in general practice? (Chapter 2); 
b. Which way of expressing the immediate bronchodilating response is most repro­
ducible and least dependent on the prebronchodilator lung function? (Chapter 3); 
с Is it possible to detect patients at risk (with a large decline in lung function and a 
high exacerbation rate) on the basis of a single cross-sectional assessment of lung 
function, respiratory symptoms, quality of life, allergy and physical signs of the 
chest! (Chapter 4); 
d. Is bronchial hyperresponsiveness a 'cause' or a 'consequence' of airway obstruc­
tion in asthma or COPD? (Chapter 5); 
Treatment 
e. Does treatment with inhaled corticosteroids decelerate the deterioration of asthma 
or COPD during bronchodilator therapy alone? (Chapters 6 and 7); 
f. Which clinical characteristics in asthma and COPD can predict the two-year re­
sponse to an inhaled corticosteroid? (Chapter 8); 
g. Does treatment with inhaled corticosteroids improve the quality of life in patients 
with asthma or COPD? (Chapter 9); 
h. How good is long-term compliance with and inhaler technique of an inhaled corti­
costeroid in patients with asthma and COPD? (Chapter 70); 
i. What is the course of asthma and COPD after stopping maintenance treatment 
with inhaled corticosteroids? (Chapter 11). 
1.3 Outline of the study 
Patient selection 
29 General practitioners were asked to select all their patients aged 30 and over with 
symptoms of asthma or COPD (25,44). Only those patients who showed moderate 
airway obstruction (FEVi or FEVi/EVC had to be two standard deviations below 
their predicted value (55), but higher than 50% of the predicted value) and/or bron­
chial hyperresponsiveness to histamine (PC20 ^  8 mg/ml) were included by the inves­
tigators. Exclusion criteria were: dependence on corticosteroids, chronic heart failure, 
malignant disorders or other severe, life-threatening diseases. The study was ap­
proved by the Medical Ethics Committee of the University of Nijmegen. All patients 
gave informed consent. 
Part one 
Patients were randomly allocated to two parallel treatment groups (25): 
1. continuous bronchodilator treatment of salbutamol 400 μg or ipratropium bromide 
40 μg, four times daily (dry powder inhalations) 
2. bronchodilator treatment 'on demand' during periods of dyspnoea or exacerba­
tions with dry powder inhalations of salbutamol 400 μg or ipratropium bromide 
40 μ
β
. 
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Within these parallel groups, a cross-over comparison was made between salbutamol 
and ipratropium bromide: patients used each drug for one year. The order of the 
drugs was determined at random. In an eight-week wash-out period before the start 
of the study, bronchopulmonary medication other than the trial medication was 
stopped (corticosteroids, sodium cromoglycate, theophylline, etc). 
Part two 
56 Patients with an unfavourable course of disease (an annual decline in FEVi of at 
least 80 ml/yr in combination with at least two exacerbations/yr) during treatment 
with bronchodilators alone (part one of the study) were selected for additional treat­
ment with inhaled beclomethasone dipropionate (BDP). 
During the third and fourth year, the 56 patients were additionally treated with 
BDP 400 μg two times daily in combination with salbutamol 400 μg or ipratropium 
bromide 40 μg four times daily (all dry powder inhalations). The bronchodilator in­
haled during the second year was also used in the third and fourth year. 
Once every three months, proper inhalation technique as well as compliance with 
the prescribed medication were checked. Patients were instructed to rinse their mouth 
after the dry powder inhalations. 
Study design 
random 
allocation to: 
two-year period two-year period 
к '- »« '- • 
IB 
IB BDP+IB 
BDP+S 
(n=28 ) 
(n=28: 
BDP = beclomethasone dipropionate 
IB = ipratropium bromide 
5 ^salbutamol 
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2. Accuracy, precision and linearity of the portable 
flow-volume meter Microspiro HI-298* 
Abstract 
The accuracy, precision and linearity of a new portable flow volume meter, the Microspi­
ro HI-298 (Chest Corporation, Tokyo, Japan), was investigated using a Fleisch no 4 pneu­
motachograph as a standard After connection and calibration of the pneumotachograph and 
the Microspiro, a healthy subject performed 44 forced vital capacity (FVC) manoeuvres at 
different levels of lung inflation The FVC of these expirations ranged from 2 5 to 5 1 litres 
Linear regression of Microspiro values (dependent variable) on Fleisch pneumotachograph 
values (independent variable) showed that a good linear relationship existed Pearson correla­
tion coefficients ranged from 0 938-0 985 Linearity of the Microspiro was good except for 
the peak-flow rate (PEFR) and the maximal expiratory flow at 25% of expired volume 
(MEFTS) The random error (measure of precision) of all flow-volume (F-V) indices was 
lower than 5% The systematic error (measure of accuracy) was low for the forced expiratory 
volume in one second (FEV ι) and the FVC ( 1 0% and 4 6% respectively) but much higher for 
the instantaneous expiratory flows (PEFR 11 0%, MEF75 7 0%, MEF50 8 5%, MEF25 11 4%) 
Only the total error in FEVi complied with the tolerance of 4% of the European Coal and 
Steel Community (ECSC) When the measured values were adjusted according to the regres­
sion equations of this study, all F-V indices were accurate and precise within 5% 
It was concluded that the portable Microspiro HI-298 is a useful instrument for bedside, 
work-site spirometry and for use in General Practice As the accuracy of the instantaneous ex­
piratory flows (PEFR, MEF7S, MEF50 and MEF25) is moderate, it is advised to adjust these 
values with the regression equations of this study 
2.1. Introduction 
The forced expiratory manoeuvre is a widely used method for assessing the degree of 
airflow obstruction in patients with asthma and Chronic Obstructive Pulmonary Dis­
ease (COPD) It is well-known that the variability of flow-volume (F-V) indices is 
rather high (1-3) One of the sources of variability is the random error of the instru­
ment by which the F-V parameters are measured (4) Therefore both the American 
Thoracic Society (ATS) and the European Coal and Steel Community (ECSC) for­
mulated extensive recommendations on the accuracy and precision of spirometers in 
order to improve the quality of the F-V data (5-7) As a number of tested devices ap­
peared to be inadequate (8,9), it was advised to test new available spirometers 
(10,11) During the past few years the need for simple but reliable spirometers for 
bedside, work-site spirometry and for use in general practice has been rising A 
promising instrument in this field may be the portable Microspiro HI-298® (Chest 
* Onginalh published as Dompeling E, Van Schayck CP Folgenng H Van den Hoogen HJM Van 
Weel С Accuracy precision and linearity of the portable flow-volume meter Microspiro HI 298 Fur 
RespirJ 1991 4 612-615 
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Corporation, Tokyo, Japan). It is a very compact, light apparatus with useful possi­
bilities. Although the Microspiro is widely used, the reliability has not been tested. 
Therefore this study intends to investigate the accuracy, precision and linearity of the 
Microspiro. 
2.2. Methods 
Instrument 
The Microspiro HI-298® is produced by the Chest Corporation, Tokyo, Japan. Fig­
ure 2.1 shows a schematic drawing of this portable flow-volume meter. The appara­
tus measures instantaneous flows which are integrated electronically into volumes. 
The following indices are measured: slow expiratory vital capacity (EVC), forced 
vital capacity (FVC), forced expiratory volume in one second (FEVi), peak expira­
tory flow rate (PEER), maximal expiratory flows at 25%, 50% and 75% of the ex­
pired volume (MEF75, MEF50, MEF25 respectively). The measured values, predicted 
values, and measured values as percentages of predicted values are shown on a liquid 
crystal display together with a spirogram and a F-V curve. The two best efforts (the 
FVC-manoeuvres with the largest sum of FEVi and FVC (6)) are stored in the mem­
ory and can be printed. The print-out takes 2-3 minutes. The predicted values are 
based on the equations of the ECSC for adults (5) and of Dickman et al. (12) or Za-
pletal et al. for children (13). It is possible to adjust the predicted volume values for 
different ethnic groups. Measured values are body temperature and pressure saturated 
(BTPS) corrected. The bronchodilator responsiveness is automatically calculated, as 
the instrument stores prebronchodilator values and compares them with data after 
bronchodilatation. The warming-up takes five minutes. The Microspiro has a flow 
range of 0 to 14 1/s. The volume range is 0.4 to 8.0 liters. The measurement time for a 
FVC-manoeuvre takes 18 seconds at most. These specifications are in accordance 
Figure 2.1 A schematic drawing of the Microspiro ΗΙ-298Γ 
Swirl meter 
Operation keyboard 
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with the standards of the ATS and the ECSC (5-7). The Microspiro HI-298 is a 
forced oscillatory flow meter (14). It contains a swirl sensor (15). The sensing tech­
nique of this meter is based on a relatively new method of measuring flows (14,15). 
A set of stationary swirl blades forces gas entering the swirl meter to spin around the 
central axis of the meter, forming vortices. The vortices advance through the meter 
like screws. The frequency of the vortices shows a linear relationship with the veloc­
ity of the gas. A sensor probe in the meter senses the passage of these vortices. The 
sensor in the meter is a thermistor (a resistor which changes its resistance with tem­
perature). A constant current passes the thermistor causing the device to heat. The 
gas passing along the thermistor removes heat. As the velocity of the gas changes 
when a vortex passes along the thermistor the heat removal from the thermistor also 
changes. In this way each vortex is accompanied by resistance change in the sensor. 
As a constant current passes through the sensor the voltage across the sensor varies 
as each vortex passes. This change of voltage is AC coupled into the electronic sys­
tem and after suitable processing is counted and interpreted as flow velocity. An ad­
vantage of the Microspiro is that is does not sample flows but measures the whole 
flow stream. It is known that through sampling of flows or volumes large errors can 
result (7,10). 
Experiment 
The Microspiro was connected in series with a standard instrument, the Fleisch no.4 
pneumotachograph (4,16). The maximal error of the Fleisch pneumotachograph is 
not more than 3% (16). Up to a flow of 11 1/s the linearity of a type 4 Fleisch pneu-
motachometer was shown to be good (16). The Fleisch pneumotachometer was a 
commercial type: Discom -21®, Chest Corporation, Tokyo, Japan. The transducer 
(5 cm ID) is heated to 37 degrees. At both sides of the transducer, a conical attach­
ment ensures a laminar flow through the transducer. The pneumotachometer 
measures instantaneous flows which are integrated electronically into volumes. At 
the start of the experiment, the pneumotachograph (in series with the Microspiro) 
was calibrated with a one litre syringe. A healthy subject performed 44 forced expira­
tions through the connected instruments at different levels of lung inflation. The FVC 
of these expirations ranged from 2.5 to 5.1 litres. Paired data were taken for the FVC, 
FEV 1, PEFR and MEF-values. Linear regression analysis was applied to the paired 
data, in which the Fleisch values were the independent variables and the Microspiro 
values the dependent variables. The distance from the line of identity to the regres­
sion line, M=a.F+b (M= Microspiro value, F= Fleisch value, a= regression coeffi­
cient and b= the intercept), was defined as systematic error, which is a measure for 
the accuracy of the instrument (17). For all F-V parameters except the PEFR the re­
gression lines went through the origin (b=0). In this case the systematic error in % is 
given by a constant: (a.F/F).100%=100.a%. In the case of the PEFR a mean syste­
matic error was calculated. The deviation of Microspiro values from the regression 
line was defined as the random error, which is a measure for the precision of the 
Microspiro (17). The random error in % was calculated by determining the % vari­
ance which was not explained by the model (ЦІ-г2). 100% in which r= Pearson 
correlation coefficient) (17,18). The total error was defined as systematic error 
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+ random error. Linearity was assessed in the following way. First the gain (G) of the 
system was calculated by dividing Microspiro values by the corresponding Fleisch 
values (G=Microspiro value/Fleisch value) (16). The percentage difference between 
the largest and smallest gains (AG%) in a specified flow or volume range is a 
measure for the linearity of the system (16,19). 
2.3. Results and discussion 
A good linear relationship was found between the Fleisch pneumotachograph values 
and the Microspiro values for all F-V indices (Table 2.1 and Figure 2.2). Pearson 
correlation coefficients ranged from 0.938 to 0.985 (Table 2.1). The AG% of F-V in­
dices was lower than 10% (except for the PEFR and the MEF75), indicating that the 
linearity of most F-V indices (FVC, FEVi, MEF50 and MEF25) was good. The Micro-
spiro gave systematic over-readings for the FVC, systematic under-readings for the 
other F-V indices. The systematic error ranged from 1.0% for the FEVi (good accu­
racy) to 11.4% for the MEF25 (low accuracy). The random error of all indices was 
within the 5% limit advised for spirometry (10). However, only the FEVi had a total 
error within the tolerance limits of 4% of the ECSC (5). Therefore, the portable 
Microspiro is a reliable meter for measuring the FEVi but it is less accurate in 
measuring instantaneous forced expiratory flows (PEFR, MEF75, MEF50 and MEF25). 
However, the accuracy can be increased by adjusting the values according to the li­
near regression equations of this study (Table 2.1). With these adjustments the total 
error of all F-V indices will be lower than 5%. As the swirl sensor itself probably is 
accurate and linear within 1% (14,15), the manufacturer may change the electronic 
amplifier and signal conditioner. These parts of the electronic system are the links 
where the sources of error may exist. The Microspiro can be used in general practice, 
for bedside and work-site spirometry and for epidemiological purposes. The automat­
ic calculation of the reversibility of bronchial obstruction (in percentages of the in­
itial FEVi ) is a convenient additional feature. Because of the moderate accuracy of 
the instantaneous expiratory flow rates, it is advisable to use the adjusted values. 
Table 2.1 The regression lines, values of total error (systematic error ± random error), 
linearity (AG%) and Pearson's correlation coefficients (r) of six F-V indices. The intercept 
of PEFR is given in litre/second. The standard errors are given between parentheses. 
Variable 
FVC 
FEVi 
PEFR 
MEF75 
MEF50 
MEF25 
Regression line 
Regr.coefficient 
1 045 (0 007) 
0 990 (0 007) 
0 794 (0 029) 
0 930 (0 009) 
0 915 (0 008) 
0 886 (0 017) 
Intercept 
_ 
-
0 698 (0 204) 
-
-
-
r 
0 978 
0 985 
0 975 
0 981 
0 982 
0 938 
Error (%) 
+ 4 6±4 3 
- 1 0±3 0 
-11 0±5 0 
- 7 0±3 9 
- 8 5±3 6 
-11 4±3 9 
Δ0% 
8 5 1 
9 5 } 
39 6 2 
1 6 7 3 
i g 3 
1 6 J 
range of FVC and FEVi 1 - 4 litres, 2 range of PEFR 15-10 litre/sec, 3 range of MEF-values 1 - 8 litre/sec 
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Figure 2.2 The regression of the FEVi measured by the Microspiro (vertical axis) on the 
FEVi of the Fleisch pneumotachograph (horizontal axis) 
FEVÏ (Microspiro in I 1 
τ 1 1 1 г 
1 2 3 4 5 
FEVi (Fleisch) in I 
It was concluded that the Microspiro HI-298® only gives reliable values for the 
FEVi. However, when the measured values of the other F-V indices are corrected 
with the regression equations of this study, all values will be accurate and precise 
within 5%. 
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3. A comparison of six different ways of expressing 
the bronchodilating response in asthma and 
COPD 
Reproducibility and dependence on prebronchodilator FEVi* 
Abstract 
Various indices are used to express the bronchodilating response It is unclear, however, which 
index is most informative The aim of this study was to compare six expressions of the bronchodi 
lating response and to examine 1) the independence of the prebronchodilator forced expiratory 
volume in one second (FEVi), and 2) the reproducibility of the bronchodilating response Bron­
chodilating responses (increases in FEVi 60 minutes after salbutamol 400 μg and ipratropium bro­
mide 80 μg) on six test occasions, during two years, of 183 patients (72 asthma, 111 COPD) from a 
large bronchodilator intervention study were used The dependence of the prebronchodilator FEVi 
was investigated both between-patients (cross-sectional analysis) and withm-patients (longitudinal 
analysis) by means of linear regression analysis The reproducibility of the bronchodilating re­
sponse was calculated by means of the coefficients of variation (CVs) of the six bronchodilating re­
sponses during two years The CVs of the six expression indices were compared by analysis of 
variance (ANOVA) 
The results showed that no index was independent of the prebronchodilator FEV] However, 
some indices were significantly more dependent of the prebronchodilator lung function and, there­
fore, less reproducible than others The '% initial' index (change as a percentage of the prebron­
chodilator value) was the most dependent of the prebronchodilator lung function and had the worst 
reproducibility (CV ranged from 50-61%) The '% possible' (change as a percentage of the pre­
dicted minus prebronchodilator value) and '% achievable' (absolute change as a percentage of the 
maximal postbronchodilator minus prebronchodilator value) indices were the least dependent of the 
prebronchodilator value and had the highest reproducibility (CV ranging from 34-53%) 
The way in which bronchodilating responses should be expressed depends on the purpose of the 
test It was concluded that the '% initial' index was most dependent of the prebronchodilator FEV ι 
and had the worst reproducibility, whereas for the '% possible' or '% achievable' indices the oppo­
site was found In bronchodilator studies, the latter expression indices increase the possibility of de­
tecting differences in bronchodilating efficacy between different drugs 
3.1. Introduction 
Assessment of the responsiveness to bronchodilators in patients with airway obstruc­
tion is a test often used in clinical and experimental situations (1) The bronchodilat­
ing response, mostly assessed by the increase in forced expiratory volume in one sec­
ond (FEVi), provides objective information about the degree of reversibility of air­
way obstruction (2) and the response to different types of drugs (3) Various indices 
are used to express the response to bronchodilators: absolute change (4-6) and abso­
lute change as a percentage of the prebronchodilator value (7,8), of the predicted 
value (5,9), of the maximal response (10), of the maximal postbronchodilator minus 
* Onginally published as Dompeling E, Van Schayck CP. Molema J, Akkermans R, Folgenng H, Van 
Grunsven PM, Van Weel С A comparison of six different ways of expressing the bronchodilaung re­
sponse in asthma and COPD, reproducibility and dependence on prebronchodilator FEVi Eur Respir J 
1992 5 975 981 
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prebronchodilator value (10,11) or of the predicted minus prebronchodilator value 
(12). It is not clear, however, which method of expressing the bronchodilating re-
sponse is most informative (1,13). Particularly in asthma, marked fluctuations in pul-
monary function may occur both throughout the day and from day-to-day (14,15). As 
a consequence, the bronchodilating response may fluctuate correspondingly, which 
may lower the comparability of responses both between- and within-subjects. The 
use of an index independent of the prebronchodilator FEVi and with reproducible 
values may generally be most appropriate (13). It is not clear which index (if any) for 
expressing reversibility has these properties. Two cross-sectional studies on this sub-
ject led to contradicting results. Postma et al. (16) observed that the '% possible' 
index (absolute change as a percentage of the predicted minus prebronchodilator 
value) was independent of the prebronchodilator lung function. Weir and Bürge (13) 
claimed that not '% possible' but '% predicted' (change as a percentage of the pre-
dicted value) was independent of the prebronchodilator lung function. However, 
these findings were based on a single cross-sectional assessment in patients with 
non-asthmatic chronic airway obstruction in which reversibility of obstruction and 
fluctuations of pulmonary function are not 'characteristic'. 
In a prospective controlled study, during two years, in both asthma and Chronic 
Obstructive Pulmonary Disease (COPD), we investigated which bronchodilator 
index was independent of the prebronchodilator FEVi and compared the reproduci-
bility of six indices for expressing reversibility. Data on six bronchodilating respon-
ses, during two years, of 183 patients participating in a bronchodilator intervention 
study were used for this purpose (17,18). 
3.2. Methods 
Patients 
An extensive description of patient selection, in- and exclusion criteria of the bron-
chodilator intervention study was given previously (17,18). In summary: 29 general 
practitioners in the catchment area of the University of Nijmegen were asked to se-
lect all their patients aged 30 and over with symptoms of asthma or COPD. Only pa-
tients who showed mild to moderate airway obstruction (FEVi >50% of the predicted 
value (19)) and/or increased bronchial responsiveness to histamine (provoking con-
centration of histamine that produces a 20% fall in FEVi (PC20) ^8 mg/ml) were in-
cluded by the investigators. The diagnosis of asthma or COPD was based on the 
criteria of the American Thoracic Society (ATS)(14). Asthma was defined as the 
combination of ( 17,18): 1. reversible obstruction (increase in FEV 1 one hour after the 
administration of 400 μg salbutamol and 80 μg ipratropium bromide >15% of the 
prebronchodilator value); 2. bronchial hyperresponsiveness to histamine (PC20 
<8 mg/ml); 3. dyspnoea; 4. allergy (at least one positive test out of seven radio-aller-
gosorbent tests (RAST) (Pharmacia, Sweden. Pollen: weeds, grasses, trees; animals: 
cats and dogs; house dust mite; Aspergillus Fumigatus)) and/or wheezing. 
COPD was defined as the combination of (17,18): 1. chronic cough or chronic 
sputum production for at least three months during at least two consecutive years; 2. 
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continuous airway obstruction (FEVi less than 85% of the predicted value). Patient 
characteristics are shown in Table 3.1. The study was approved by the University 
Ethics Committee. All patients gave informed consent. 
Table 3.1 Clinical characteristics of patients with COPD and asthma. Data are presented 
as mean values with SD in parentheses. Differences between patients with asthma and 
those with COPD are tested by means of a chi-square test (dichotomous variables) or 
unpaired Student's t-test (continuous variables). 
COPD Asthma p-value 
Number 
Age (years) 
Sex (M/F) 
Current smokers (+/-) 
Pack years 
Allergic (+/-)# 
FEVT (L) 
FEVI %pred 
FEVi-maxpost (U 
VC(L) 
VC % pred 
VC-maxpost (L) 
Reversibility in FEVi 
- 'absolute' (L) 
- '% initial' 
- '% predicted' 
- '% maximal' 
- '% possible' 
- '% achievable 
CV-PEFR (%)## 
PC20 (mg hist /ml) ### 
111 
53 
68/43 
67/44 
19 
20/89 
2 4 4 
77 
2 81 
3 60 
90 
3 95 
0 26 
13 
8 
63 
34 
64 
9 
11 3 
(13) 
(17) 
(0 82) 
(18) 
(0 83) 
(1 03) 
(16) 
(1 01) 
(0 14) 
(9) 
(4) 
(14) 
(19) 
(16) 
(5) 
72 
51 
33/39 
27/45 
13 
25/46 
2 18 
73 
2 77 
3 53 
92 
3 95 
0 46 
25 
15 
66 
44 
72 
13 
1 2 
(13) 
(16) 
(0 77) 
(20) 
(0 84) 
(106) 
(18) 
(1 06) 
(0 27) 
(16) 
(7) 
(17) 
(23) 
(16) 
(6) 
0 22 
0 040 
0 003 
0015 
0011 
0 039 
019 
0 80 
0 66 
0 39 
0 99 
0 0001 
0 0001 
0 0001 
019 
0 004 
0 0013 
0 0001 
0 0001 
# Allergy was defined as at least one positive test out of seven RAST 
## coefficient of variation of the weekly measured morning peak-flow during a four-week period at the 
start of the study 
### geometric mean PC20 values are given 
Bronchodilator therapy 
At the start of the study, all patients were randomly allocated to one of the two treat­
ment regimens: continuous use of a bronchodilator (ipratropium bromide of 160 μg 
daily or salbutamol of 1,600 μg daily) or inhalation on demand. Within these treat­
ment regimens, a cross-over comparison was applied between ipratropium bromide 
and salbutamol. All patients used ipratropium bromide during one year and salbuta­
mol during the other. The sequence of salbutamol and ipratropium bromide was 
determined by random allocation. No corticosteroids, cromoglycate or bronchodila-
tors other than the medication mentioned above (ipratropium bromide or salbutamol) 
were permitted. 
Spirometry and bronchodilator testing 
At the start of the study and after 6, 12, 13, 18 and 24 months, respectively, assess­
ments were made by two trained laboratory technicians during an exacerbation-free 
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period. Patients were requested to abstain from bronchodilating medication for at 
least eight hours prior to the lung function tests. Smoking or exercise just before or 
during the experiments was not permitted. The FEV ι and the forced vital capacity 
(FVC) were assessed three times by means of the Microspiro HI-298 (Chest Corpor­
ation, Japan) (20). The data from the flow-volume curve with the highest sum of 
FVC and FEV ι were used for calculations. The FEVi was measured before and one 
hour after the inhalation of 400 μg salbutamol and 80 μg ipratropium bromide (both 
metered dose aerosol). The bronchodilating response of each patient on every test oc­
casion was expressed in six different ways: 
(1) Absolute change ( 'absolute ') (4-6):(FEVipost-FEVipre) 
(2) Change as a percentage of prebronchodilator value ( '% initial') (7,8): 
F E V , p o s t - F E V , p r e )
x l 0 0 % 
FEVi pre 
(3) Change as a percentage of predicted value ( '% predicted ') (5,9): 
F E V , P o g t - F E V i p r e ) x l 0 0 % 
FEVipred 
(4) Change as a percentage of the maximal absolute response ever recorded during 
the two-year study period (" % maximal ')( 10) : 
F E V l p o s t ^ F E V . p r e ) ^ ^ 
AFEVjmax 
(5) Change as a percentage of predicted value minus prebronchodilator 
value ( '% possible ') (12): 
(FEV,post-FEV,pre) 
(FEVipred- FEV ipre) 
(6) Change as a percentage of the highest postbronchodilator value ever recorded 
during the two-year study period minus prebronchodilator value ('% achiev-
oWe'XlO.ll): 
(FEVipost-FEVipre)
 χ m % 
(FEV ι max - FEVipre) 
Analysis 
Cross-sectional analysis. In order to investigate the dependence of the six indices for 
expressing reversibility of the prebronchodilator FEVi, linear regression analysis of 
the bronchodilating response (dependent variable) on the prebronchodilator FEVi 
(independent variable) was applied on six different test occasions. The Pearson corre­
lation coefficient (r) was taken as a measure for the extent of the relationship (21 ). 
Longitudinal analysis. The reproducibility of the bronchodilating response was 
determined by calculating the coefficient of variation (CV = SD/mean χ 100%) 
(22,23) of the six assessments. A low CV implies a high reproducibility and vice 
versa. The dependence of the six indices of the prebronchodilator FEVi was also 
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determined within-subjects. For this purpose, the six bronchodilating tests of an indi­
vidual were incorporated in a linear regression analysis of the bronchodilating re­
sponse (dependent variable) on the prebronchodilator lung function (independent 
variable). The r-square (% of explained variance) was taken as a measure for the ex­
tent of the relationship. Individual r-squares were averaged to get the mean r-square 
of that index in asthma or COPD. The mean CVs and mean r-square of the six in­
dices were statistically compared with each other by ANOVA. 
3.3. Results 
Cross-sectional analysis 
In Table 3.2 and Figure 3.1, the Pearson correlation coefficients of the relation be­
tween the bronchodilating response and the prebronchodilator FEVi at cross-sec­
tional assessments are represented for six different indices of reversibility. The Pear­
son correlation coefficients of a particular index of reversibility varied substantially 
between the different cross-sectional assessments (Table 3.2). In asthma, the 'abso­
lute change' and '% possible' indices had no statistically significant correlations with 
the prebronchodilator FEVi at any test occasion. In COPD, only the '% possible' and 
'% achievable' indices had no significant correlations at any test moment. In both as­
thma and COPD, the average Pearson correlation coefficient was low (<0.20) for the 
'absolute change', '% possible' and '% achievable' indices but high (>0.45) for the 
'% initial' index. 
Table 3.2 Results of the cross-sectional analyses. The Pearson correlation coefficients of 
the relation between the bronchodilating response and the prebronchodilator FEVi are 
calculated at six different cross-sectional assessments for six indices of reversibility 
(between-subject analysis}. The statistical significance of the correlations are also 
represented. 
Index 
Asthma 
'Absolute' 
'% Initial' 
'% Predicted' 
'% Maximal' 
'% Possible' 
'% Achievable' 
COPD 
'Absolute' 
'% Initial' 
'% Predicted' 
'% Maximal' 
'% Possible' 
'% Achievable' 
1 
-0 06 
-0 39t 
-0 24* 
-0 28* 
-0 22 
- 0 1 6 
-0 19* 
-0 45t 
-0 35* 
-огв**' 
-0 09 
-0 13 
2 
-0 07 
-0 47* 
-0 26* 
-0 22 
- 0 1 0 
+0 04 
- 0 1 6 
-0 48* 
-0 35t 
' -0 22* 
+0 01 
- 0 1 9 
Bronchodilator test 
3 
+0 10 
-0 32** 
-0 05 
+0 07 
-0 04 
+0 26* 
-0 09 
-0 48* 
-0 30*** 
-0 08 
-0 10 
+0 04 
4 
-0 03 
-0 46* 
- 0 2 1 
- 0 1 8 
+0 11 
+0 08 
- 0 1 1 
-0 39* 
-0 26** 
-0 07 
+0 15 
-0 03 
5 
+0 04 
-0 5 1 * 
-0 21 
-0 05 
- 0 1 0 
+0 26* 
-0 25** 
- 0 5 1 * 
-0 40* 
-0 23* 
+0 04 
-0 08 
6 
-0 22 
-0 53* 
-0 39*** 
-0 39t 
-0 09 
+0 05 
-0 27*** 
-0 49* 
-0 42* 
- 0 3 1 * * * 
+0 12 
- 0 1 6 
mean 
0 09 
0 45 
0 23 
0 20 
011 
0 14 
018 
0 47 
0 35 
0 20 
0 09 
011 
* p<0 05, " * p<0 01. * " " p<0 005, t p<0 001, * p<0 0001 
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Figure 3.1 The correlation between response and prebronchodilator FEVi (cross-
sectional analysis) of six different expression indices. The absolute Pearson correlation 
coefficients (mean of six different tests) are given in asthma (top) and COPD separately. 
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Longitudinal analysis 
The results of the longitudinal analysis are shown in Table 3.3. All indices of revers-
ibility demonstrated a pronounced relationship between the bronchodilating response 
and the prebronchodilator FEVi, as represented by the high r-square. The reproduci-
bility of the bronchodilating response was low: the CVs ranged from 34-50% in as-
thma to 46-61% in COPD. '% Possible' and '% achievable' appeared to be the in-
dices with the lowest r-square and CV in both asthma and COPD. 
Table 3.3 The results of the longitudinal analyses. The CVs of bronchodilating responses 
of six indices of reversibility. Moreover, the r-square (% of explained variance) of the 
relation between the bronchodilator response and the prebronchodilator lung function 
are also presented (within-subject analysis). The CVs and r-square of '% initial' were 
statistically compared with the other indices by ANOVA. 
Index 
'Absolute' 
'% Initial' 
'% Predicted' 
'% Maximal' 
'% Possible' 
'% Achievable' 
Asthma 
CV 
43 (24) 
50 (25) 
43 (24) 
43 (24) 
34 (23)** 
36 (21)** 
* p<0 05, * * p<0 001, " " p<0 0001 
A100% 
54 (34) 
63 (33) 
54 (34) 
54 (34) 
49 (34)* 
40 (32)*** 
COPD 
CV 
57 (29) 
61 (30) 
57 (29) 
57 (29) 
46 (24)** 
53 (27)* 
r2x100% 
47 (32) 
51 (33) 
47 (32) 
47 (32) 
45 (33) 
38 (33)** 
The influence of the bronchodilator treatment regimen 
During the two-year study period, there was a decline in the baseline FEVi of 85 
(SEM 16) ml/yr during continuous bronchodilator treatment, but of only 39 (SEM 
16) ml/yr during treatment on demand (unpaired Student's t-test, p<0.05). The in-
fluence of the treatment regimen on the reproducibility of the bronchodilating re-
sponse is given in Table 3.4 for the six different expression indices. It appeared that, 
in general, no differences existed in CV between continuous and on demand treated 
patients with asthma or COPD with one exception. In COPD, the CV of '% achiev-
Table 3.4 The influence of the treatment regimen during two years (continuous 
bronchodilator therapy versus treatment on demand) on the reproducibility of the 
bronchodilating response of six different expression indices. Differences in CV between 
continuous and on demand treatment group were tested by the unpaired Student's t-test. 
Index 
'Absolute' 
'% Initial' 
'% Predicted' 
'% Maximal' 
'% Possible' 
'% Achievable' 
Asth 
Continuous 
47 (22) 
55 (22) 
47 (22) 
43 (24) 
52 (55) 
41 (24) 
ma 
On demand 
49 (25) 
58 (30) 
49 (25) 
54 (34) 
38 (29) 
39 (22) 
COPD 
Continuous On demand 
58 (31) 61 (27) 
66 (36) 64 (28) 
58 (31) 61 (27) 
57 (29) 47 (32) 
50 (32) 58 (35) 
46 (22)* 62 (28) 
* p<0 005 
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able' was higher in patients treated on demand (62%) than in patients treated con-
tinuously (46%) (p<0.005). 
3.4. Discussion 
Nowadays, a number of indices to express the bronchodilating response are used, all 
of them with specific advantages and drawbacks. It is difficult to give general state-
ments about the way bronchodilating responses should be expressed, because the 
method of expressing depends on the purpose of the bronchodilating test (1). Is the 
test used to separate asthmatics from subjects with COPD? Is it used to evaluate the 
bronchodilating efficacy of drugs or to predict the decline in lung function? It is not 
likely that only one index is most appropriate for answering all these different ques-
tions and indeed our study does not suggest 'one optimal index'. 
Two general aspects of expressing the bronchodilating response were investigated 
in our study: the dependence on the prebronchodilator FEVi and the reproducibility 
of the bronchodilating response. In general, the use of an index independent from the 
prebronchodilator FEVi will increase the comparability of bronchodilating responses 
between different subjects and of repeated tests within the same subjects. Moreover, 
an index that gives more reproducible values will increase the validity of the test re-
sult. Therefore, an index least dependent on the prebronchodilator FEVi and with 
most reproducible values has many advantages. 
Our study demonstrated that every index of expressing the bronchodilating re-
sponse was to some extent dependent on the prebronchodilator FEVi, in contrast to 
previous claims (13,16). However, some were clearly more dependent and, therefore 
less reproducible than others. The most common way to express the bronchodilating 
response ('% initial') was most dependent on the prebronchodilator FEVi and had 
the worst reproducibility. On the contrary, the '% possible' and '% achievable' in-
dices were least dependent on the prebronchodilator FEVi and were most reproduc-
ible. This does not imply that bronchodilating responses should always be expressed 
as '% possible' or '% achievable'. For instance when the bronchodilating test is used 
to separate asthma from COPD, the data of our study and those of others (5) suggest 
that these indices might not give an optimal separation between the two disease ca-
tegories and are, therefore, not appropriate for this purpose. In our study, the 'abso-
lute', '% initial' and '% predicted' indices gave an optimal separation between as-
thmatics and subjects with COPD. Meslier et al. (6) and Eliasson et al. (5) found that 
the '% predicted' index was most useful in this respect. 
When the bronchodilator test is used to evaluate the bronchodilating efficacy of a 
certain drug, the '% possible' or '% achievable' indices might be more useful than 
the other indices because of the higher reproducibility. Based on our results, the 
standard error of a single bronchodilator test can be estimated at 34-61%, dependent 
on the expression index. This indicates that at an individual level the value of a single 
bronchodilator test is limited. As the standard error generally decreases with the 
square root of the number of assessments (21), about 14 tests will bring the standard 
error of the mean within the 15% limit, when expressed as '% initial' in asthma. With 
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the '% possible' and '% achievable' indices, however, just seven assessments will 
give the same accuracy. Therefore, in bronchodilator trials, comparing the bronchodi-
lating efficacy of different drugs within asthma or COPD, the '% possible' or 
'% achievable' indices might increase the possibility of detecting differences in bron-
chodilating efficacy between different drugs. 
The index widely used is the one that expresses the absolute improvement in 
FEVi as a percentage of the prebronchodilator value. An advantage of this index is 
that it is easy to use and to calculate. A drawback is the strong dependence of the pre-
bronchodilator FEVi. Small absolute changes become large percentage changes in 
patients with a low FEVi, so that these patients with the greatest impairment of lung 
function usually appear to have the greatest reversibility (5,13). In this study, the low 
reproducibility appeared to be another drawback of this index. Expressing the bron-
chodilating response as an absolute change is also very easy, but this index is de-
pendent on sex and height: tall male patients are more likely to demonstrate a certain 
degree of reversibility than small female patients (6). Moreover, we found that the 
'absolute change' index was also dependent of the prebronchodilator value, although 
to a smaller extent than the '% initial' index. 
A recent cross-sectional study in non-asthmatic patients claimed that the '% pre-
dicted' index was the only index independent of the prebronchodilator FEVi (13). 
However, our study clearly demonstrated that this index is also dependent on the pre-
bronchodilator FEVi, both between- and within-subjects. The Pearson correlations of 
the relation between bronchodilating response and the prebronchodilator lung func-
tion varied substantially between different cross-sectional assessments in our study. 
Therefore, only one cross-sectional measurement of the bronchodilating response as 
in the studies of Weir et al. (13) and Postma et al. (16) is not sufficient to compare 
different indices of reversibility. 
The '% maximal' index (absolute change as a percentage of the maximal absolute 
response ever recorded) is not often used and appeared to have no specific advant-
ages in this study. Data from our study showed that it is of no value in separating as-
thmatics from patients with COPD. 
The '% possible' and '% achievable' indices are difficult to calculate, because pre-
dicted or maximal postbronchodilator values are necessary. In patients with little ven-
tilatory impairment, bronchodilating responses expressed as '% possible' may be 
exaggerated because the prebronchodilator FEVi may reach the predicted value of 
the FEVi. The '% achievable' index does not have this drawback but repeated tests 
are necessary to determine the individual maximal postbronchodilator value. These 
limitations make this index useless in clinical practice. 
The patients in this study were selected from 29 general practices and were repre-
sentative for the adult population aged 30 and over with asthma or COPD (17,18). 
The FEVi varied widely between the patients in our study. It ranged from 50-130% 
at the start to 22-140% at the end of the two year study period. 
In our study, high dosages of both an adrenergic and an anticholinergic agent were 
given. It is possible that the reproducibility of bronchodilating responses is worse 
when only one drug is given, when lower dosages are used, or when the bronchodi-
lating responses are handled as a 'all-or-nothing' phenomenon (no response or a clear 
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response) (24). From the study of Lindgren et al. in five asthmatic patients, it could 
be inferred that the reproducibility of the bronchodilating response decreased (the CV 
increased by 6-22%), when instead of 2.25 mg, 0.25 mg terbutaline sulphate was ad-
ministered (10). 
The bronchodilator treatment regimen (continuous treatment or therapy on de-
mand) appeared to have no influence on the reproducibility of the bronchodilating re-
sponse. The only significant difference in CV between COPD patients treated con-
tinuously and those treated on demand (the CV of '% achievable') was probably an 
artifact. The reversibility at the start of the study appeared to be slightly higher in the 
on demand treated patients than in the COPD patients treated continuously. However, 
the baseline or prebronchodilator FEVi declined more rapidly during continuous 
bronchodilator treatment than during treatment on demand. This may have been the 
consequence of an increased exposure to allergens, cigarette smoke or other environ-
mental triggers during continuous bronchodilator treatment (17,18). As a conse-
quence of the decline in prebronchodilator lung function, the bronchodilating re-
sponse increased in the course of time when expressed as 'absolute', '% initial', '% 
predicted' or '% maximal', but it did not change when expressed as '% possible' or 
'% achievable'. This might indicate that the '% possible' or '% achievable' indices 
are more useful in following the degree of reversibility in the course of time than the 
other indices. 
The method in which bronchodilating responses should be expressed depends on 
the purpose of the test. From this study, it was concluded that the most common 
method of expressing bronchodilating responses ('% initial') appeared to be most de-
pendent on the prebronchodilator FEVi and had the lowest reproducibility of the 
bronchodilating response. The '% possible' (change as a percentage of the predicted 
minus the prebronchodilator value) and '% achievable' (change as a percentage of 
the maximal postbronchodilator minus prebronchodilator value) indices were least 
dependent on the prebronchodilator FEVi and had the best reproducibility of the 
bronchodilating response. In bronchodilator studies, the latter expression indices in-
crease the possibility of detecting differences in bronchodilating efficacy of different 
bronchodilator drugs. 
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4. Early detection of patients with fast progressive 
asthma or chronic bronchitis in general practice 
Abstract 
The morbidity and mortality due to asthma and chronic bronchitis arc still rising in several coun­
tries The aim of this study was to investigate whether early detection of patients with fast pro­
gressive asthma or chronic bronchitis in general practice was possible from a cross-sectional as­
sessment of symptoms, smoking behaviour, quality of lite, physical signs of the chest, allergy, and 
lung function Data of 162 patients who had participated in a long term randomised controlled in­
tervention study in general practice were analysed 56 out of the 162 patients showed fast pro­
gressive disease (FPD, a rapid annual decline in the forced expiratory volume in one second 
(FEVi) in combination with a high exacerbation rate) Measurements at the start of the study were 
used in a logistic regression analysis in order to detect the patients at nsk (with FPD) A lower 
maximal expiratory flow at 50% of expired volume (MEFso) was related to an increased risk of 
FPD in both asthma and chronic bronchitis (relative risks of 16 8 and 8 0 respectively, p<0 05) 
Most lung function indices, but also quality of life and pack years, were significant predictors of 
FPD in chronic bronchitis (p<0 05) However, it was not possible to detect FPD reliably with these 
predictors separately or even with the combination of several relevant clinical variables, 18% of the 
patients with chronic bronchitis and 22% of the patients with asthma were still misclassified 
It was concluded from this study that more than one measurement over time (monitoring) is 
necessary to detect the patients at nsk Momtonng should include assessments of objective ventila­
tory function indices (PEFR, FEVi or MEF50) 
4.1. Introduction 
Both asthma and chronic bronchitis arc considered to be progressive diseases in 
adulthood (1-3) Studies of the long-term course of asthma or chronic bronchitis 
showed that the annual decline in lung function was two to four times higher in pa­
tients than in random population samples (1-3) At an advanced stage of the disease, 
severe limitations in daily life may occur as a consequence of a low lung function 
level (4) In particular, patients with a rapid decline in lung function are at risk of dis­
ability or death at an early age due to chronic airflow obstruction. It has been hypo­
thesized that adequate treatment at an early stage might prevent or decelerate dete-
noration in patients with airflow obstruction (5) Therefore, early detection and treat­
ment of patients at nsk (1 e with a rapid decline in lung function) is important As 
most patients with airflow obstruction are treated in primary health care, general 
practitioners in particular should be able to detect these patients at nsk, preferably at 
an early stage It is unclear how this can be earned out easily and effectively In a 
randomised controlled intervention study in the Netherlands, the influence of bron-
* Originally published as Dompeling E, Van Gransven PM, Molema J, Verbeek ALM, Van Schayck CP, 
Van Weel С Early detecüon of patients with fast progressive asthma or chronic bronchitis in general 
practice ScandJ Prim Health Care 1992 10 143-150 
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chodilator monotherapy on the progression rate was assessed in 162 patients with as-
thma or chronic bronchitis during two years (6,7). A subgroup of 56 patients showed 
fast progressive disease (rapid annual decline in lung function, high number of 
exacerbations per year). The present study investigated the possibility of predicting a 
fast progression rate at an early stage. Data from a single cross-sectional assessment 
of symptoms, smoking behaviour, quality of life, physical signs, allergy, and lung 
function indices at the start of the study were used for this purpose. 
4.2. Methods 
Patients 
An extensive description was given previously of inclusion and exclusion criteria for 
patient selection (6,7). In summary: 29 general practitioners selected all their patients 
aged 30 and over with symptoms of asthma or chronic bronchitis. Only those patients 
who showed moderate airflow obstruction (FEVi or FEVi/VC had to be two SD 
below their predicted value, but more than 50% of predicted value (8)) and/or bron-
chial hyperresponsiveness to histamine (PC20 ^8 mg/ml) were included. The criteria 
for diagnosis of asthma or chronic bronchitis were based on the standards of the 
American Thoracic Society (4,7). During the two-year study period, patients only re-
ceived monotherapy with inhaled bronchodilators (salbutamol or ipratropium bro-
Table 4.1 Characteristics at the start of the study of patients with FPD and SPD. SD in 
parenthesis. Differences between patients with SPD and FPD were tested by the 
chi-square test (dichotomous variables) or unpaired Student's t-test (continuous 
variables). 'FEVi decline' and 'exacerbations' were measured during the study. 
Characteristic 
Number 
Age (years) 
Sex (M/F) 
Pack years 
Current smoker (+/-) 
Symptom score 
Quality of life 
- pain score 
- energy score 
Allergy (+/-)# 
FEVi %pred 
FEV1/IVC (%) 
BDR-FEVi (%) 
PC20 (mg/ml) ## 
FEVi decline (ml/yr) 
Exacerbations (no /yr) 
Asth 
FPD 
28 
49 
12/16 
13 
11/17 
1 4 
12 
30 
13/15 
67 
57 
15 
1 9 
-165 
1 3 
(12) 
(14) 
(1 4) 
(26) 
(39) 
(17)* 
(15) 
(9) 
(2 6) 
(132) " 
(0 9)** 
ma 
SF 
33 
50 
16/17 
12 
14/19 
1 1 
6 
27 
11/21 
78 
61 
17 
27 
* +49 
0 6 
»D 
(13) 
(16) 
(1 4) 
(16) 
(30) 
(21) 
(18) 
(13) 
(1 9) 
(177) 
(0 7) 
Chronic bronchitis 
FPD 
28 
52 
16/12 
23 
20/8 
1 8 
19 
35 
2/24 
70 
63 
7 
8 6 
-124 
1 6 
(10) 
(17) 
(18) 
(29) 
(37)* 
(14)** 
(13) 
(4) 
(2 4)* 
(167)** 
(1 2)*** 
SPD 
73 
53 
45/28 
16 
43/30 
1 1 
10 
17 
15/58 
82 
66 
7 
16 
+31 
0 5 
(13) 
(16) 
(1 6) 
(19) 
(27) 
(16) 
(12) 
(7) 
(16) 
(143) 
(0 6) 
*p<0 05, *"p<0 01, *"*p<0 001 
# Allergy was defined as at least one positive test out of seven RAST 
## geometric mean PC20 values are given 
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mide). 162 Patients participated during the two-year study period. No corticosteroids, 
theophyllines or cromoglycate were permitted. The study was approved by the Medi­
cal Ethics Committee of the University of Nijmegen. All patients gave informed con­
sent. The characteristics of patients with FPD and slowly progressive disease (SPD) 
are shown in Table 4.1. 
Initial assessments 
• Questionnaire on respiratory symptoms, duration of the disease, smoking history and 
quality of life. The severity of respiratory symptoms was assessed by means of the 
questionnaire of the Medical Research Council (Dutch version) in a score of 0-8 
(6,7). The duration of the disease was defined as the current age minus age at which 
the first symptoms of asthma or chronic bronchitis appeared. The smoking history 
was assessed in pack years. Current smoking behaviour (smoker or non-smoker) was 
documented. The quality of life was assessed by using the Nottingham Health Profile 
(Dutch version, part one) (7). The items 'energy score' and 'pain score' (total range 
from 0-100%) were used in the analysis. A higher percentage corresponds with a lo­
wer experienced quality of life. 
• Lung function measurements. All lung function measurements were carried out by 
two laboratory assistants. The bronchodilator medication was discontinued at least 
eight hours before the measurements. Firstly, static spirometrie indices (FRC, IVC, 
RV, TLC) were assessed with the wet Gould® spirometer. Secondly, dynamic spiro­
metry (FVC, FEVi, PEFR, MEF50, FIVi) was carried out with the Microspiro HI-
298® (Chest Corporation, Japan) (9). Thirdly, the bronchial (hyper)responsiveness to 
histamine was measured according to the method described by Cockcroft et al. and 
expressed as the provoking concentration of histamine in mg/ml producing a 20% 
fall in FEVi (PCzo-histamine values) (7). Finally, the bronchodilating response 
(BDR-FEVi) was assessed 60 minutes after the inhalation of 400 μg salbutamol and 
80 μg ipratropium bromide (metered dose aerosols). The response in FEVi was ex­
pressed as a percentage of the predicted or the prebronchodilator value. 
• Physical examination. Physical examination of the chest (inspection, percussion and 
auscultation) was carried out by two trained medical doctors. Each of the following 
abnormal findings counted for one point in the physical sign score (maximum of 9 
points): barrel-shaped chest, low-standing diaphragm, decreased diaphragmatic ex­
cursions, decreased expiratory breath sounds, prolonged expiratory phase, wheezing, 
noisy inspiratory sounds without auscultation, fine crackles and coarse crackles. 
• Allergy. Patients were considered allergic if at least one of a 7-RAST tests was posi­
tive (RAST® test, Pharmacia, Sweden. Pollen: weeds, grasses, trees; Animals: cats 
and dogs; house dust mite; Aspergillus fumigates) (7). 
Follow-up measurements 
Assessments of the FEVi were repeated at six-month intervals during the two-year 
study period. Besides, the number of exacerbations during the two-year period were 
recorded by the general practitioner. Exacerbations were defined according to 
Fletcher et al. with small modifications of Boman et al. (10). 56 of the 162 patients 
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had fast progressive disease (FPD), which was defined as the combination of A. 
(lung function criteria) and B. (criteria for exacerbations): 
A. an annual decline in FEVi of at least 80 ml/yr and/or irreversibility of airway ob­
struction to a bronchodilator (the increase in FEVi, 60 minutes after maximal 
bronchodilatation with 80 μg ipratropium bromide and 400 μg salbutamol was 
smaller than 10% of the prebronchodilator value during at least one of the six 
test occasions during two years). 
B. total number of exacerbations of at least one per year and/or total duration of 
exacerbations of at least three weeks per year. 
All patients who did not meet the criteria for FPD had a slowly progressive disease 
(SPD). 
Analysis 
The annual decline in FEVi was estimated by linear regression of seven assessments 
during two years. Variables measured at the start of the study were used as predictors 
of FPD in a logistic regression analysis (11). For this purpose, all parameters were di­
chotomised (< mean value / > mean). The relative risks, the 95% confidence limits 
and the statistical significance were calculated for all predictors separately (univari­
ate analysis) and for a combination of clinically relevant predictors (multivariate ana­
lysis). Receiver-operating characteristic (ROC) curves were calculated for the multi­
variate models in asthma and chronic bronchitis by plotting sensitivity (vertical axis) 
against 1-specificity (horizontal axis)(l 1). The area under the ROC-curve (AUC) is a 
measure for the predictive value; it is optimal when AUC is 0.95-1.00, minimal when 
AUC is near 0.50 (11). The AUC represents the probability of ranking patients cor­
rectly as having FPD or SPD. 
4.3. Results 
The relative risks (95% confidence limits in brackets) and the statistical significance 
of all separate predictors are presented in Table 4.2. In asthma, the MEF50 was the 
only statistically significant predictor of FPD (p<0.05). The risk of FPD in patients 
with a MEF50 below 1.7 1/s was almost four times as high as in patients with a MEF50 
above 1.7 1/s. In chronic bronchitis patients, a higher number of pack years and a 
lower reported quality of life (energy score) were associated with an increased risk of 
FPD. Moreover, a lower ventilatory function (PEFR, FEVi, MEF50) a higher 
FRC/TLC and a lower degree of bronchial responsiveness to histamine (PC20) were 
related to an increased risk of FPD in chronic bronchitis. In both asthmatic and 
chronic bronchitis patients, the MEF50 was the strongest predictor (relative risk of 3.9 
and 4.5 respectively). 
The results of the multivariate analysis are shown in Table 4.3. In asthmatic pa­
tients, the duration of the disease was also a significant predictor of FPD after adjust­
ing for the MEFso- No other variables at the start of the study in asthma were statisti­
cally significant predictors of FPD. In chronic bronchitis patients, age, pack years 
and the MEF50 were independent predictors of FPD (p<0.05). By means of a step-
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Table 4.2 The predictive value of all predictors separately (univariate logistic regression 
analysis). Relative risks (95% confidence limits in brackets) and the statistical significance 
are shown. 
Parameter Relative risk p-value 
Asthma 
Age (<49 yrs/>49) 
Sex (M/F) 
Height (<1 7m/>1 7) 
Pack years (<12/>12) 
Current smoking (+/-) 
Duration of disease (<22 yrs/>22) 
Symptom score (<5/>5) 
Quality of life 
- energy score (<29/>29) 
- pain score (<9/>9) 
Physical sign score (<1 3/>1 3) 
Allergy (+/-) 
FEVi (<73% pred/>73) 
BDR-FEVi (<16%/>16) 
PEFR (<5 1 s_1/>5) 
MEF50(<1 7 ls" 1 />1 7) 
PC20 (<3 2 mg т Г 1 / > 3 2) 
TLC (<6 l/>6) 
FIV1/IVC (<83%/>83) 
FRC^LC (<54%/>54) 
Helium slope (<3% s 1/>3) 
Chronic bronchitis 
Age (<52 yrs/>52) 
Sex (M/F) 
Height (<1 7m/>1 7) 
Pack years (<18/>18) 
Current smoking (+/-) 
Duration of disease (<20 yrs/>20) 
Symptom score (<5/>5) 
Quality of life 
- energy score (<22/>22) 
- pain score (<13/>13) 
Physical sign score (<1 3/>1 3) 
Allergy (+/-) 
FEVi (<78% precV>78) 
BDR-FEVi <<8%/>8) 
PEFR (<6 1 s"1/>6) 
MEF5o(<2 1 ls"1/>2 1) 
Р С г о ^ І б т д т І
 1/>16) 
TLC (<6 l/>6) 
FIV1/IVC (<86%/>86) 
FRC^LC (<52%/>52) 
Helium slope (<3% s"1/>3) 
142 
0 80 
0 98 
0 75 
0 92 
1 81 
0 67 
1 06 
0 99 
0 67 
1 52 
2 35 
1 14 
0 75 
3 90 
1 33 
0 94 
1 36 
0 82 
0 67 
1 25 
0 83 
2 22 
0 33 
1 70 
064 
0 40 
0 31 
064 
0 47 
0 6 4 
4 4 4 
0 66 
2 92 
4 4 8 
2 80 
1 53 
0 70 
0 31 
0 41 
(0 51-3 90) 
(0 29-2 19) 
(0 35-2 72) 
(0 27-2 08) 
(0 30-2 78) 
(0 64-5 10) 
(0 24-1 87) 
(0 36-3 09) 
(0 29-3 38) 
(0 23-1 94) 
(0 54-4 24) 
(0 81-6 84) 
(0 41-3 18) 
(0 27-2 08) 
(1 26*12 1) 
(0 48-3 70) 
(0 34-2 58) 
(0 49-3 74) 
(0 30-1 89) 
(0 24-1 89) 
(0 52-3 00) 
(0 34-2 00) 
(0 91-5 40) 
(0 13-0 81) 
(0 71411) 
(0 27-1 54) 
(0 15-1 07) 
(0 12-0 76) 
(0 27-1 54) 
(0 19-1 15) 
(0 27-1 54) 
(1 61-12 2) 
(0 27-1 58) 
(1 11-7 71) 
(1 53-13 06) 
(1 10-7 17) 
(0 64-3 68) 
(0 29-1 70) 
(0 12-0 78) 
(0 17-1 03) 
0 50 
0 66 
0 97 
0 58 
0 88 
0 26 
0 44 
0 92 
0 98 
0 46 
0 43 
012 
0 80 
0 58 
0 02 
0 58 
0 91 
0 55 
0 69 
0 45 
0 61 
0 68 
0 08 
0 02 
0 24 
0 32 
0 07 
001 
0 36 
0 1 0 
0 36 
0 004 
0 35 
0 03 
0 006 
0 03 
0 34 
0 44 
0 01 
0 06 
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Table 4.3 The predictive value of the combination of several clinically relevant predictors 
(multivariate logistic regression analysis). Relative risks (95% confidence limits in 
brackets) and the statistical significance are shown. 
Parameter Relative risk p-value 
Asthma 
Age (<49 yrs/>49) 
Pack years (<12/> 12) 
Current smoking (+/-) 
Duration of disease (<22 yrs/>22) 
Symptom score (<5/>5) 
Quality of life 
- energy score (<29/>29) 
- pain score (<9/>9) 
Physical sign score (<1 3/>1 3) 
Allergy (+/-) 
BDR-FEVi (<16%/>16) 
MEFsotel 7 ls" 1 />1 7) 
PC20 (^3 2 mg т Г 1 / > 3 2) 
Chronic bronchitis 
Age (<52 yrs/>52) 
Pack years (<18/> 18) 
Current smoking (+/-) 
Duration of disease (<20 yrs/>20) 
Symptom score (<5/>5) 
Quality of life 
- energy score (<22/>22) 
- pain score (<13/>13) 
Physical^ign score (<1 3/>1 3) 
Allergy (+/-) 
BDR-FEVi (<8%/>8) 
MEF50(<2 1 ls"1/>2 1) 
Р С г о К І б т д т І
 1/>16) 
1 04 
1 01 
0 75 
5 25 
0 33 
2 16 
1 16 
0 74 
1 94 
1 83 
168 
1 19 
1 07 
0 19 
1 27 
0 68 
0 62 
0 35 
0 40 
0 71 
0 66 
1 02 
7 98 
131 
(0 95-1 13) 
(1 19-5 38) 
(0 15-3 83) 
(1 22-22 5) 
(0 07-1 45) 
(0 37-12 5) 
(0 20-6 82) 
(0 15-3 53) 
(0 35-10 6) 
(0 44-7 61 ) 
(2 6-107 4) 
(0 32-4 35) 
(0 52-3 00) 
(0 13-0 81) 
(0 71-411) 
(0 27-1 54) 
(0 15-1 07) 
(0 12-0 76) 
(0 27-1 54) 
(0 19-1 15) 
(0 11-3 83) 
(0 34-3 04) 
(1 76-36 3) 
(0 40-4 34) 
0 41 
0 99 
0 73 
0 026 
014 
0 39 
0 87 
0 70 
0 45 
0 40 
0 003 
0 80 
0 026 
0 020 
0 67 
0 48 
0 42 
0 08 
0 22 
0 58 
0 64 
0 98 
0 007 
0 66 
wise forward procedure, it was investigated whether the remaining variables, which 
were not included in the multivariate model added significantly to the predictive 
value of the multivariate model. It appeared that in asthmatic patients no variables 
entered the model. In chronic bronchitis patients, only the FIVi/IVC was added to the 
other variables already in the model (Relative risk=0.25 (95% confidence limits 0.07-
0.92), p=0.033). 
The ROC-curves of the multivariate models in asthma and chronic bronchitis are 
shown in Figures 4.1 and 4.2, respectively. The AUC was 0.78 in asthma and 0.82 in 
chronic bronchitis. This implies that (100-78)%=22% of the patients with asthma 
and (100-82)%= 18% of the patients with chronic bronchitis are misclassified in the 
FPD or the SPD category. Adding the FIVi/IVC to the multivariate model in chronic 
bronchitis did not significantly enlarge the AUC (AUC was 0.85, p=0.28). 
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Figure 4.1 The Receiver-Operating Characteristic (ROC) curve of the combination of 
clinically relevant predictors in asthma. 
Sensitivity 
100 
80 
60 
¿0-
20 
80 100 
1-specificity (%) 
4.4. Discussion 
Morbidity and mortality due to asthma and chronic bronchitis are still rising in sev-
eral countries (12,13). Underdiagnosis and undertreatment of asthma and chronic 
bronchitis have been reported in general practice (6,14). Various factors at both pa-
tient and doctor level may be responsible for this situation (14,15). Moreover, there 
are indications that certain bronchopulmonary drugs may be involved in the increase 
of morbidity and mortality (7,16). Continuous monotherapy with bronchodilators, 
though effective in relieving symptoms, appeared to have an accelerating influence 
on the long-term progression of asthma and chronic bronchitis (7). The current un-
derstanding that inflammation plays a major role in the pathophysiology of airway 
obstruction led to a shift in treatment policy towards the early introduction of inhaled 
steroids (17). This study deals with the early detection in general practice of patients 
at risk, i.e. with a high annual decline in ventilatory function and a high number of 
exacerbations per year. These patients with FPD are at risk of disability or death due 
to chronic airway obstruction at an early age. There is evidence that early detection 
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Figure 4.2 The Receiver-Operating Characteristic (ROC) curve of the combination of 
clinically relevant predictors in chronic bronchitis* 
Sensitivity (%) 
100-1 
80-
60-
¿o-
20 
80 100 
1-specificity (7.) 
" The curves of a model with the FIV1/IVC ( - ) and without this parameter ( • ) are shown 
of these patients is useful. A trial with an inhaled corticosteroid (beclomethasone di-
propionate of 800 μg daily) during one year after the present study demonstrated that 
FPD was decelerated, particularly in asthma (18). From the present study, it appeared 
that one cross-sectional assessment of several clinically relevant variables was not 
enough to detect all patients at risk already at an early stage. 18-22% of the patients 
were still misclassified. Burrows et al. investigated the predictive value of screening 
spirometry for the annual decline in FEVj in a sample from the general population 
( 19). They also observed that one assessment of spirometry was not enough to detect 
all patients at risk, particularly in women. More measurements in time would prob­
ably make the detection more reliable, i.e. monitoring of patients with asthma and 
chronic bronchitis. A fast progression in the patients of this study was not accompa­
nied by a worsening of symptoms. This may indicate that (change of) symptoms 
poorly reflect(s) the severity and progression of airway obstruction. Therefore, meas­
urements of ventilatory function are essential in following the course of asthma and 
chronic bronchitis (19) and will greatly improve the quality of care in chronic respir­
atory disorders. 
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The patients in our study were not a selected group of patients but were repre­
sentative of the adult patient population (30 years and over) with asthma and chronic 
bronchitis in 29 general practices (6,7). It may be argued that the definition of FPD in 
this study was rather subjective. However, we also carried out multiple linear regres­
sion, using the annual decline in FEVi, the number and duration of exacerbations as 
separate dependent variables. Almost the same variables as in the logistic regression 
analysis appeared to be of significance. The annual decline in FEVi is the most im­
portant measure for progression in studies on this subject (1-3). The number of 
exacerbations per year is an important measure for the clinical severity of the disease 
(10) and it was also related to the annual decline in lung function (3). To be sure 
about the progressive nature of the disease, FPD was defined in terms of both lung 
function decline (physiological parameter) and exacerbation rate (clinical parameter). 
In our study, several factors in asthma and chronic bronchitis were related to an in­
creased risk of FPD. In asthma, a shorter duration of the disease (current age minus 
the age at which the first symptoms occurred) was related to a higher occurrence of 
FPD. Although asthma is often looked upon as a disease of the young, it is possible 
that symptoms of asthma do not manifest themselves before the age of 40 or 50 (4). 
This late-onset type of asthma may have a more progressive character. It is probably 
this type of asthma that explained our finding that a shorter duration of the disease 
was a risk factor for FPD. In chronic bronchitis, a higher number of pack years (>18) 
was a risk factor for FPD. This is not strange in a disease in which smoking is 
thought to be the main aetiologic factor (4). This finding once again stressed the im­
portance of quitting or reducing smoking. The general practitioner plays a crucial 
role in achieving this difficult goal. In both asthma and chronic bronchitis, a lower 
ventilatory function was accompanied by an increased occurrence of FPD. This sug­
gested that airway obstruction itself is a risk factor for a more rapid progression of 
disease. This phenomenon was previously described by Burrows et al. as the 'horse-
racing effect' (19). 
It was concluded that the early detection of patients who run the risk of develo­
ping fast progressive asthma or chronic bronchitis was hardly possible on the basis of 
one cross-sectional assessment of clinically relevant variables. Repeated measure­
ments (monitoring of patients) are necessary to make the detection more reliable. 
Monitoring patients with airway obstruction also implies assessments of ventilatory 
function. 
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5. Does bronchial hyperresponsiveness precede or 
follow airway obstruction in asthma or COPD?: 
Abstract 
The following hypothesis was tested The degree of bronchial hyperresponsiveness (BHR) is a risk 
factor for the progression of airway obstruction in asthma, while in COPD it reflects the existing 
airway obstruction The relationships between the (annual change in) PC20-histamine and the (an­
nual change in) FEW ι were investigated in a two-year prospective controlled study The FEV ι and 
the PC20-histamine were assessed at six-month intervals 183 Patients (74 asthma, 109 COPD) par­
ticipated The investigated relationships were assessed by means of multiple analysis of vanance 
(MANOVA) Patients used bronchodilator therapy alone No steroids were permitted during the 
study 
The results demonstrated that the PC20 at the start of the study was related to the subsequent an­
nual decline of FEVi in asthma (r=0 32, p<0 05) but not in COPD (r=-0 10, p=0 885) Asthmatic 
patients with a PC20-value <2 mg/ml had an average decline of-118 ml/yr, those with a PC2ü-value 
>2 mg/ml of -27 ml/yr The change of PC20-histamine during the two-year study penod was related 
to the annual change of FEVi in COPD (r=0 45, p<0 05), but not in asthma (r=0 06, p=0 898) The 
disturbing influence of possible confounders was investigated and if necessary controlled for (age, 
sex, height, past and current smoking, allergy, FEV], bronchodilator response, PC20, exacerbations 
and the bronchodilator treatment during the study) 
It was concluded that BHR, assessed with the РСго-Ьіstamme, is involved in the progression of 
airway obstruction in asthma In COPD, however, the degree of BHR probably only reflects the de 
gree of existing airway obstruction 
5.1. Introduction 
Nonspecific hyperresponsiveness of the bronchi (BHR) is regarded as a hallmark of 
asthma (1,2) and is often present in Chronic Obstructive Pulmonary Disease (COPD) 
(3). The degree of BHR correlates with the seventy of the disease in terms of treat­
ment requirement in asthma (2,4) and of ventilatory function impairment in both as­
thma (5,6) and COPD (7) An important question is whether BHR is a risk factor for 
the progression of airway obstruction in asthma and COPD (8). In several studies, a 
relationship was found between BHR and the annual decline in ventilatory function 
(9-13) In many of these studies, however, BHR was assessed at the end of the study 
penod Therefore, it was not clear whether BHR preceded or followed the loss in 
lung function (8) BHR may be a nsk factor for the decline in lung function Particu­
larly in asthma, BHR is related to inflammation of the airways Release of eosino­
philic proteins, oxygen radicals and proteolytic enzymes from vanous inflammatory 
cells may damage the epithelium and may increase BHR (14,15) Chronic inflamma-
* Submitted for publication as Dompeling E, Van Schayck CP, Molema J, Folgenng H, Van Grunsven 
PM, Van Weel С Does bronchial hyperresponsiveness precede or follow airway obstruction in asthma or 
COPD'' 
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tion may lead to structural changes such as hypertrophy of airway smooth muscle 
and thickening of the basement membrane (14,15) which may result in loss of lung 
function. On the other hand, the measurements of BHR may reflect the already exist­
ing airway obstruction. Particularly in COPD, the response to bronchodilator and 
bronchoconstrictor stimuli is known to be determined to a large extent by the geo­
metry of the airways (8,16-17). It has been suggested that the role of BHR in the pro­
gression of asthma and COPD may be different (8,18); BHR may be a risk factor for 
the progression of airway obstruction in asthma but not in COPD. 
The aim of this study was to test the hypothesis that BHR is a risk factor for pro­
gression of airway obstruction in asthma, while in COPD it only reflects the degree 
of existing airway obstruction. During two years, a prospective controlled study was 
carried out with 74 asthmatic patients and 109 patients with COPD. 
5.2. Methods 
Patients 
An extensive description of patient selection, in- and exclusion criteria of the two-
year study has been given before (19-21). In summary: 29 general practitioners were 
asked to select all their patients aged 30 and over with symptoms of asthma or 
COPD. Only those patients who showed moderate airway obstruction (FEVi or 
FEVi/EVC had to be two standard deviations below their predicted value but higher 
than 50% of the predicted value) and/or bronchial hyperresponsiveness to histamine 
(РСго <8 mg/ml) were included by the investigators. The predicted values were based 
on the equations of the European Coal and Steel Community (22). Exclusion criteria 
were: dependence on corticosteroids, chronic heart failure, malignant disorders or 
other severe, life-threatening diseases. A study of random samples of patients who 
refused to participate or who were excluded by their general practitioner for reasons 
other than their pulmonary disease revealed no differences in clinical characteristics 
between the patients in the study and the excluded subjects (19). Therefore, no re­
cruitment bias had been introduced in the selection procedure. The criteria for diag­
nosis of asthma and COPD was based on the standards of the American Thoracic So­
ciety (ATS) (1). Asthma was defined as the combination of (20,21): 1. Bronchial 
hyperresponsiveness to histamine (PC20 ^8 mg/ml); 2. Reversible obstruction (FEVi 
improved more than 15% of the prebronchodilator value, 60 minutes after the admin­
istration of 80 μg ipratropium bromide and 400 μg salbutamol); 3. Dyspnoea; 4. Al­
lergy and/or wheezing. 
COPD was defined as the combination of (20,21): 1. Chronic cough or chronic 
sputum production in at least three months during at least two consecutive years; 2. 
Continuous airway obstruction (FEVi <85% of the predicted value). 
Although separate features of asthma and COPD were not mutually exclusive (i.e. 
some patients with COPD had PC2o-values <8 mg/ml, some asthmatic patients suf­
fered from chronic cough), the combination of features was: no patients with asthma 
also had COPD and vice versa. The study was approved by the Medical Ethics Com­
mittee of the University of Nijmegen. All patients gave informed consent. 
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Treatment 
Patients were either treated continuously (salbutamol 400 μg or ipratropium bromide 
40 μg, four times daily) or 'on demand' (only dry powder inhalations of salbutamol 
or ipratropium bromide during periods of dyspnoea or exacerbations). Patients using 
ipratropium bromide during the first year crossed-over to salbutamol during the sec­
ond and vice versa. The treatment regimen (continuous or on demand) and the order 
of the drugs was determined by random allocation. In an eight-week wash-out period 
before the start of the study, bronchopulmonary medication other than the study 
medication was stopped (corticosteroids, sodium cromoglycate, theophylline, etc). 
Measurements 
Spirometry was carried out at the start of the study and after 1,6, 12, 13, 18 and 
24 months (7 measurements) with the Microspiro HI-298® (Chest Corporation, 
Japan) (23). Bronchodilator medication was discontinued at least eight hours before 
the spirometrie tests. On all occasions, each patient had to perform three satisfactory 
forced vital capacity (FVC) manoeuvres. Data were taken from the curve with the 
highest sum of FVC and FEVi. The bronchodilating response was measured by the 
relative increase in FEVi compared to the predicted value, 60 minutes after the inha­
lation of 400 μg salbutamol and 80 μg ipratropium bromide (both metered dose aero­
sols). Spirometrie assessments and measurements of the PC2o-histamine were carried 
out in stable periods of the disease, at least six weeks after an exacerbation. 
BHR to histamine was assessed according to the method described by Cockcroft 
et al. (2) at the start, and after 6, 12, 18 and 24 months. Subjects first performed spi­
rometry correctly three times on the Microspiro HI-298®. An aerosol of buffered 
saline was then inhaled, followed by aerosols of histamine acid phosphate in dou­
bling concentrations from 0.03 to 32 mg/ml at five minute intervals. Spirometry was 
repeated once after 30, and after 90 seconds following each inhalation. The inhala­
tions of histamine were discontinued when there was a fall in FEVi of 20% of the 
value before saline inhalation or when 32 mg/ml of histamine had been administered. 
The 20% fall had to be found during either the 30 or the 90 second test after each 
dose. The histamine provocation test was not performed when the FEVi was below 
50% of the predicted value. 
At the start of the study, presence of allergy (7-RAST tests, Pharmacia, Sweden. 
Pollen: weeds, grasses, trees; animals: cats and dogs; house dust mite; Aspergillus 
Fumigatus) was assessed. Patients were considered allergic if at least one of the 
seven tests was positive. Smoking history was retrospectively assessed in pack years. 
During the study, the number of exacerbations was recorded by the general practi­
tioner. Current smoking habits (number of cigarettes smoked per day) were recorded 
by the patients in a weekly diary. 
Analysis 
Multiple analysis of variance (MANOVA) was applied to assess the following rela­
tionships: 
1. between the PC20 and the FEVi at the start of the study (cross-sectional assess­
ments); 
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2. between the PC20 at the start of the study and the subsequent annual decline in 
FEVi; the annual decline in FEVi was estimated by linear regression of FEVi in 
the course of time. The PC20 was handled continuously (l0log normal) and dicho-
tomously (< mean / > mean). 
3. between the annual change of PC20 and the annual decline in FEVi during the 
study. The annual change of PC20 was estimated by linear regression of 10log PC20 
in the course of time. 
A possibly confounding influence of the following covariates on the above men-
tioned relationships was investigated: age, sex, height, allergy, pack years, smoking, 
number of exacerbations per year, bronchodilating response, treatment regimen dur-
ing the study and (dependent on the investigated relationship) initial FEVi and PC20 
(10log transformed). When a covanate was to some extent related to the dependent 
variable (p<0.10) it remained in the multivariate model in order to correct for a poss-
ibly confounding influence. 
Two-sided p-values <0.05 were considered statistically significant. 
5.3. Results 
Clinical characteristics 
At the start of the study, patients with asthma were characterized by a lower number 
of smokers, less pack years, more allergic patients, a higher reversibility of obstruc-
tion and a severer bronchial hyperresponsiveness than patients with COPD (Table 
5.1). 
Table 5.1 Clinical characteristics of patients with asthma and COPD in this study. The 
differences between asthma and COPD were tested by means of the unpaired Student's 
t-test (normally distributed variables) or by the chi-square test (class variables). Standard 
deviations are given in parentheses. 
Variable 
Number 
Age (years) 
Sex (M/F) 
Smoking 
- current 
- ex 
- never 
Pack years 
Allergy (+/-)# 
FEVi (% pred) 
Bronchodilating response (%) 
PC20 (mg/ml)## 
Asthma 
74 
51 
34/40 
29 
24 
21 
13 
25/48 
73 
15 
24 
(13) 
(16) 
(21) 
(10) 
* 
** 
# 
*** 
tt* ## 
*» »» 
COPD 
109 
53 (13) 
66/43 
65 
31 
13 
19 (17) 
16/91 
78 (17) 
7 (6) 
140 
* p < 0 05. " * p < 0 01. * * * p<0 005. * * * * p < 0 0001 
# Allergy was defined as at least one positive test out of seven RAST 
## geometric mean PC20-values are given 
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Cross-sectional assessments 
At the start of the study, a significant relationship existed between the PC20 and FEVi 
(cross-sectional assessment). However, the relationship was stronger in COPD 
(r=0.71, p<0.0001 ) than in asthma (r=0.51, p<0.01 ). 
The relationship between the initial PC20 and the subsequent annual 
decline in FEVi 
When the PC20 at the start of the study was related to the subsequent annual decline 
in FEVi, a significant relationship was found in asthma (r=0.32, p<0.05) but not in 
COPD (r=-0.10, p=0.885). In asthma, the annual decline in FEVi in patients with a 
PC20 ^2 mg/ml was -118 ml/yr but only -27 ml/yr in those with a PC20 >2 mg/ml 
(Table 5.2). In patients with COPD, the annual decline in FEVi of -83 ml/yr in pa-
tients with a PC20 ^8 mg/ml was not different from the decline of -90 ml/yr in those 
with a PC20 >8 mg/ml (Table 5.2). 
Table 5.2 The annual decline in FEVi in patients, dichotomized according to their PC20 at 
the start of the study (< rounded mean /> rounded mean). The annual decline in FEVi 
between the two PC20-classes was statistically compared by the unpaired Student's 
t-test. Standard error of the mean between parenthesis. 
Asthma 
Change in FEVi (ml/yr) 
COPD 
Change in FEVi (ml/yr) 
PC20-histamine 
> 2 mg/m < 2 mg/ml 
-27(51) -118(39) 
(n=29) (n=37) 
PC20-histarTiine 
> 8 mg/ml < 8 mg/ml 
-90(31) -83(47) 
(n=71) (n=26) 
p-value 
0 042 
p-value 
0 885 
The relationship between the annual change in PC20 and the annual 
decline in FEVi 
Only in patients with COPD was the annual change of the PC20 significantly related 
to the annual decline of FEVi (r=0.47, p=0.048) (Figures 5.1 and 5.2). In asthma, no 
relationship was found (r=0.06, p=0.898). 
Confounding factors 
The bronchodilating response (reversibility of obstruction) at the start of the study 
was to some extent related to the decline in FEVi in both asthma (estimate +3.1 (SEM 
1.6) ml/yr, p=0.061) and COPD (estimate +3.2(1.8), p=0.069). No other covariates 
(e.g. the FEVi at the start of the study or allergy) were related to the annual decline in 
FEV). Smoking was not a confounder in COPD as neither in the group as a whole 
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Figure 5.1 The relation between the annual change of the PC20 and the annual decline of 
FEVi in asthma. The regression line is not depicted, because the estimate did not differ 
significantly from zero.* 
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nor in the current smokers, the PC20 was related to the annual decline in FEVi 
(p=0.885 and p=0.825 respectively). 
In asthma, the annual change in PC20 was only related to smoking (estimate 
+0.80(SEM 0.33) doubling dosc/yr, p=0.020). In COPD, the annual deterioration in 
PC20 was larger in patients with a higher number of exacerbations per year (estimate 
-0.37(SEM 0.10), p=0.0009). In MANOVA, the investigated relationships were ad-
justed for these possible confounders. 
5.4. Discussion 
The present longitudinal study demonstrated an important difference in BHR be-
tween asthmatics and patients with COPD. The PCzo-histamine at the start of the 
two-year study was related to the subsequent annual decline in FEV] in asthma but 
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Figure 5.2 The relation between the annual change of the PC20 and the annual decline of 
FEVi in COPD. * 
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Π 
0 -
- 1 -
-1000 ι 1— 
-800 -600 -¿00 -200 0 200 ¿00 Change FEV, (ml/yr) 
* change PC20 =-0 047 + 0 00048 change FEVi (r=0 45, p=0 022) 
not in COPD. Moreover, changes in PC20 during two years were closely related to the 
changes in FEVi in COPD but not in asthma. These findings supported the hypo-
thesis that the degree of bronchial hyperresponsiveness (BHR) is a risk factor for the 
progression of airway obstruction in asthma, while in COPD it reflects the existing 
airway obstruction. It might indicate that BHR is a 'cause' of airflow obstruction in 
asthma whereas it is a 'consequence' of airflow obstruction in patients with COPD 
(8). It also suggests distinctive mechanisms of BHR in asthma and COPD (18). 
There is currently a lot of interest in the similarities and discrepancies in BHR be-
tween asthma and COPD (24). In both asthma and COPD, an increased response to 
histamine or methacholine might be present ( 1 ), although BHR is more characteristic 
for asthma than for patients with COPD. Asthmatics and patients with COPD differ 
in the shape of the dose-response curve to histamine or methacholine (25). In asthma, 
both a leftward shift of the dose-response curve ('hypersensitivity') and a lift of the 
maximal response plateau (increase in maximal degree of airway narrowing) occur 
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(26), while in COPD, BHR is often only characterized by hypersensitivity (27). A 
leftward shift might be regarded as being the results of any augmentation of the air-
way narrowing stimuli ('prejunctional mechanism'), elevation of the maximal re-
sponse plateau the result of any increase in the response to the effector organ ('post-
junctional mechanism') (25,28). The results of the present study might fit these dif-
ferent mechanisms in asthma and COPD. 
In the COPD patients of this study, the PC20 was largely determined by the geo-
metry of the airways. Indeed, a decreased airway calibre may be one of the mechan-
isms of BHR (29). As resistance in the airways is inversely proportional to the fourth 
power of the radius, a constriction of a narrow airway causes a much greater change 
in airway resistance than the same constriction of a more dilated airway (29,30). 
Therefore, patients with a more severe airway obstruction are more likely to respond 
to a certain concentration of histamine with a 20% fall in FEVi than others with a 
less severe obstruction. This might emphasize the role of prejunctional factors as the 
mechanism for BHR in COPD. In asthma, the degree of BHR is known to be related 
to the severity of the inflammatory processes underlying the disease. Release of eosi-
nophilic proteins, oxygen radicals and proteolytic enzymes from various inflamma-
tory cells may damage the epithelium and may increase BHR (14,15). Chronic in-
flammation may lead to structural changes such as hypertrophy of airway smooth 
muscle and thickening of the basement membrane (14,15) which may result in loss 
of lung function. This concept might be an explanation for BHR as a risk factor for 
decline in lung function and for the pre- and postjunctional mechanisms of BHR in 
asthma. 
The data of the present study suggested that assessments of the PC20 in asthma 
might indicate the risk on a rapid progression of airway obstruction. Patients with a 
PC20 ^ 2 mg/ml demonstrated an average 99 ml/year faster decline in FEV 1 than sub-
jects with a PC20 >2 mg/ml. The decline in FEVi of 118 ml/yr in the subjects with 
marked BHR was surprisingly high and may also reflect the failure of bronchodilator 
therapy in addressing the inflammatory processes in the airways of these patients 
(20,31). Therefore, asthmatic subjects with marked BHR run the risk of developing a 
progressive decline in lung function. In an early stage, these patients may be treated 
with drugs which are known to decrease BHR by modulating inflammatory pro-
cesses, inhaled corticosteroids, nedocromil or cromolyn sodium. A trial with inhaled 
corticosteroids after the present study demonstrated that the loss of lung function dur-
ing bronchodilators alone was reversed by inhaled corticosteroids, particularly in as-
thma (32). 
The results of the present study were based on multiple assessments of the PC20-
histamine and the FEVi in a controlled prospective study during two years. The in-
fluence of possible confounders such as initial FEVi level, degree of bronchodilating 
response, past and current smoking on the investigated relationships was assessed 
and if necessary controlled for. During the two-year study period, patients used the 
study medication of the bronchodilator intervention study and were not permitted to 
use sodium cromoglycate or corticosteroids. The patients' PC20 and FEVi were 
measured during stable periods of the disease, at least six weeks after an exacerba-
tion. The discriminating capacity in the analysis of decline in FEVi was high be-
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cause (20): a) a relatively large number of subjects participated; b) seven measure-
ments of the FEVi were used; c) the data of the FEVi fitted clearly in a linear model. 
On account of the high discriminating capacity, a study period of two years was suffi-
cient to demonstrate relationships between the annual changes in lung function and 
the (annual changes in) BHR. 
Definition criteria of asthma and COPD were not a confounder in this study. In 
COPD, 30% of the patients had a PC20 <8 mg/ml. The presence of a PC20 <8 mg/ml 
was only one of the diagnostic criteria for asthma and did not exclude a diagnosis of 
COPD. The patients in this study were representative of the patient population with 
asthma or COPD and mild to moderate airway obstruction (FEVi > 50% of the pre-
dicted value) (19). 
As far as we know there are no other controlled prospective studies on both as-
thma and COPD in which it was investigated whether BHR preceded or followed the 
progression of airway obstruction. However, one study on asthma (10) and some 
studies on chronic airway obstruction (9,11-13) investigated the relation between the 
BHR and the annual decline in ventilatory function. A drawback of many of these 
studies is that the BHR was assessed at the end of the study period. It this case it is 
not clear whether BHR was the 'cause' or the 'consequence' of the decline in lung 
function (8). In the study of Postma et al., 81 non-allergic patients with chronic air-
way obstruction were studied (11). The nonspecific bronchial hyperresponsiveness, 
measured at the start of the study, was related to an increased decline in FEV] in the 
smokers, but not in the ex-smokers. All their patients received regular bronchodilator 
therapy and had a more severe obstruction than our patients. Taylor and coworkers 
assessed the relationship between BHR (assessed at the end of the study (8)) and the 
annual decline in FEVi in 227 smoking or ex-smoking men (13). They found that in-
creased BHR (assessed at the end of the study) was related to an accelerated annual 
decline in FEVi in smokers but not in ex-smokers. It is not clear from their study if 
they controlled for the initial FEV] level and other possible confounding factors. Re-
cently, Hopp et al. demonstrated that enhanced reactivity to methacholine preceded 
the onset of clinical asthma (33). Although their study is not comparable with ours 
(asthmatic subjects were older and had more airway obstruction), it also suggested 
that BHR is a risk factor in the development of asthma. In a recent review, Burrows 
and Martinez concluded that existing data do not indicate that BHR is a risk factor 
for COPD (34). 
The relation between the annual change in BHR and the annual decline in lung 
function has been studied even less than the relationship between the initial PC20 and 
the annual decline in lung function. Short-term trials with inhaled corticosteroids in 
asthma demonstrated that improvements in BHR by steroids were generally not re-
lated to the increases in lung function (35-38). No conclusions can be drawn from 
these short-term trials with corticosteroids, but they suggested that the course of 
BHR in asthma was independent of the development of airway obstruction. In a pros-
pective study with smokers and ex-smokers, Lim et al. observed that changes in 
PC20-histamine over four years were significantly related to the changes in FEVi 
(39). This indicated the importance of baseline airway geometry for the PC20 in these 
subjects. Although it is not mentioned whether these subjects had COPD, smoking 
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and airway obstruction were present in most subjects and a history of asthma ex­
cluded. 
Data on the present study are in accordance with these latest suggestions and ob­
servations. The BHR as assessed with the PCio-histamine appeared to be a risk factor 
in asthma, but not in COPD. This may indicate a different pathogenetic mechanism 
and the existence of at least two separate diseases (40). 
It was concluded that BHR in asthma is involved in the progression of airway ob­
struction. However, in the COPD patients of the present study, BHR is not a risk fac­
tor for the annual decline in ventilatory function, but it reflects the degree of existing 
airway obstruction. 
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6. Inhaled beclomethasone improves the long-term 
course of asthma and COPD in comparison with 
bronchodilator therapy alone 
A prospective controlled study with beclomethasone dipropionate, salbuta-
mol and ipratropium bromide during three years* 
Abstract 
The effects of inhaled beclomethasone dipropionate (BDP) of 800 μg daily on the long-term course 
of asthma and Chronic Obstructive Pulmonary Disease (COPD) were investigated in a prospective 
controlled study dunng three years Dunng the first two years, patients were only treated with a 
bronchodilator (salbutamol or ipratropium bromide) 56 Patients (28 asthma, 28 COPD) with an 
unfavourable course of disease dunng bronchodilator therapy alone (an annual decline in the forced 
expiratory volume in one second (FEVi) of at least 80 ml/yr in combination with at least one 
exacerbation/yr) were selected for additional treatment with inhaled beclomethasone of 800 μg 
daily dunng the third year The FEVi and the provoking concentration of histamine that induces a 
20% fall in FEV] (PC20) were assessed at six-month intervals. 
In asthma, the annual decline in prebronchodilator FEVi of-158 ml/yr dunng bronchodilator 
therapy alone was followed by a significant increase of +562 ml/yr dunng the months 1 -6 of BDP 
treatment (p<0 0005) Dunng the months 7-12 of BDP, the FEVi declined slightly with 31 ml/yr 
which was not statistically different from the annual decline before steroid therapy (p=0 17) In 
COPD, the increase of +323 ml/yr dunng the months 1 -6 of treatment with BDP was different from 
the annual decline of -156 ml/yr before BDP (p<0 05) The PC20-histamine improved by 3 8 dou­
bling doses during the months 1-12 of BDP in asthma (p<0 05) but not in COPD The weekly 
measured peak-flow rate (PEFR) improved by 16 7% from the value at the start of BDP therapy in 
asthma (p<0 0009) and 4 5% in COPD (p<0 05). In companson with bronchodilator therapy alone, 
the number of exacerbations decreased by 0 7/yr m asthma (p<0 0001) but not in COPD In both 
asthma and COPD, the diurnal vanation of the PEFR and the seventy of weekly recorded symp­
toms diminished dunng BDP treatment (ρκΟ 05) 
It was concluded that inhaled BDP of 800 μg daily improved the course of asthma and COPD in 
companson with bronchodilator therapy alone The effects of BDP in patients with asthma were 
more pronounced than in COPD 
6.1. Introduction 
Both asthma and COPD are progressive diseases at an adult age (1-4). The decline in 
ventilatory function is on average two to four times higher in patients (1,2) than in 
random samples of the population (5,6). At an advanced stage of the disease, severe 
limitations in activities of daily life may occur as a consequence of a low ventilatory 
capacity (7). Patients with a rapid deterioration of pulmonary function are probably 
at risk for early disability or death from chronic airway obstruction (8). Some retro­
spective, uncontrolled studies suggested that corticosteroids might slow down the 
progression of chronic airway obstruction (9). Unfortunately, this suggestion has 
never been tested in long-term, prospective, controlled studies. Whether inhaled ste­
roids could improve the course of asthma and COPD in comparison with bronchodi-
* Originally published as Dompeling E, Van Schayck CP, Molema J, Folgenng H, Van Gransven PM, 
Van Weel Inhaled beclomethasone improves the course of asthma and COPD bur Respir J 1992,5 945-
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lator therapy alone was investigated in the present prospective controlled study. At 
an earlier stage, the patients in this study (28 asthma, 28 COPD) participated in a ran­
domised controlled intervention study with bronchodilators (10-12). During two 
years of treatment with a bronchodilator alone (salbutamol or ipratropium bromide), 
patients had demonstrated an average decline in FEVi of 160 ml/yr in combination 
with almost two exacerbations/yr. Therefore, in the third year, they were additionally 
treated with inhaled beclomethasone dipropionate (BDP) of 800 μg daily. In this 
study, the hypothesis that inhaled BDP is able to decelerate the annual decline in 
FEVi in comparison with bronchodilator therapy alone was tested. 
6.2. Methods 
Patients 
An extensive description of the patient selection in the preceding bronchodilator in­
tervention study was given elsewhere (10-12). In short: 29 general practitioners in 
the catchment area of the Nijmegen University were asked to select all their patients 
of 30 years and above with symptoms of asthma and COPD. Only those patients who 
showed mild to moderate airway obstruction (FEVi < FEVi %predicted (13) minus 
two standard deviations, but larger than 50% of the predicted value) and/or bronchial 
hyperresponsiveness to histamine (PC20 ^8 mg/ml) were included by the investiga­
tors. Patients, dependent on inhaled corticosteroids, with chronic heart failure, with 
malignant disorders or other severe life-threatening diseases were excluded. One 
hundred and sixty patients completed the bronchodilator trial. During the two years 
of bronchodilator treatment, a rapid decline in FEVi (>80 ml/yr) and a relatively high 
exacerbation rate (>1 per year) was observed in a subgroup of 56 patients (=35%). 
These patients were selected for additional treatment with inhaled BDP in the third 
year. The detailed selection criteria are shown in Table 6.1. The criteria for diagnosis 
of asthma or COPD were based on the standards of the American Thoracic Society 
(7). Asthma was defined as the combination of (10-12): 1. Bronchial hyperrespon­
siveness to histamine (PC20 ^8 mg/ml); 2. Reversible obstruction (FEVi improved 
more than 15% of the prebronchodilator value, 60 minutes after the administration of 
salbutamol 400 μg and ipratropium bromide 80 μg; 3. Dyspnoea; 4. Allergy and/or 
Table 6.1 Selection criteria of the patients with fast progressive disease, treated with 
BDP during the third year of study. Patients were selected on the basis of one criteria out 
of A. and one criteria out of В.: 
A — an annual decline in FEVi ^80 ml/yr, or 
— FEVi ^ FEVi %predicted - 2 SD and increase in FEVi <10%, 60 minutes after maximal 
bronchodilatation with salbutamol 400 цд and ipratropium bromide 80 μg, 
В — number of exacerbations >2 per year, or 
— duration of exacerbation(s) >3 weeks per year, or 
— 1 per year < number of exacerbations <2 per year (but an annual decline in FEVi 
>120 ml/yr), 
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wheezing. COPD was defined as the combination of (10-12): 1. Chronic cough or 
chronic sputum production in at least three months during at least two consecutive 
years; 2. Continuous bronchus obstruction (FEVi <85% of the predicted value). 
Although separate features of asthma and COPD were not mutually exclusive (i.e., 
some asthmatic patients had chronic cough, some COPD patients had a PC20 ^8 
mg/ml), the combination of features was: no patients with asthma could also have 
COPD and vice versa. The clinical characteristics of the patients are demonstrated in 
Table 6.2. The study was approved by the Medical Ethics Committee of the Univer-
sity of Nijmegen. All patients gave informed consent. 
Table 6.2 Clinical characteristics of the patients with asthma and COPD at the start of the 
three-year intervention study. Differences between asthma and COPD were statistically 
compared with the unpaired Student's t-test for normally distributed variables and with 
the chi-square test for dichotomous variables. Standard deviation between parenthesis 
(Abbreviations: BDR-FEVi is the increase in FEVi after bronchodilatation with 
ipratropium bromide 80 ]¡.g and salbutamol 400 цд; DI-PEFR is the diurnal PEFR index). 
Variable 
Number 
Age (years) 
Sex (M/F) 
Pack years 
Smokers (+/-) 
Cigarettes/day 
Allergy (+/-)# 
FEVi %pred 
FEV1/IVC (%) 
BDR-FEVi (%) 
DI-PEFR (%) 
PC20 (mg/ml) 
Asthma 
28 
49 (12) 
12/16 
13 (14) 
14/14 
3 4 (5 3) 
14/14 
67 (17) 
57 (15) 
14 (9) 
12 4 (8.0) 
0.8 
« 
## 
*** 
ft 
t 
ft* » 
COPD 
28 
54 (2) 
16/12 
23 (3) 
17/9 
8 9 (8.5) 
2/24 
70 (16) 
63 (13) 
7 (4) 
8 8 (5.2) 
6 2 
' p<0 05, **ρ<0 01,**·ρ<0.001 
t p=0 055 
# Allergy was defined as at least one positive test out of seven RAST 
Study design and treatment 
At the start of the three-year intervention study, the patients were randomly allocated 
to one of the two parallel treatment regimens; continuous or on demand therapy with 
a bronchodilator. The patients used salbutamol during one year and ipratropium bro­
mide during the other year. The sequence of the drugs was determined by random al­
location (10). During the third year, the 56 patients were additionally treated with 
BDP 800 μg daily in combination with salbutamol 1600 μg or ipratropium bromide 
160 μg daily (all dry powder inhalations). The bronchodilator inhaled during the sec­
ond year was also used in the third year. Once every three months, proper inhalation 
of the medication as well as compliance to the prescribed medication were checked. 
During the first two years of study, 27 of the 56 patients received bronchodilator 
therapy on demand (15 asthma, 12 COPD). The mean daily dose of salbutamol or 
ipratropium bromide in the patients treated on demand was 1.2 (SEM 0.3) in asthma, 
0.8 (0.2) in COPD. During the third year, 28 patients used salbutamol (15 asthma, 13 
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COPD), 28 ipratropium bromide (13 asthma, 15 COPD). During the third year, all 
patients used bronchodilators continuously, during the first and second year only the 
patients of the continuous treatment group. 
Pulmonary function, non-specific bronchial responsiveness 
The FEVi, the bronchial responsiveness to histamine (PC2o-histamine values) and the 
reversibility of airway obstruction were assessed at six-month intervals. All measure­
ments were carried out by two qualified laboratory assistants by means of the Micro­
spiro HI-298 (Chest Corporation, Japan) (14). No bronchodilator was inhaled during 
at least eight hours before the ventilatory function tests. First, dynamic spirometry 
was performed. The best of three forced expiratory manoeuvres, with the highest 
sum of the forced vital capacity (FVC) and FEVi, was used for data analysis. Sec­
ondly, bronchial responsiveness to histamine was measured according to the method 
described by Cockcroft et al. (15). Results were expressed as the provoking concen­
tration of histamine required to produce a 20% fall in FEVi (PC2o-value). After the 
FEVi had returned to the baseline value, the bronchodilating response was assessed 
60 minutes after the administration of ipratropium bromide 80 μg and salbutamol 
400 μg (metered dose aerosol). The bronchodilating response was expressed as the 
relative increase of FEVi compared to the predicted value of the FEVi. 
Peak-flow assessments 
Peak-flow measurements were performed with the Assess peak flow meter in the 
morning and in the evening, weekly at the same day and time (16). The highest value 
out of three measurements was taken for analysis. The diumal PEFR index (absolute 
difference between evening value and morning value divided by the highest value) 
was calculated. 
Exacerbations 
Exacerbations were defined according to Fletcher (1) with small modifications of 
Boman et al. (17). In case of an exacerbation, a ten day course with oral prednisone 
was given. 
Symptoms and adverse effects 
All patients made weekly recordings of the presence and severity of symptoms 
(cough, phlegm, dyspnoea) on a scale of 0-4. Adverse effects of medication (dyspho-
nia and oropharyngeal irritation) were recorded by the patients once every three 
months. Moreover, every six months, the presence and severity of oral candidiasis 
was assessed by means of a questionnaire. 
Smoking habits 
At the start of the study, the smoking history was assessed retrospectively in pack 
years. During the study, the average number of cigarettes smoked per day was also 
recorded in the diary on a weekly basis. 
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Analysis 
Values of outcome variables before the use of BDP were compared with data during 
steroid treatment. Differences were tested with the paired Student's t-test for nor­
mally distributed variables and chi-square test for dichotomous variables. Prior to 
analysis, the PC20 values were 2log transformed. The annual change in FEVi and 
PC20 was calculated by linear regression of FEVi and 2logPC2o in the course of time. 
A possible influence of the preceding bronchodilator treatment (continuous versus on 
demand) or of the bronchodilator in the third year (salbutamol versus ipratropium 
bromide) on the changes in outcome variables during steroid treatment was assessed 
by multiple analysis of variance (MANO VA). 
6.3. Results 
Forty-eight of the 56 patients completed one year of treatment with BDP. Reasons 
for drop-out were: refusal to inhale steroids (1 asthma, 1 COPD), bronchial carcino­
ma (1 COPD), chronic heart failure (1 COPD), persistent oral candidiasis and dys-
phonia (1 COPD), serious non-compliance (1 COPD) and personal reasons (1 as­
thma, 1 COPD). 
Asthma 
In asthma, the pre- and postbronchodilator FEVi increased by +0.281 (SEM 0.074) li­
ters and +0.100(0.053) liters respectively during the months 1-6 of steroid treatment 
(p=0.0009 and p=0.070. Figure 6.1). These increases in ml/yr were significantly dif­
ferent from the annual declines measured before steroid treatment {Table 6.3). Dur­
ing the months 7-12 of BDP treatment, the prebronchodilator FEVi deteriorated 
slightly with 31 ml/yr but tended to remain different from the annual decline of 158 
ml/yr before steroid treatment (p=0.170, Table 6.3). During BDP treatment, the 
PEFR increased by 16.7(5.7)% and the PC20 improved by 3.8(1.4) doubling doses 
from the value at the start of treatment with BDP (p=0.0009 and p=0.024 respective­
ly, Figures 6.2 and 6.3). The number of exacerbations per year, the severity of symp­
toms (cough, phlegm and dyspnoea) and the diumal variation of the PEFR decreased 
during treatment with BDP (Table 6.3). 
COPD 
In COPD, the effects of BDP 800 μg daily were less apparent than in asthma. Al­
though the prebronchodilator FEVi increased by +0.161 (SEM 0.091) liters in the 
first six months of treatment with BDP (this increase was different from the annual 
decline before the use of BDP, p=0.041), during the months 7-12 the FEVi decreased 
by -141 ml/yr (Table 6.3 and Figure 6.1). During the year's treatment with the ste­
roid, the peak flow increased by 4.5(2.3)% whereas the PC20 tended to decrease by 
1.8(0.9) doubling dose (p=0.055 and p=0.066 respectively, Figures 6.2 and 6.3). The 
average number of exacerbations per year was not influenced by BDP (Table 6.3). 
The severity of symptoms decreased during the months 7-12 of treatment (Table 
6.3). Moreover, BDP diminished the diumal variation of the PEFR (Table 6.3). 
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Table 6.3 Outcome variables in the period before, during 1-6 and 7-12 months of 
treatment with BDP. The values during SDP therapy were compared with the values 
before BDP treatment by the paired Student's t-test. The standard errors are between 
parenthesis. For exacerbations, the value in the whole year of BDP is shown. 
Variable 
Asthma 
Change FEVi-pre (ml/yr) 
Change FEVi-post (ml/yr) 
Change PC20 (doubling dose/yr) 
Diurnal PEFR index (%) 
Exacerbations (no /yr) 
Total symptom score 
Cough score 
Phlegm score 
Dyspnoea score 
COPD 
Change FEVi-pre (ml/yr) 
Change FEVi-post (ml/yr) 
Change PC20 (doubling dose/yr) 
Diurnal PEFR index (%) 
Exacerbations (no /yr) 
Total symptom score 
Cough score 
Phlegm score 
Dyspnoea score 
* p < 0 05, * * p < 0 005, " * " p < 0 0005, 
before 
-158 
-115 
-0 38 
132 
1 3 
3 9 
0 74 
0 71 
0 99 
-156 
-77 
-0 51 
108 
1 8 
62 
1 12 
1 00 
1 52 
(26) 
(23) 
(0 80) 
(1 6) 
(0 2) 
(0 8) 
(0 15) 
(0 12) 
(0 17) 
(26) 
(23) 
(0 46) 
(1 4) 
(0 3) 
(0 7) 
(0 17) 
(0 10) 
(0 16) 
Treatment with BDP 
1-6 months 
+562 
+201 
+4 44 
103 
0 6 
3 4 
054 
0 59 
0 85 
+323 
-10 
-3 70 
92 
1 8 
62 
1 11 
0 97 
1 51 
* * * * p < 0 0001 , tp<0 10 
(148)*** 
(106)* 
(3 60)t 
(1 4)* 
(0 1 * * * * 
(0 8)* 
(0 16)** 
(0 14)t 
(0 94) 
(183)* 
(64) 
(2 23) 
(1 3)*** 
(0 4) 
(0 8) 
(0 21) 
(0 13) 
(0 22) 
7-12 months 
-31 
-90 
+2 80 
8 9 
0 6 
3 5 
0 63 
0 62 
0 77 
-141 
-75 
-1 38 
8 6 
1 8 
57 
0 92 
084 
1 36 
(95) 
(51) 
(2 21)t 
(1 3)** 
(0 1)**** 
(0 8) 
(0 16) 
(0 17) 
(0 19)t 
(98) 
(50) 
(2 19) 
(1 2)** 
(0 4) 
(0 6)* 
(0 16)* 
(0 11)* 
(0 17)* 
Adverse effects 
During one year's treatment with steroids, 14% of patients developed oral candidiasis 
(Chi-square test, p=0.007). Moreover, complaints of dysphonia tended to increase 
during steroid treatment (Chi-square test, p=0.095). 
Influence of bronchodilator therapy preceding and during steroid treatment 
No influence of the treatment regimen in the first two years (continuous or on de-
mand) or of the type of bronchodilator (salbutamol or ipratropium bromide) in the 
third year could be demonstrated on the changes in outcome variables during steroid 
treatment. 
Smoking during the study 
In asthma, the proportion of current smokers/non-smokers was 14/14 during the first 
two years, 11/17 during the third year (p>0.05, two-samples, paired proportion test). 
Two of the three asthmatics who stopped smoking during the third year had smoked 
less than 0.1 cigarettes/day during bronchodilator treatment alone. Therefore, these 
patients were almost non-smokers during the three-year intervention study. In 
COPD, the proportion of current smokers/non-smokers was 19/9 during the first two 
years, 18/10 during the third year (p>0.05, two-samples, paired proportion test). One 
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Figure 6.1 Course of the pre- and postbronchodilator FEVi in asthma (top) and COPD 
during the three years of study. The standard errors of the mean are also represented. 
Differences in FEVi after six and 12 months of treatment with BDP were compared with 
the initial value at the start of the BDP period (month 24 in the figure) by means of the 
paired Student's t-test. 
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Figure 6.2 Course of the PC20 in asthma (top) and COPD during the three years of study. 
The standard errors of the mean are also represented. Differences in PC20 after six and 
12 months of treatment with BDP were compared with the initial value at the start of the 
BDP period (month 24 in the figure) by means of the paired Student's t-test. 
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Figure 6.3 Course of the peakflow m asthma (top) and COPD during three years. The 
peakflow during treatment with BDP was statistically compared with the value just 
before the start of BDP treatment by means of the paired Student's t-test. The standard 
errors are also represented. 
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patient with COPD stopped smoking during the third year. However, this patient was 
not incorporated in our analysis because of serious non-compliance to BDP. 
6.4. Discussion 
This study confirmed the hypothesis that daily inhalation of BDP of 800 μg during 
one year is able to decelerate the decline in FEVi during bronchodilator treatment 
alone in both asthma and COPD. In asthma, steroid treatment during one year even 
reversed the deterioration during two-year bronchodilator treatment. However, this 
effect was less apparent in patients with COPD. 
Study design 
In this self-controlled study, values of outcome measures during bronchodilator ther­
apy alone were compared with the ones during additional inhaled corticosteroid ther­
apy (within-patient comparison of treatments). This design can produce results that 
are statistically and clinically valid when no period ('natural variation') or carry-over 
effects (influence of preceding medication) are present (18). Our study meets these 
criteria for a valid self-controlled design. Therefore, from a methodological point of 
view, a placebo group was not absolutely necessary in this trial and (more importan­
tly) from an ethical point of view even unacceptable. It is unethical to treat patients 
with an annual decline in FEVi of 160 ml/yr and almost two exacerbations per year 
with a placebo. In our study, no carry-over effect of the preceding bronchodilator 
medication in either of the outcome variables during steroid treatment could be dem­
onstrated. No period effect was assessed in the number of exacerbations. Neither in 
COPD patients who were treated with BDP nor in the other COPD patients of the in­
tervention study (treated only with bronchodilators during the third year of study) did 
a change in exacerbations occur. A period effect in FEVi decline is not probable. The 
within-patient decline was assessed by linear regression of seven measurements of 
the FEVi during two years with a relatively high percentage of explained variance 
(31 %). Moreover, regression-to-the-mean (because of our selection of patients with a 
decline in FEVi of more than 80 ml/yr during bronchodilator therapy alone) did not 
explain the observed changes in FEVi during BDP therapy. We calculated the effect 
of regression-to-the-mean in annual decline of FEVi by means of the equations 
presented by Gardner et al. and Das et al. (19,20). This effect appeared to be 28(SEM 
7) ml/yr in asthma and 28(12) ml/yr in COPD. After adjusting the changes in FEVi 
during BDP therapy for regression-to-the-mean, almost the same results were found 
(the unadjusted versus adjusted changes in prebronchodilator FEVi during the 
months 1-6 of BDP were +562 and +547 ml/yr in asthma, +323 and +309 ml/yr in 
COPD respectively). The adjusted changes remained statistically different from the 
decline before steroid therapy in both asthma and COPD. Therefore, the observed 
changes in outcome measures were a real reflection of the effects of inhaled BDP 
treatment. 
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Effects of corticosteroids 
In asthma, the course of the FEVi, the PEFR and the PC20 improved during BDP 
treatment in comparison with bronchodilator therapy alone. BDP was also useful in 
the prevention of exacerbations, the reduction of respiratory symptoms and diminu­
tion of the diurnal variation of the PEFR. BDP not only decelerated the annual de­
cline of the FEV] in asthma but almost completely reversed the deterioration in pul­
monary function and bronchial hyperresponsiveness during the preceding two years. 
In COPD, the effects of BDP were less apparent. Although an improvement in FEVi 
and PEFR was observed, the PC20 and the number of exacerbations were not in­
fluenced by BDP. The steroid did reduce the severity of symptoms and the diurnal 
variation of the PEFR. 
Corticosteroids probably act on various components of the inflammatory response 
(21,22). They inhibit the release of mediators from macrophages and eosinophils 
(21), microvascular leakage and influx of inflammatory cells in the lungs. Late and 
(after prolonged treatment) early responses to allergens are blocked by steroids (22). 
Several studies in asthma have demonstrated beneficial effects of inhaled steroids on 
the ventilatory function, bronchial hyperresponsiveness and respiratory symptoms 
(23-27). The efficacy of corticosteroids in the treatment of COPD is less clear than in 
asthma (28). This prospective controlled study is the first long-term one showing that 
an inhaled steroid (BDP) of 800 μg daily during one year has several beneficial ef­
fects in patients with COPD. A relatively large increase in FEVi was found during 
the first six months of BDP treatment in COPD. This was followed by a slight (statis­
tically non-significant) fall during the subsequent six months of BDP treatment. 
Longer follow-up is necessary to evaluate whether this trend proceeds or not. The 
treatment with BDP in all patients was continued for another year. The differences in 
efficacy of BDP between asthma and COPD were not caused by a better compliance 
to BDP in asthma than in COPD. A study of the patient compliance to BDP by count­
ing capsules (single blind) revealed that no difference between asthma and COPD 
existed in this respect (29). Patients had used on average 82% of the prescribed dose 
of BDP. 
Adverse effects of inhaled steroids 
No serious adverse effects are recorded from inhaled corticosteroids (30). With a 
daily dose below 1,500 μg, no inhibition of the hypophyseal-pituitary-adrenal axis or 
other systemic effects were observed (21). In fact, dysphonia and oral candidiasis are 
the most serious side-effects (31). In our study, 14% of the patients suffered from 
oral candidiasis. When the BDP was inhaled through a spacer device (31), the com­
plaints diminished or disappeared and patients (except one) were able to continue ste­
roid treatment. 
Bronchodilator versus anti-inflammatory therapy 
In several recent reviews, inhaled corticosteroids have been advocated as a first-line 
therapy in asthma which should be introduced at an early stage (21,32). Bronchodila-
tors may not influence inflammation, may mask the inflammatory processes by re­
lieving symptoms and may increase the exposure to allergens, cigarette smoke and 
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other irritants (10,11,21) The findings of our previous study showed that regular ver­
sus on demand use of a bronchodilator (salbutamol or ipratropium bromide) without 
anti-inflammatory medication was accompanied by an accelerated annual decline in 
ventilatory function in both asthma and COPD (10) These results corresponded to 
the findings of Sears et al (33) The most important observation of the present study 
was that deletenous effects of bronchodilator therapy alone during two years were al­
most completely abolished by additional treatment with BDP during one year in as­
thma However, in COPD, the adverse effects were only partly reversible Although 
the two-year deterioration of the ventilatory function and bronchial hyperresponsive-
ness was reversible in asthma, it is advisable to start with inhaled steroids at an early 
stage of the disease, particularly when the pulmonary function deteriorates rapidly 
Chronic inflammation may lead to irreversible changes (3) such as hypertrophy of 
airway smooth muscle and thickening of basement membrane which probably are in­
hibited by early steroid therapy (21) 
It was concluded that inhalation of BDP of 800 μg daily during one year improved 
the long-term course of asthma and COPD in comparison with bronchodilator ther­
apy alone The effects of BDP were larger in asthma than in COPD 
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7. Slowing the deterioration of asthma and COPD 
during bronchodilator therapy by adding 
inhaled corticosteroids 
A four-year prospective study* 
Abstract 
Study Objective. To investigate whether deterioration of asthma or COPD dunng bronchodilator 
therapy alone could be improved by additional treatment with an inhaled corticosteroid. 
Design A four-year prospective study. 
Setting. 29 general practices in the catchment area of the University of Nijmegen. 
Patients. 56 Patients (28 asthma, 28 COPD) with an annual decline in the forced expiratory vol­
ume in one second (FEVi) of at least 80 ml/year in combination with at least two exacerba­
tions/year dunng bronchodilator therapy alone participated 
Intervention During the first two years, patients were only treated with a bronchodilator (salbuta-
mol 400 μg or ipratropium bromide 40 μg). Dunng the third and fourth year, additional treatment 
with beclomethasone dipropionate 400 μg, two times daily was given. 
Results- A large initial increase in prebronchodilalor FEV ι of +458 ml/yr (95% CL, 233 to 683) 
during the first six months of beclomethasone treatment was followed by a decrease of-102 ml/yr 
dunng months 7-24 The annual decline in FEVi dunng beclomethasone treatment was less than 
the decline of -160 ml/yr before beclomethasone therapy (difference 58 ml/yr, 95% CL, 2 to 87). 
Only in asthmatics did beclomethasone treatment improve the bronchial hyperresponsiveness (as­
sessed by the provoking concentration of hisumine that produced a 20% fall in FEVi, PC20) by 3.0 
doubling doscs/yr (95% CL, 0 8 to 5 2) Besides, beneficial effects of beclomethasone were found 
on the (diumal variation of the) weekly measured PEFR, exacerbations and symptoms in both as­
thma and COPD 
Conclusion: In the 56 patients of this study, additional treatment with beclomethasone of 800 μg 
daily improved an unfavorable course of disease dunng bronchodilator therapy alone. However, 
this effect was more evident in asthmatics than in patients with COPD 
7.1. Introduction 
There are indications that morbidity and mortality due to asthma and Chronic Ob­
structive Pulmonary Disease (COPD) have increased in the last two decades (1,2). 
One of the explanations might be that bronchodilator therapy without anti-inflamma­
tory medication is related to this increase in morbidity and mortality (3,4). Recently, 
two independent studies have found adverse effects of regular bronchodilator treat­
ment on control of asthma (5) and the progression of asthma and COPD (6). In our 
study (6), continuous treatment with a bronchodilator (ipratropium bromide 40 μg or 
salbutamol 400 μg, four times daily) was accompanied by a much higher annual de­
cline in the forced expiratory volume in one second (FEVi) than treatment on de­
mand in 160 patients with asthma or COPD. It is unclear whether an unfavorable 
* Accepted for publication b\ Annals of Internal Medicine as. Dompeling b, Van Schayck CP, Van 
Grunsvcn PM, Van Herwaarden CLA, Akkermans R, Molema J, Folgenng H, Van Weel С Slowing the 
detenoration of asthma and COPD during bronchodilator therapy by adding inhaled corticosteroids A 
four-year prospective study 
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course of asthma or COPD during bronchodilator therapy alone can be reversed or 
decelerated by additional anti-inflammatory therapy with inhaled corticosteroids. The 
present study deals with 56 of the 160 patients who had an unfavorable course of dis­
ease during bronchodilator therapy alone (an annual decline in FEVi of at least 80 
ml/yr in combination with at least two exacerbations/year). These 56 patients (28 as­
thma, 28 COPD) were additionally treated with an inhaled steroid (beclomethasone 
dipropionate 800 μg daily), during the third and fourth year of the study. It was in­
vestigated whether the worsening of their disease during bronchodilator therapy 
alone was reversed or decelerated by additional anti-inflammatory treatment with be­
clomethasone. The outcome measures were dynamic lung function indices (annual 
decline in pre- and postbronchodilator FEVi, peak-flow rate (PEFR), forced inspira­
tory volume in one second (FIVi)), static lung function indices (residual volume 
(RV), ratio residual volume/total lung capacity (RV/TLC), inspiratory vital capac­
ity (IVC)), nonspecific bronchial responsiveness (PC2o-histamine), exacerbations and 
respiratory symptoms. 
7.2. Methods 
Patients 
An extensive description of the patient selection in the preceding bronchodilator in­
tervention study was given elsewhere (6). In short: 29 family physicians in the catch­
ment area of the Nijmegen University selected all their patients aged 30 years and 
over with symptoms of asthma and COPD. Only those patients who showed mild to 
moderate airway obstruction (FEVi >50% of the predicted value (7)) and/or bron­
chial hyperresponsiveness to histamine (provoking concentration of histamine that 
induces a 20% fall in FEVi (PC20) ^8 mg/ml) were included by the investigators. Pa­
tients dependent on inhaled corticosteroids, with chronic heart failure, with malignant 
disorders or other severe life-threatening diseases were excluded. Of these patients, 
160 (59 asthma, 101 COPD) completed the bronchodilator trial. During the two years 
of bronchodilator treatment, a rapid decline in FEVi (>80 ml/yr) and a relatively high 
exacerbation rate (>1 per year) were observed in a subgroup of 56 patients (35%). 
These patients with an unfavorable course of disease were selected for additional 
treatment with inhaled beclomethasone during two years. The criteria for diagnosis 
of asthma or COPD were based on the standards of the American Thoracic Society 
(8). Asthma was defined as the combination of (6,8): 1. Bronchial hyperresponsive­
ness to histamine (PC20 ^8 mg/ml); 2. Reversible obstruction (FEVi improved by 
more than 15% of the prebronchodilator value, 60 minutes after the administration of 
both salbutamol 400 μg and ipratropium bromide 80 μg); 3. Dyspnea; 4. Allergy 
(which was defined as at least one positive test out of seven radioallergosorbent tests 
(RAST, Pharmacia, Sweden. Pollen from weeds, grasses, and trees; Cats and dogs; 
house dust mite; Aspergillus fumigatus)) and/or wheezing. COPD was defined as the 
combination of (6,8): 1. Chronic cough or chronic sputum production for at least 
three months during at least two consecutive years; 2. Continuous bronchus obstruc­
tion (FEVi <85% of the predicted value). Although separate features of asthma and 
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COPD were not mutually exclusive (for instance, some asthmatic patients had 
chronic cough, some COPD patients had a PC20 ^ 8 mg/ml), the combination of fea­
tures was: no patients with asthma also had COPD and vice versa (6). The study was 
approved by the Medical Ethics Committee of the University of Nijmegen. All pa­
tients gave informed consent. 
Study design and treatment 
At the start of the four-year intervention study, the patients were randomly allocated 
to one of the two parallel treatment regimens: continuous bronchodilator therapy 
(four times daily) or treatment on demand (only dry powder inhalations during peri­
ods of complaints) (6). The patients used dry powder inhalations of salbutamol 400 
μg (Glaxo, Zeist, The Netherlands) during one year and of ipratropium bromide 40 
μg (Boehringer Ingelheim, Alkmaar, The Netherlands) during the other year. The se­
quence of the drugs was determined by random allocation. During the third and 
fourth year, the 56 patients were additionally treated with beclomethasone 400 μg 
(Glaxo, Zeist, The Netherlands), two times daily in combination with salbutamol 
400 μg or ipratropium bromide 40 μg, four times daily (all dry powder inhalations). 
The bronchodilator inhaled during the second year was also used in the third and 
fourth year. 
During the first two years of the study, 27 of the 56 patients received bronchodila­
tor therapy on demand (15 asthma, 12 COPD). The mean daily number of dry pow­
der inhalations of salbutamol or ipratropium bromide in the patients treated on de­
mand was (mean ± SEM) 1.2 ± 0.3 in asthma, 0.8 ± 0.2 in COPD. During the third 
and fourth year, 28 patients used salbutamol (15 asthma, 13 COPD) and 28 ipratro­
pium bromide (13 asthma, 15 COPD). 
Once every three months, the inhalation technique as well as compliance with the 
prescribed medication were checked. Patients were instructed to rinse their mouth 
after the dry powder inhalations. During the second year of beclomethasone therapy, 
a single-blind prospective study was carried out on the patient compliance with be­
clomethasone and the additional bronchodilator. Compliance was measured by 
counting capsules at the end of a four-month period. Patients were unaware that their 
medication was counted after this period. 
Lung function, non-specific bronchial responsiveness and reversibility 
All measurements were carried out by two qualified laboratory assistants during 
exacerbation-free periods. No bronchodilator was inhaled during at least eight hours 
before the pulmonary function tests. At the start and after 24 and 48 months of the 
study, the inspiratory vital capacity (IVC), residual volume (RV), functional residual 
capacity (FRC) and total lung capacity (TLC) were assessed by means of the wet 
Gould spirometer according to the standards of the European Coal and Steel Com­
munity (ECSC) (7). The FEVi, bronchial responsiveness to histamine (PC2o-his-
tamine values) and the reversibility of airway obstruction were assessed at six-month 
intervals by means of the Microspiro HI-298 (Chest Corporation, Japan) (9). More­
over, the FEVi and the reversibility were also assessed after 1 and 13 months of 
study (6). The best of three forced expiratory maneuvres, with the highest sum of the 
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forced vital capacity (FVC) and FEVi, was used for data analysis. The bronchial re­
sponsiveness to histamine was measured according to the method described by Cock-
croft and colleagues (10). Results were expressed as the provoking concentration of 
histamine that produces a 20% fall in FEVi (PC20-value). After the FEVi had re­
turned to the baseline value, the bronchodilating response (reversibility) was assessed 
60 minutes after the administration of both ipratropium bromide 80 μg and salbuta-
mol 400 μg (metered dose aerosol) (6). The bronchodilating response was expressed 
as the relative increase of FEVi compared to the predicted value of the FEVi. 
Peak expiratory flow assessments 
Once a week, peak expiratory flow (PEFR) measurements were performed with the 
Assess peak flow meter (11) in the morning and in the evening, on the same day and 
at the same time. The highest value out of three measurements was taken for ana­
lysis. The diurnal PEFR index (absolute difference between evening value and morn­
ing value divided by the highest value) was calculated. 
Exacerbations 
Exacerbations were defined according to Fletcher with small modifications of Boman 
and colleagues (12). In case of an exacerbation, a ten-day course with oral predni­
sone was given. Patients received 25 mg for two days, 20 mg for two days, 15 mg for 
two days, and so on. 
Symptoms and adverse effects 
All patients made weekly recordings of the presence and severity of symptoms 
(cough, phlegm, dyspnea, fatigue, disturbed sleep at night) on a scale of 0-4. Adverse 
effects of medication (dysphonia and oropharyngeal irritation) were recorded by the 
patients once every three months. Moreover, every six months, the presence and se­
verity of oral candidiasis was assessed by means of a questionnaire (no, light or 
severe complaints). 
Smoking habits 
At the start of the study, the smoking history was assessed in pack years. During the 
study, the average number of cigarettes smoked per day was also recorded in the 
diary every week. 
Power calculations 
Assuming that the clinically relevant, decreased annual decline in FEVi during be-
clomethasone treatment is 25 ml/yr and the residual standard deviation 50 ml/yr, the 
CV (coefficient of variation) is 25/50=0.5. With an of 0.05 and a ß of 0.20 (power of 
( 1 -0.2)=0.8), the required number of patients is 51. With an estimated drop-out rate 
of 10%, the required initial number of patients is 56. 
Analysis 
Values of outcome variables before the use of beclomethasone were compared with 
data during beclomethasone treatment. Differences were tested by repeated measures 
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analysis of variance and the paired Student's t-test for normally distributed variables, 
the Wilcoxon paired signed-rank test for not normally distributed variables. Prior to 
analysis, the PC20 values were 2log transformed. The annual changes in FEVi and 
PC20 were calculated by linear regression of individual FEVi and 'logPC2o values in 
the course of time. For values in groups, the individual regression coefficients were 
averaged. The weekly measured PEFR was averaged for three-month periods and 
statistically compared with the value just before the start of beclomethasone therapy. 
Patients with asthma and COPD were analyzed together and separately. 
The gain in FEVi caused by two-year additional treatment with beclomethasone 
was calculated. This was done by comparing the end-point of FEVi after the two-
year treatment with beclomethasone with the extrapolated end-point if bronchodilator 
therapy alone had been continued during the third and fourth year (point E in Figure 
7.1). Because some degree of spontaneous improvement might have occurred during 
the third and fourth years if beclomethasone had not been administered, we adjusted 
the extrapolated end-point E for the disturbing influence of regression to the mean 
(point E' in Figure 7.1). The effect of regression to the mean was calculated by the 
equations of Gardner and colleagues and Das and colleagues (13,14). The gain in 
FEVi with and without correction for regression to the mean was calculated. 
Figure 7.1 Course of the pre- and postbronchodilator FEVi during four years in the 
group as a whole (n=48) * 
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Rgure 7.1 continued Course of the pre- and postbronchodilator FEVi during four years 
in asthma (n=26) and in COPD (n=22) 
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7.3. Results 
Baseline characteristics 
In comparison with COPD patients, asthmatics had smoked less in the past and also 
during the study, were more often allergic, had a higher bronchodilating response in 
FEVi, had more diurnal variation in peak flow and more bronchial hyperresponsive-
ness at the start of the four-year intervention study {Table 7.1). Of the 9 non-smokers 
with COPD at the start of the four-year study, 6 were ex-smokers. Only 3 COPD pa­
tients had never smoked. 
Table 7.1 Clinical characteristics of the patients with asthma and COPD at the start of the 
four-year intervention studyt 
Variable 
Number 
Age, yr 
Sex, M/F 
Pack years, η 
Smokers, +/-
Cigarettes/day, 
Allergy, +/-
η 
FEVi, % predicted 
FEVi/IVC, % 
Reversibility, % 
Diurnal PEFR in 
PC20, mg/ml 
FEVi predicted 
idex, % 
Asthma 
28 
49 ±12 
12/16 
1 3 ± 1 4 
14/14 
4 2 ± 6 7 
14/14 
67 ±17 
57 ±15 
1 4 ± 9 
1 2 ± 8 
0 8 
* 
» 
* * 
* · 
t 
** 
COPD 
28 
52 ± 1 0 
16/12 
2 3 ± 1 7 
19/9 
1 0 0 ± 9 2 
2/24 
7 0 ± 1 6 
63 ±13 
7 + 4 
9 + 5 
6 2 
* p<0 05, * * p<0 001, t p=0 057 
t absolute numbers or mean ± SD 
Drop-outs 
Of the 56 patients, 48 completed two-year treatment with beclomethasone. Reasons 
for dropping out were: refusal to use corticosteroids ( 1 asthma, 1 COPD), bronchial 
carcinoma (1 COPD), chronic heart failure (1 COPD), persistent oral candidiasis and 
dysphonia (2 COPD) and personal reasons ( 1 asthma, 1 COPD). 
Compliance 
The single-blind study about the patient compliance with medication showed that in­
dividual compliance rates (mean ± SD) were on average 82 ± 30% for the prescribed 
amount of beclomethasone and 98 ± 29% for the additional bronchodilator. Individ­
ual compliance rates were not related to the changes in outcome measures (lung 
function, bronchial hyperresponsiveness, and exacerbations) during beclomethasone 
treatment (all p-values >0.35). 
FEVi 
Because of the patient selection in this study, the annual decline in pre- and postbron-
chodilatorFEVi before steroid treatment was large (see Table 7.2 and Figure 7.1). In 
the group as a whole, repeated measures analysis of variance demonstrated an overall 
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Table 7.2 Changes in pre- and postbronchodilator FEVi before, during the months 1-6 
and the months 7-24 of treatment with beclomethasone 
Category 
Total 
(n=48) 
Asthma 
(n=26) 
COPD 
(n=22) 
Variable 
Change FEVi-prei, ml/yr 
Change FEVi-post*, ml/yr 
Change FEVi-pre*, ml/yr 
Change FEVi-postt, ml/yr 
Change FEVi-pret, ml/yr 
Change FEVi-posti, ml/yr 
Period of tr 
Before§ 
-160 
-98 
-173 
-115 
-146 
-79 
eatment with bee 
1-6 monthst 
+458*** 
+105** 
+562*** 
+201* 
+335* 
-5 
ilomethasone 
7-24 months 
-102* 
-120 
-100t 
-120 
-104 
-120 
* p<0 05, * * p<0 01, * * * p<0 0001, t p=0 059 
t Change FEVi-pre = annual change in prebronchodilator FEVi, change FEVi-post = annual change in 
postbronchodilator FEVi 
§ The 'before' column refers to the annual decline in FEVi during bronchodilator therapy alone for the 
period of two years preceding intervention with beclomethasone 
I) During months 1-6 of BDP treatment, annualized changes in FEVi are shown 
treatment effect of beclomethasone during the third and fourth year with respect to 
both the pre- and postbronchodilator FEVi (p=0.0001 and p=0.01 respectively). The 
increases in the pre- and postbronchodilator FEVi were +458 ml/yr and +105 ml/yr 
respectively during months 1 -6 of beclomethasone therapy, which differed from the 
preceding annual decreases during bronchodilator therapy alone (difference 618 
ml/yr [95% CL, 363 to 8731 and 205 ml/yr [95% CL, 56 to 354] respectively) {Table 
7.2). After the initial improvement, a decline in the pre- and postbronchodilator FEVi 
was found during month 7-24 of steroid treatment. However, the annual decline in 
prebronchodilator FEV ι of -102 ml/yr during months 7-24 of steroid therapy was 
less than that before steroid treatment (difference 58 ml/yr; 95% CL, 2 to 87) {Table 
7.2). Assessing the changes in FEVi for patients with asthma and COPD separately, 
it appeared that the effects of beclomethasone were more pronounced in asthma than 
in COPD {Table 7.2). 
The gain in prebronchodilator FEVi (adjusted for regression to the mean) was 
+0.36 liter in asthma (95% CL, 0.20 to 0.52) and +0.20 liter in COPD (95% CL, 
-0.02 to 0.42). No statistically significant gains in postbronchodilator FEVi values 
were observed. The effects of beclomethasone with and without correction for re­
gression to the mean were the same. 
PEFR 
During the whole treatment period with beclomethasone in asthmatics, the PEFR sig­
nificantly improved compared to the value at the start of beclomethasone treatment 
with a maximal increase (mean ± SEM) of 0.7 ± 0.2 L/s during months 13-15 of be­
clomethasone treatment (p=0.0006). The diumal variation of the PEFR in asthmatics 
diminished from 13.2% in the preceding period of bronchodilator therapy alone to 
9.7% during month 4-24 of beclomethasone treatment (p=0.017). In patients with 
COPD, the PEFR increased (mean ± SEM) by 0.21 ± 0.09 L/s compared to the value 
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at the start of steroid treatment during month 4-9 of beclomethasone treatment 
(p=0.039), which was not the case during the rest of the beclomethasone treatment 
period. In COPD, the diurnal variation of the PEFR decreased from 10.7% in the 
preceding period of bronchodiiator therapy alone to 8.4% during month 4-24 of be­
clomethasone therapy (p=0.0004). 
Other lung function indices 
In asthma, beclomethasone not only improved the course of the forced expiratory 
flows but also of several other lung function indices (Table 7.3). In comparison with 
bronchodiiator therapy alone, the RV decreased by 0.49 L (95% CL, 0.18 to 0.80), 
the RV/TLC ratio diminished by 9 % (95% CL, 3 to 15), the IVC increased by 0.50 L 
(95% CL, 0.16 to 0.86) and the FIV, increased by 0.41 L (95% CL, 0.10 to 0.72) dur­
ing treatment with beclomethasone. In COPD, no statistically significant changes 
were found (Table 7.3). 
Table 7.3 Change in static lung function indices and forced inspiratory volume in one 
second (FIVT) before and during the use of beclomethasone treatment t 
Disease 
Asthma 
(n=26) 
COPD 
(n=22) 
Change in 
TLC, L 
FRC. L 
RV, L 
Н ЯІ-С, % 
IVC, L 
FIVi, L 
TLC, L 
FRC, L 
RV, L 
R ^ L C , % 
IVC, L 
FIVi.L 
Before beclomethasone 
-0 158 
+0 040 
+0 166 
+4 0 
-0 339 
-0 169 
+0 077 
+0 134 
+0210 
+1 4 
-0 140 
-0 179 
± 0 091 
± 0 081 
± 0 077 
± 1 5 
+ 0 096 
± 0 086 
± 0 1 5 5 
± 0 132 
± 0 150 
± 1 3 
± 0 061 
± 0 059 
During beclomethasone 
-0 169 
-0 227 
-0 331 
- 4 7 
+0 161 
+0 189 
-0 074 
-0 097 
-0 018 
- 0 7 
-0 055 
+0 003 
± 0 1 1 2 
± 0 106 
± 0 1 0 1 
± 1 7 
± 0 1 0 5 
± 0 099 
± 0 123 
± 0 102 
± 0 1 0 6 
± 0 9 
± 0 082 
± 0 077 
p-value 
0 95 
012 
0 006 
0 009 
0011 
0019 
0 56 
0 25 
0 35 
0 71 
0 49 
015 
t Mean values ± SEM are presented 
PC2o 
The course of the PC20 is shown in Figure 7.2. In asthma, the course of the PC20 im­
proved by 3.0 doubling doses/yr during beclomethasone treatment in comparison 
with bronchodiiator therapy alone (95% CL, 0.8 to 5.2). In COPD, however, the PC20 
showed no significant change. The annual change of -0.3 doubling dose/yr before 
beclomethasone therapy was not different from the value of-1.6 doubling dose/yr 
during beclomethasone treatment (p=0.24) (Figure 7.2). 
Exacerbations 
In asthma, the number of exacerbations decreased from 1.3 per year before beclo­
methasone to 0.6 during beclomethasone therapy (difference 0.7; 95% CL, 0.4 to 
1.0). In the first year of beclomethasone treatment, the duration of exacerbations de­
creased from 1.2 to 0.4 weeks/year (difference 0.8; 95% CL, 0.5 to 1.1). In COPD, 
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Figure 7.2 Course of the PC20-histamine during four years in asthma (n=26) (top) and in 
COPD(n=22)* 
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the number of exacerbations diminished from 1.7 to 1.3 per year in the second year 
of beclomethasone treatment (difference 0.5; 95% CL, 0.1 to 0.9). 
Symptoms 
In asthma, the severity of weekly recorded total symptoms showed a decrease of 
17% during the first three months of beclomethasone compared to the period before 
beclomethasone treatment (p=0.01 ). This also appeared to be the case for the dyspnea 
score (19%, p=0.054) and the cough score (28%, p=0.005). During the rest of the 
treatment period, no significant improvements were found for the total symptom 
score. In COPD, the severity of cough, phlegm and dyspnea was only reduced during 
month 7-12 of beclomethasone treatment (13%, p=0.033). 
Adverse effects 
On average, no increase in the severity of dysphonia and irritation of the oropharynx 
were found during treatment with beclomethasone in comparison with the severity 
just before treatment, neither in the group as a whole (all p-values >0.37) nor in as-
thma or COPD separately. However, the severity of oral candidiasis increased after 
one year of beclomethasone therapy compared to the value at the start of steroid 
treatment (score 0.21 versus 0.02, p=0.01). On account of oral candidiasis, 6 patients 
had to use their medication with a spacer. Four patients were able to continue the 
study with a spacer, 2 dropped out for persistent oral candidiasis and dysphonia. 
Smoking 
In asthma, the proportion of current smokers/non-smokers was 14/14 during the first 
two years, 12/16 during the third and fourth year (p>0.05, two samples paired pro-
portion test). Two of the three asthmatics who stopped smoking had smoked less 
than 0.1 cigarettes/day during bronchodilator therapy alone. Therefore, these patients 
can be regarded as non-smokers during the four-year study period. One asthmatic pa-
tient started smoking during beclomethasone therapy. In COPD, the proportion of 
current smokers/non-smokers was 19/9 during the first two years, 17/11 during be-
clomethasone treatment (p>0.05, two samples, paired proportion test). One of the 
two COPD patients who stopped smoking during beclomethasone therapy dropped 
out because of personal reasons. 
Influence of preceding bronchodilator treatment on the change in outcome 
measures during beclomethasone therapy 
No influence of the treatment regimen in the first two years (continuous bronchodila-
tor therapy or treatment on demand) or of the sequence of the bronchodilators during 
this study period (salbutamol-ipratropium bromide or ipratropium bromide-salbuta-
mol) on the changes in outcome measures during beclomethasone therapy was found. 
Delay in reaching severe airflow obstruction 
It is very useful to know to what extent inhaled corticosteroids can induce a delay in 
reaching a certain low level of lung function (severe degree of chronic airflow limita-
tion). It is possible to get an impression of this topic by simple calculations from the 
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Figure 7.3 A theoretical comparison in the group as a whole between the effects of 
beclomethasone therapy and ongoing bronchodilator therapy on the time fin years) 
before reaching a certain severe degree of chronic airflow limitation on the basis of the 
extrapolated data in this study* 
without steroids 
with steroids 
25 
Time ( yrs) 
* The prebronchodilator FEVi at the start of the four-year intervention study was 2 07 liters, the annual 
decline without inhaled steroids 0 160 liter/year and with steroids 0 100 liter/year (both asthmatics and 
COPD patients) It is assumed that the annual decline in FEVi is stable m the course of time Time (X) 
before level of 1 0 L is reached without intervention with steroids X = (2 07-1 0)/0 160 = 6 7 years, and 
with steroid intervention X' = 0 5 + (2 07+0 23-1 0)/0 100 = 13 5 years (0 5 is the delay because of the rise 
in FEVi during months 1-6 of beclomethasone, 0 23 is the absolute increase in FEVi during this period) 
Time (Y) before FEVi level of 0 5 L is reached without intervention with steroids Y = (2 07-0 51/0 160 = 9 8 
years and with steroid intervention Y' = 0 5 + (2 07+0 23-0 51/0 10 = 18 5 years It appears that 
intervention with steroids almost doubles the time before low levels of lung function (0 5-1 0 L) are reached 
data in our study. Assuming that the decline in FEVi in the course of 10 to 20 years 
is stable, it can be calculated that the time in years before a certain (low) FEVi level 
of 0.5 to 1.0 L is reached in our patients population is almost doubled when inhaled 
steroids are substituted (Figure 7.3). 
7.4. Discussion 
Crossover and self-controlled study designs can produce results that statistically and 
clinically are as valid as the parallel study design, even with a lower required number 
of patients (15). However, two conditions have to be fulfilled: no period or carry-
over effects should be present. In our study, no carry-over effect of the preceding 
bronchodilator medication on either of the outcome measures during beclomethasone 
treatment was found. No period effect was assessed in the number of exacerbations 
and the FEVi decline. We can assume that the decline in FEVi would have continued 
if patients had not received additional beclomethasone during the third and fourth 
year. There are three reasons for this assumption: 1) a stable annual decline in FEVi 
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during a period of several years (linear loss of FEV ι in the course of time) was in­
variably found in studies on patients (16-19) or on random population samples (20-
23); 2) in the 56 patients of this study, the annual decline in FEVi during bronchodi-
lator therapy alone was stable. The decline during the first year was (mean ± SEM) 
-149 ± 42 ml/year and the one during the second year -156 ± 60 ml/year, which is 
comparable; 3) regression to the mean did not explain the observed improvement in 
FEVi during beclomethasone therapy. No change in exacerbations occurred during 
the four-year study period in the other patients of the intervention study, who conti­
nued bronchodilator treatment during the third and fourth year of study. Our study 
meets the criteria for a valid self-controlled trial. Therefore, from a methodological 
point of view, a placebo group was not absolutely necessary and, more important, 
from an ethical point of view this would even be unacceptable. It is unethical to treat 
patients who showed an average annual decline in FEVi of 160 ml/yr and almost two 
exacerbations per year, with a placebo. The observed improvements in outcome 
measures during the third and fourth year of study must have been the result of addi­
tional beclomethasone therapy. 
Our study shows that in the 56 patients with asthma or COPD, additional treat­
ment with an inhaled corticosteroid (beclomethasone) of 800 μ§ daily during two 
years improves the unfavorable course of disease during bronchodilator treatment 
alone. The increase in FEVi reached a plateau during the first six months of beclo­
methasone treatment after which a decline in FEV ι was found. However, the annual 
decline in FEVi during month 7-24 of beclomethasone treatment was significantly 
less than the decline during bronchodilator therapy alone. The large improvement in 
FEV ι during the first six months of beclomethasone treatment probably is the conse­
quence of a rapid initial decrease in the thickness of airway mucosa and submucosa 
by inhibition of oedema, microvascular leakage and mucus production from glands. 
The inflammatory processes underlying asthma or COPD in this study are probably 
not completely abolished by beclomethasone treatment as the annual decline in FEVi 
during months 7-24 of beclomethasone treatment was still larger than the physiologi­
cal decline of 20-40 ml/yr found in random population samples. Nevertheless, these 
findings indicate that inhaled corticosteroids not only have a short-term influence 
during several months but also a long-term influence during two or more years. The 
clinically significant gain in FEVi after two-year treatment with beclomethasone 
demonstrated that patients were in a more favorable clinical condition than they 
would have been if bronchodilator treatment alone had been continued for another 
two years. This gain was not statistically significant in the separate group of 22 pa­
tients with COPD. In our power analysis, we assumed an influence of beclometha­
sone on the annual decline in FEVi in asthmatics as well as patients with COPD. 
Only in the whole group of 56 patients, we had sufficient statistical power to demon­
strate that the annual decline in FEVi during beclomethasone treatment was statisti­
cally significant less than before steroid therapy. The data suggest that this effect may 
be more evident in asthmatics (70 ml/yr) than in patients with COPD (50 ml/yr). Fi­
nally, our calculations showed that inhaled beclomethasone may double the time be­
fore reaching low levels of lung function of 0.5 to 1.0 L (Figure 7.3). Of course, this 
is a simplification based on extrapolation for a period of 10 to 20 years but it gives an 
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impression of the delay inhaled corticosteroids might induce in reaching severe de­
grees of chronic airflow limitation. 
Apart from the effects on the FEVi, there were beneficial effects of beclometha-
sone on static lung function indices and nonspecific bronchial responsiveness (not in 
COPD patients), peak-flow rate, exacerbations and respiratory symptoms. The peak 
flow was significantly increased during the whole beclomethasone treatment period 
in asthma, but in COPD only during months 4-9. Treatment with beclomethasone had 
a beneficial influence on the indices of hyperinflation in asthma (RV, RV/TLC) but 
not in COPD. Improvements in these indices may also have a beneficial influence on 
the efficacy of gas exchange and may reduce the work of breathing (8). The PC2o-his-
tamine, which is an important indicator of the severity (10,24) and perhaps even of 
the prognosis of asthma (25), improved in the asthmatics of this study during addi­
tional beclomethasone therapy. The number of exacerbations, an important determi­
nant for the subjective well-being of patients with asthma and COPD (8), decreased 
during beclomethasone therapy. The weekly recorded symptoms temporarily dim­
inished during beclomethasone treatment in asthma and COPD. Unfortunately, com­
plaints of oral candidiasis increased during beclomethasone treatment, though most 
patients (except two) could continue with beclomethasone when this drug was in­
haled with a spacer. With a spacer, the drug deposition in the oropharynx is dim­
inished and therefore also the severity of local side-effects in this area (26,27). 
There are indications that morbidity and mortality due to asthma and COPD have 
increased in the past two decades (1,2). It is possible that bronchodilator therapy 
without anti-inflammatory medication has contributed to this world-wide trend in 
morbidity and mortality. Bronchodilators are very effective in immediately diminish­
ing bronchospasm and therefore in relieving symptoms directly, but they may have 
adverse effects on the control or progression of the disease when used continuously 
(5,6). Inflammation of the airway wall is a major factor in the pathophysiology of as­
thma (28) and perhaps also of COPD (29), which makes anti-inflammatory treatment 
of major importance (30-32). A problem for the long-term treatment with inhaled ste­
roids is patient-compliance. Patients may not notice the long-term improvements in­
duced by corticosteroids. Indeed, in the asthmatics of our study, only a temporary de­
crease in symptoms was found during the two-year beclomethasone therapy. Com­
pliance with beclomethasone 800 μg, two times daily in our study was rather good, 
but lower than with the additional bronchodilator, four times daily. Probably the, on 
average, good compliance rate in our study was the reason that we found no relation­
ship between individual compliance rates and the change in outcome measures dur­
ing beclomethasone treatment. However, during "uncontrolled" conditions in clinical 
practice, compliance with medication can be much lower (26,27). This stresses the 
importance of proper information about prophylactic steroid treatment and the moti­
vation of patients to use their inhaled steroids by physicians. 
Some other long-term studies have shown the efficacy of inhaled corticosteroids 
in asthma. Haahtela and colleagues reported the results of a two-year randomized 
double blind study with budesonide 600 μg, twice daily and terbutaline 375 μg, twice 
daily in 103 newly detected asthmatics (33). Budesonide was superior to terbutaline 
in its effect on the peak flow, the PC15, respiratory symptoms and the use of rescue 
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medication. Two recent one-year studies of Juniper and colleagues, one in 32 steroid-
dependent asthmatics (34) and the other one in 32 nonsteroid dependent asthmatics 
(35), have demonstrated that treatment with budesonide during one year induced a 
gradual improvement in PC20, asthma symptoms, exacerbations and bronchodilator 
use. In the steroid-dependent asthmatics, also an improvement in the FEVi was 
found. Our study confirms that inhaled corticosteroids are a first-line therapy of as­
thma, particularly when the need for bronchodilators is increasing (30-32). 
The efficacy of inhaled corticosteroids in the treatment of COPD has long been 
subject of controversy (8). No prospective long-term controlled studies have been re­
ported, although two retrospective studies suggested a positive influence of corticos­
teroids on the annual decline in FEVi (36,37). Several short-term studies found no 
effects of corticosteroids in COPD, whereas others observed the opposite (38). A re­
cent editorial about the efficacy of systemic corticosteroids in patients with stable 
COPD suggested that these drugs arc potentially of benefit in COPD (38). In the 
present four-year prospective study, inhaled beclomethasone had a beneficial in­
fluence on the course of the FEVi, the (diurnal variation of the) PEFR, the number of 
exacerbations and the severity of symptoms in patients with COPD. Therefore, a 
rapid annual decline in FEVi during bronchodilator therapy alone is probably a good 
indication that additional treatment with inhaled corticosteroids in patients with 
COPD is necessary and effective. 
We concluded that in the 56 patients of this study, the deterioration of disease dur­
ing bronchodilator therapy alone improved by additional treatment with beclometha­
sone of 800 μg daily. This effect was more evident in asthmatics than in patients with 
COPD. 
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8. The relationship between clinical characteristics 
and the two-year response to an inhaled 
corticosteroid (beclomethasone dipropionate) in 
asthma and COPD* 
Abstract 
The aim of the present study was to investigate which patients with asthma and COPD benefit in 
particular from a two-year treatment with an inhaled corticosteroid The relationship between clini­
cal characteristics (sex, age, smoking habits, symptoms, quality of life, allergy, static and dynamic 
spirometry, bronchodilating response, bronchial responsiveness to histamine) and the two-year re­
sponse to inhaled beclomethasone dipropionate 400 μg, two times daily was investigated in 56 pa­
tients (28 asthma, 28 COPD) All patients had participated in a preceding two-year bronchodilator 
intervention study The outcome measures of BDP therapy were the FEVi (both pre- and postbron-
chodilator) and the PC20-hibtamine, which were assessed at six-month intervals The postbron-
chodilator FEV] was assessed one hour after bronchodilatation with salbutamol 400 μg and ipratro­
pium bromide 80 μg Clinical characteristics measured at the start of treatment with BDP were re­
lated to the change in outcome measures during BDP therapy by means of analysis of variance 
(ANOVA) 
In asthmatics, the average increase in FEV ι during BDP therapy was larger in patients with a 
better bronchodilating response (FEVi-pre- r=0 62, p<0 0001), a higher diumal peak-flow rate 
index (FEV ι-post r=0 42, p<0 05), a severer degree of bronchial hyperresponsiveness (FEV ι -pre 
r=-0 64, p=0 066), a lower FIVi (FEVi-post r=0 42, p<0 05), a higher transfer coefficient (FEVi-
pre p=0 76, p<0 01) and a larger annual FEVi decline during bronchodilator therapy alone (FEVi-
post r=-0 62, p<0 001) It was not possible to predict the improvement in bronchial hyperrespon­
siveness to BDP from these clinical characteristics In COPD, the average increase in FEVi during 
BDP treatment was larger in patients with a better bronchodilating response (FbVi-pre r=0 89, 
p<0 0001), a lower РЕ іЛ С (FEV|-pre r^-0 54, p<0 05), and a larger decline in FEVi dunng 
bronchodilator therapy alone (FEV]-pre r=-0 77, jxOOOOl) No variables were significantly re­
lated to the change in postbronchodilator FEVi dunng BDP therapy in COPD 
It was concluded that m asthmatics and patients with COPD the two-year response in FEVi to 
inhaled BDP 400 μg two times daily was larger in patients with more reversibility, more initial air 
way obstruction and a larger annual FEVi decline dunng bronchodilator therapy alone Only in as 
thmatics the response to inhaled BDP was more pronounced in patients with a greater degree of 
bronchial hyperresponsiveness, more diumal vanations in peak-flow rate and a higher transfer 
coefficient 
8.1. Introduction 
In the past few years, treatment with inhaled corticosteroids has become increasingly 
important in asthma (1,2). It appeared that inflammation of the airway wall is a major 
pathophysiologic mechanism underlying asthma (3) and perhaps also COPD (4). 
Some long-term studies dunng one and two years have shown that maintenance 
treatment with inhaled corticosteroids is beneficial in asthma (5-7). In contrast to as-
* Submitted for publication as Dompeling E, Van Schayck CP, Molema J, Van Grunsven PM, Folgenng 
H, Van Weel С The relationship between clinical characteristics and the two-year response to an inhaled 
corticosteroid (beclomethasone dipropionate) in asthma and COPD 
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thma, the efficacy and therefore the precise role of corticosteroids is less clear in the 
treatment of COPD (8,9). However, a meta-analysis of available short-term studies 
suggested that corticosteroids are also beneficial in COPD (8). It is probable that sub­
groups of COPD patients will respond adequately to corticosteroids (9). Besides the 
general finding that corticosteroids are more efficacious in asthma than in COPD, 
little is known about the relationship between clinical characteristics (i.e. allergy, 
level of airway obstruction, degree of bronchial hyperresponsiveness etc.) and the 
long-term response to inhaled corticosteroids in asthma and COPD. It is important to 
know which patients in particular will benefit from inhaled corticosteroids, because it 
will increase our understanding of the mechanism of steroid action and it may refine 
the treatment policy of asthma and COPD. As far as we know, no studies on this sub­
ject have been reported in asthma. In COPD, the relationship between various char­
acteristics (the degree of airway obstruction, the bronchodilating response, the day-
to-day variation in lung function and sputum or blood eosinophilia) and the response 
to systemic corticosteroids for a period of a few weeks has been investigated in sev­
eral studies (10-17). However, no studies on this subject have been reported concern­
ing the long-term response to corticosteroids -for a period of some years- or the re­
sponse to inhaled corticosteroids. This kind of studies may be even more important 
because COPD patients may only respond adequately to corticosteroids after six 
months to two years of therapy ( 18). Because of the few systemic side-effects, in­
haled corticosteroids are preferred to oral corticosteroids in the long-term manage­
ment of asthma and COPD (19). 
Therefore, we assessed the relationship between clinical characteristics (age, al­
lergy, smoking habits, dynamic and static spirometry, reversibility of obstruction, 
nonspecific bronchial hyperresponsiveness, respiratory symptoms and quality of life) 
and the two-year response to an inhaled corticosteroid (beclomethasone dipropionate 
400 μg two times daily) in 56 patients with asthma or COPD. 
8.2. Methods 
Patients 
Data of 56 patients (28 asthma, 28 COPD) from a four-year intervention study were 
analyzed. During the first two years of bronchodilator treatment alone (20), 56 of the 
160 patients had an annual decline in FEVi of at least 80 ml/year and an exacerbation 
rate of almost two per year. Therefore, these 56 subjects were additionally treated 
with BDP 400 μg two times daily in the subsequent two years. The study was ap­
proved by the Medical Ethics Committee of the University of Nijmegen. AU patients 
gave informed consent. Of the 56 patients 48 completed two years of treatment with 
BDP. Reasons for drop-out were: refusal to use inhaled corticosteroids ( 1 asthma, 1 
COPD), bronchial carcinoma (1 COPD), chronic heart failure (1 COPD), persistent 
oral candidiasis and dysphonia (2 COPD) and personal reasons (1 asthma, 1 COPD). 
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Study design and treatment 
During the two-year treatment period with BDP the 56 patients were either treated 
with: 
( 1) BDP 400 μg two times daily and salbutamol 400 μg four times daily or 
(2) BDP 400 \ig two times daily and ipratropium bromide 40 μg four times daily (all 
dry powder inhalations). 
The type of bronchodilator (salbutamol or ipratropium bromide) depended on the 
random allocation in the preceding bronchodilator intervention study period. Salbuta­
mol was used by 28 patients (15 asthma, 13 COPD) and ipratropium bromide by the 
other 28 (13 asthma, 15 COPD). Once every three months, proper inhalation of the 
medication as well as compliance with the prescribed medication were checked. 
Lung function, nonspecific bronchial responsiveness and reversibility 
All measurements were carried out by two qualified laboratory technicians. No bron­
chodilator was inhaled during at least eight hours before the lung function tests. At 
the start of treatment with BDP, the inspiratory vital capacity (IVC), residual volume 
(RV) and total lung capacity (TLC) were assessed by means of the wet spirometer 
(Pulmonet HI, Sensormedics, Bilthoven, The Netherlands) according to the standards 
of the European Coal and Steel Community (ECSC) (21). The FEVi, bronchial re­
sponsiveness to histamine (PC2o-histamine values) and the reversibility of airway ob­
struction were assessed at six-month intervals by means of an integrating flowmeter 
(Microspiro HI-298, Chest Corporation, Japan). The best of three forced expiratory 
manoeuvres, with the highest sum of the forced vital capacity (FVC) and FEVi, was 
used for data analysis. The bronchial responsiveness to histamine was measured ac­
cording to the method described by Cockcroft et al (22). Results were expressed as 
the provoking concentration of histamine that produces a 20% fall in FEVi (PC20-
value). After the FEVi had returned to the baseline value, the bronchodilating re­
sponse was assessed 60 minutes after the administration of ipratropium bromide 80 
μg and salbutamol 400 μg (both metered dose aerosols). The bronchodilating re­
sponse was expressed as the relative increase of FEVi compared to the predicted 
value of the FEVi and as the absolute increase in litres. 
Peak-flow assessments 
Peak-flow measurements were performed with the Assess peak flow meter on the 
same day every week, at the same time in the morning and in the evening. The hig­
hest value of three measurements was taken for analysis. The diurnal PEFR index 
(DI-PEFR, absolute difference between evening and morning value divided by the 
highest value) was calculated from a 12-week period just before the start of the BDP-
trial. The coefficient of variation of the weekly measured peak-flow measurements 
(CV-PEFR) was calculated during the same period of time (SD of measurements 
divided by the mean value). 
Allergy 
Allergy was assessed by specific IgE determinations for seven common inhalation al­
lergens (RAST test, Pharmacia, Sweden. Pollen: weeds, grasses, trees; Animals: cats 
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and dogs; house dust mite; Aspergillus fumigatus). Patients were considered allergic 
if at least one of the RAST was positive. 
Symptoms 
Respiratory symptoms were assessed at the start of the BDP treatment by means of 
the Medical Research Council questionnaire (Dutch Version) and quantified by addi-
tion in a score of 0-8. 
Quality of life 
Quality of life was assessed at the start of the BDP trial by the Inventory of Subjec-
tive Health (ISH) (23). The ISH contains 21 questions related to subjective physical 
complaints. The overall ISH score is made up by the number of affirmative answers. 
The more physical complaints are reported, the higher the score. 
Smoking habits 
At the start of the study, the smoking history was assessed in pack years. During the 
study, the average number of cigarettes smoked per day was also recorded in the 
diary every week. 
Analysis 
The variables assessed at the start of treatment with BDP were related to the changes 
in FEVi and PC20 during the two-year BDP treatment by means of analysis of vari-
ance (ANOVA). The change in PC20 was estimated by linear regression of PC20 in 
the course of time. As the change in FEVi during BDP treatment was non-linear 
(Figure 7.1, page 75), an average increase in pre- and postbronchodilator FEVi dur-
ing two-year BDP therapy was calculated and related to the clinical characteristics. 
Correlation coefficients, the estimates and p-values were calculated. Two-tailed p-
values <0.05 were considered statistically significant. 
8.3. Results 
Clinical characteristics 
At the start of the two-year study period with BDP, asthmatics were characterized by 
a lower number of pack years, a lower number of smokers and of cigarettes smoked 
per day, more allergic patients, a higher reversibility, a higher coefficient of variation 
of peak flow and a lower PC20 in comparison with COPD patients (Table 8.1). 
Effects of BDP on the outcome measures in asthma compared to COPD 
BDP significantly improved the course of the prebronchodilator FEVi in asthma 
(p<0.0001) and COPD (p<0.05) in comparison with bronchodilator therapy alone 
(Figure 7.1, page 75). The average increase in prebronchodilator FEVi during BDP 
therapy in asthma was 0.228 litres which was not statistically different from the in-
crease of 0.098 litres in COPD (Table 8.2). In asthma, there was a small improve-
ment in the postbronchodilator FEVi of 0.015 litres, which was not statistically dif-
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Table 8.1 The clinical characteristics of the patients with asthma and COPD at the start of 
the treatment with inhaled BDP. Differences between asthma and COPD were statistically 
compared by means of the unpaired Student's t-test for normally distributed variables 
and by the chi-square test for dichotomic variables. Standard errors between 
parentheses. 
Variable Asthma COPD 
Number 28 28 
Age(yrs) 51 (2) 54 (2) 
Sex(M/F) 12/16 16/12 
Pack years 13 (3) * 23 (3) 
Smokers (+/-) 11/17 t 17/9 
Cigarettes/day (no ) 2 3 (0 7) ** 81 (1 8) 
Allergy (+/-)# 13/15 * " 2/24 
FEVi %pred 57 (4) 63 (3) 
FEVi/IVC(%) 51 (2) 57 (3) 
Reversibility FEVi (% predicted) 18 (2) * 12 (2) 
Coefficient of variation PEFR (%)## 8 5 (0 9) * 6 3 (0 7) 
PC20 (mg/ml)### 0 6 * * * 8 4 
*p<0 05. **p<0 005. ***p<0 001, t p=0 055, t p=0 065 
# Allergy was defined as at least one positive test out of seven RAST 
## coefficient of variation of the weekly measured morning peak-flow during a four-week period at the 
start of the study 
### geometric mean PC20 values are given 
Table 8.2 The average increase in FEVi and the total change in PC20 (value at the end 
minus baseline value) during the two-year BDP treatment period. Values in asthma and 
COPD were statistically compared by the unpaired Student's t-test. Standard errors of 
the mean between parentheses. 
Outcome measure Asthma COPD 
FEVi-pre(L) 0 228 (0 068) 0 098 (0 089) 
FEVi-post(U 0 015 (0 050) -0 068 (0 029) 
PC20 (doubling doses) 21 (1 7) * -3 2 (16) 
* p<0 05 
ferent from the deterioration of 0.068 litres in COPD either (Table 8.2). In asthma, 
the PC20 gradually improved by 2.1 doubling doses during the two-year study period, 
whereas in COPD a decrease of 3.2 doubling doses was found during the same peri-
od (p<0.05) (Table 8.2). 
Asthma 
In asthma, a larger average increase in prebronchodilator FEVi during BDP therapy 
was found in patients with a higher reversibility of obstruction, a higher transfer 
coefficient and a higher annual decline in prebronchodilator FEVi during bronchodi-
lator therapy alone (Table 8.3 and Figure 8.1). Tendencies towards a larger average 
increase in prebronchodilator FEVi were found in patients with a higher diurnal 
peak-flow rate index and a severer degree of bronchial hyperresponsiveness (p=0.052 
and p=0.066 respectively) (Table 8.3 and Figure 8.1). The average increase in post-
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Table 8.3 The relationship between clinical characteristics and the change in FEVi and 
PC20 during two-year BDP treatment as assessed by ANOVA. The estimate of FEVi is 
given in 10' L (SEM between parentheses) and that of PC20 in doubling doses per year. 
For the AD-FEVi, prebronchodilator FEVi values were taken for the relationship with the 
change in FEVi-pre and PC20 during BDP treatment, postbronchodilator values for the 
change in FEVi-post. For abbreviations, see list of abbreviations. 
Variable 
A s t h m a 
Pack years 
Smoking (+/-) 
Allergy (+/-) 
FEVi %pred 
FEVi/IVC(%) 
BDR-FEVi (10 3 L ) 
F I V i ( 1 0 3 L ) 
AD-FEVi (10 3 L/yr) 
2logPC20 
DI-PEFR (%) 
CV-PEFR (%) 
В ЯІ-С (%) 
TI/VA (mol/s/kPa/ml) 
MRC-score 
ISH-score 
COPD 
Pack years 
Smoking (+/-) 
Allergy (+/-) 
FEVi %pred 
FEV1/IVC (%) 
F I V i ( 1 0 " 3 U 
AD-FEVi (10 3L7yr) 
BDR-FEVi (L) 
2logPC20 
DI-PEFR {%) 
CV-PEFR (%) 
HVfTLC (%) 
T|/VA (mol/s/kPa/ml) 
MRC-score 
ISH-score 
FEVvpre 
Estimate 
-3 2 
-136 
220 
- 5 0 
- 6 6 
0 76 
- 0 046 
1 8 
^15 6 
13 11 
11 7 
-1 2 
36 2 
- 6 3 
-30 7 
4 6 
319 
-81 
- 8 1 
- 1 5 6 
- 0 053 
1 7 
0 95 
-3 9 
6 0 
27 7 
- 0 2 
-13 6 
23 4 
29 9 
(5 0) 
(142) 
(131) 
(3 4) 
(5 2) 
(0 21) 
(0 079) 
(0 5) 
(20 9) 
(6 4) 
(151) 
(5 8) 
(10 2) 
(39 8) 
(16 7) 
(5 1) 
(176) 
(430) 
(5 2) 
(6 0) 
(0 082) 
(0 3) 
p-value 
0 5 4 
0 35 
0 1 1 
0 16 
0 21 
0 002 
0 57 
0 001 
0 066 
0 052 
0 45 
0 8 4 
0 006 
0 88 
0 079 
0 38 
0 086 
0 85 
0 14 
0 0 1 8 
0 52 
0 0001 
( 0 1 1 ) 0 0001 
(17 7) 
(12 9) 
(29 4) 
(9 3) 
(11 4) 
(46 8) 
(18 4) 
0 8 3 
0 65 
0 36 
0 98 
0 25 
0 62 
0 1 2 
FEVi-post 
Estimate 
-1 5 
-102 
31 
- 4 3 
- 2 7 
0 0 4 
- 0 1 1 
1 3 
^ 5 8 
9 9 
1 5 7 
7 3 
8 8 
11 0 
- 9 2 
- 0 3 
8 
-170 
- 0 3 
0 6 
0 0 1 9 
0 4 
-0 03 
11 1 
3 2 
11 5 
1 9 
- 0 9 
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- 5 0 
(3 7) 
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(2 4) 
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(0 05) 
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(22 6) 
(4 6) 
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(15) 
(6 4) 
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0 69 
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0 50 
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0 050 
0 001 
0 083 
0 045 
0 1 6 
0 077 
0 37 
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0 86 
0 90 
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0 86 
0 78 
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0 1 0 
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0 42 
0 46 
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0 82 
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PC20 
Estimate 
0 07 
1 9 
-2 5 
0 03 
- 0 003 
- 0 005 
0 0019 
0 007 
- 0 4 
- 0 1 6 
- 0 16 
- 0 02 
- 0 05 
- 0 05 
- 0 24 
+0 06 
+0 6 
0 0 4 
- 0 043 
0 003 
- 0 003 
0 002 
- 0 3 
- 0 09 
- 0 21 
- 0 14 
- 0 06 
- 0 49 
0 19 
(0 07) 
(1 8) 
(1 7) 
(0 06) 
(0 07) 
(0 003) 
p-value 
0 29 
0 29 
0 17 
0 59 
0 97 
0 1 2 
(0 001) 0 065 
(0 007) 
(0 4) 
(0 09) 
(0 18) 
(0 08) 
(0 12) 
(0 55) 
(0 13) 
(0 04) 
(1 6) 
0 34 
0 31 
0 088 
0 38 
0 75 
0 69 
0 93 
0 098 
0 1 7 
0 70 
not estimable 
(0 04) 
(0 067) 
0 35 
0 5 4 
(0 001) 0 021 
(0 004) 
(0 002) 
(0 3) 
(010) 
(0 17) 
(0 07) 
(0 12) 
(0 40) 
(0 22) 
0 55 
0 30 
0 41 
0 38 
0 25 
0 072 
0 6 4 
0 23 
0 39 
bronchodilator FEVi during BDP was larger in patients with a lower FIVi, a higher 
diurnal peak-flow rate index and a faster annual decline in postbronchodilator FEVi 
(Table 8.3 and Figure 8. /). No variables were significantly related to the increase in 
PC20 during BDP therapy. 
COPD 
In COPD, the increase in prebronchodilator FEVi during BDP treatment was larger 
in patients with more reversibility of obstruction, more airway obstruction as as­
sessed by the FEVi/IVC and a larger decline in prebronchodilator FEVi before ste-
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Figure 8.1 The influence of the PC20, the diurnal peak-flow rate index, the broncho-
dilating response on the response in FEVi during two-year BDP therapy in asthma. 
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Figure 8.1 continued 
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Figure 8.2 The influence of the FEVi/IVC, the bronchodilating response and the annual 
decline in FEVi during bronchodilator therapy alone on the response in FEVi during BDP 
therapy in patients with COPD. 
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roid therapy (Table 8.3 and Figure 8.2). No clinical variables at the start of BDP 
treatment were significantly related to the change in postbronchodilator FEV ι during 
two-year BDP therapy. With respect to the PC20, only the FIVi was significantly re­
lated to the two-year change in PC20. 
8.4. Discussion 
It has become clear in the last few years that mucosal inflammation is a major patho­
physiologic feature of asthma (1-3) and perhaps also of COPD (4). This makes in­
haled corticosteroids increasingly important for treatment of asthma (1,2) and (to a 
smaller extent) COPD. This shift in treatment policy may be strengthened by the 
possibility that long-term, continuous use of bronchodilators may have adverse ef­
fects in both asthma and COPD (20,23,24). 
Attempts to characterize clinical features in asthma and COPD related to the re­
sponse to corticosteroids were limited so far to patients with COPD, who were 
treated with systemic corticosteroids for a period of a few weeks. In the present 
study, clinical characteristics in both asthmatics and patients with COPD were related 
to the two-year response to an inhaled corticosteroid, beclomethasone dipropionate 
of 800 μg daily. Outcome measures were the average increase in pre- and postbron­
chodilator lung function (FEVi) and the improvement in nonspecific bronchial re­
sponsiveness (PC20). Before BDP treatment, these 56 patients were treated with bron­
chodilators alone (20). 
In both asthma and COPD, the bronchodilating response at the start of the BDP 
treatment period, the initial level of airway obstruction and the annual FEVi decline 
in the preceding period of bronchodilator therapy alone were related to the two-year 
response to inhaled BDP. A better bronchodilating response (more reversibility) was 
accompanied by a larger average increase in prebronchodilator FEVi during BDP 
treatment. The reversibility on a bronchodilator appeared to predict the possibility of 
improvement by inhaled corticosteroids. Airways that respond only slightly to bron­
chodilators in the presence of significant airway obstruction may have some degree 
of irreversible damage like loss of lung elastic recoil, hypertrophy of airway smooth 
muscle and thickening of basement membrane, which cannot be reversed, neither by 
bronchodilators nor by corticosteroids (25,26). In some of the short-term studies on 
COPD, a significant relationship was found between the bronchodilating response 
and the response to oral corticosteroids given for some weeks (11,14,16). 
In both asthma and COPD, more airway obstruction (as indicated by a lower FIVi 
in asthma and a lower FEVi/IVC in patients with COPD) was accompanied by a 
larger increase in FEVi during BDP therapy. It is probable that more airway obstruc­
tion is accompanied by a larger response in FEV: during BDP treatment because of 
the greater possibility of improvement in these patients. A comparable explanation 
has been given for the relationship between the bronchodilating response and the pre­
bronchodilator lung function (27). In general, the response to bronchodilators is 
larger in patients with more initial airway obstruction, particularly when expressed as 
a percentage of the prebronchodilator value. 
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The annual FEV] decline during bronchodilator therapy alone was an important pre-
dictor of the subsequent response in FEVi during two-year BDP therapy. Although 
this relationship may partly be explained by regression-to-the-mean, it is certainly 
not the only explanation for this relationship. Regression-to-the-mean appeared to 
explain less than 5% of the changes observed during BDP treatment in asthma and 
less than 10% in COPD. It is probable that the patients with the largest increase in 
airway obstruction (and inflammatory processes) during bronchodilator therapy 
alone will demonstrate the largest improvements in FEVi during treatment with the 
inflammation-reversing corticosteroids. Therefore, in patients with COPD, a large 
annual decline in FEVi in the absence of anti-inflammatory treatment is probably a 
useful indication for additional treatment with inhaled corticosteroids. 
In asthmatics, but not in COPD, the diurnal PEFR index and the PC20 were related 
to the increase in FEVi during BDP treatment. Both bronchial hyperresponsiveness 
(i.e. PC20 ^ 8 mg/ml) and high diurnal variations of the peakflow (i.e. >15%) are im-
portant features of asthma (3,28), which are very much related (28) because they 
both express bronchial lability of the airways of asthmatics. The degree of nonspe-
cific bronchial responsiveness is closely related to the severity of inflammation in as-
thma (3). In this way, it could be explained that the subjects with severe bronchial 
hyperresponsiveness demonstrate the largest responses to inhaled corticosteroids. 
However, neither in this study nor in the short-term study of James et al. was an indi-
cation for such a relationship found in the patients with COPD (29). It is possible that 
bronchial hyperresponsiveness in COPD does not mark inflammation as it does in as-
thma, and is probably rather an expression of the degree of existing airway obstruc-
tion (30). 
Asthmatic patients with a low diffusion capacity demonstrated smaller increases 
in FEVi during BDP treatment. A low diffusion capacity in these patients probably 
indicated the existence of structural changes on an alveolar level (21), as other lung 
diseases related to a low diffusion capacity (fibrosis, oedema, embolism) were exclu-
sion criteria for participation in this trial. Emphysema was not excluded in our study. 
This stressed the importance of preventing structural damage to the airways of pa-
tients with asthma, because otherwise their disease will not only worsen but they will 
also become less responsive to corticosteroids in the long run (31). 
No clinical features in asthma could significantly predict the two-year improve-
ment in bronchial hyperresponsiveness during inhaled corticosteroid treatment. The 
only other study in asthma on this topic also found no significant predictors of the 
improvement in bronchial hyperresponsiveness during eight weeks of treatment with 
budesonide (32). Absence of significant predictors for the change in PC20 in COPD 
may be explained by the absence of an overall treatment effect in this outcome 
measure. A short-term study in patients with COPD also found no positive effect of 
an inhaled corticosteroid on nonspecific bronchial responsiveness (33). 
The influence of allergy on the response to BDP in asthmatics in this study was 
less pronounced than expected. Allergic asthmatics tended to respond better to BDP 
than non-allergic patients, but this was not statistically significant (p=0.11). As per-
haps not the presence but more the intensity of allergy was related to the corticoste-
roid response, we also related the total number of positive RAST to the response to 
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BDP, but there was no relationship with the improvement in FEVi or PC20 during 
BDP therapy either. Perhaps the absence of a statistically significant influence of al­
lergy on the response to corticosteroids in asthma may be explained by the wide 
range of anti-inflammatory effects of corticosteroids. They do not only have an effect 
on eosinophils but also on macrophages, monocytes etc, so that also the non-allergic 
asthmatics benefit from inhaled corticosteroid therapy. We were not able to assess the 
possible influence of allergy on the response to BDP in patients with COPD, because 
we only had two allergic COPD patients in our study. 
Current smoking was not related to the response to inhaled BDP, neither in asthma 
nor in patients with COPD. It is possible that the beneficial effects of BDP dim­
inished the harmful effects of smoking in our patients. However, in an analysis not 
reported here, we found an influence of the smoking history on the annual FEVi de­
cline during BDP therapy in the same study population: patients with a higher num­
ber of pack years had a larger decline in FEVi than patients with a lower number. 
This may point to the relevance of the amount and duration of smoking to the long-
term response to corticosteroids. More pack years may be accompanied by more (ir­
reversible) damage to the airways and a lower sensitivity to corticosteroids in asthma 
and COPD. 
The symptom score and quality of life scores at the start of the study were not re­
lated to the two-year response to BDP. neither in asthma nor in COPD. It is difficult 
to predict the objective response to corticosteroids on the basis of the experienced 
symptoms or quality of life. A poor correlation was described in other studies be­
tween objective parameters like lung function (or annual decline in lung function) 
and bronchial hyperresponsiveness on the one hand and the subjective variables of 
symptoms and quality of life on the other (23,34). 
Chronic inflammation of the airways in asthma may cause irreversible changes 
(1,2). In the present study, indicators of the severity of airway inflammation (the de­
gree of bronchial hyperresponsiveness, the diurnal variation of the peak flow, the an­
nual FEVi decline during bronchodilalor therapy alone) were related to the response 
to BDP in asthmatics. Early treatment with inhaled corticosteroids is particularly be 
indicated in these asthmatics with severe airway inflammation, even when symptoms 
are well controlled by a beta-agonist once or twice daily. In COPD patients of our 
study, more reversibility, more airway obstruction and a more rapid annual FEV 1 de­
cline during bronchodilalor therapy alone were accompanied by a better response to 
inhaled BDP. In these COPD patients, treatment with inhaled corticosteroids may be 
indicated, also because of the increased risk on early morbidity and mortality in pa­
tients with a low lung function level and a high annual decline in lung function 
(35,36). 
We conclude that in asthmatics or patients with COPD the two-year response in 
ΡΈν 1 to inhaled BDP 400 μg two times daily was larger in patients with more revers­
ibility, more initial airway obstruction and a larger annual FEVi decline during bron­
chodilalor therapy alone. Only in asthmatics the response to inhaled BDP was more 
pronounced in patients with a greater degree of bronchial hyperresponsiveness, more 
diurnal variations in peak-flow rate and a higher transfer coefficient. 
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9. The influence of inhaled beclomethasone 
dipropionate on quality of life in patients with 
asthma or chronic airflow limitation* 
Abstract 
Relatively little is known about the influence of inhaled corticosteroids on general well being 
(quality of life) in patients with asthma or chronic airflow limitation In a four-year prospective 
controlled study we examined the influence of beclomethasone dipropionate (BDP) 400 μg, two 
times daily, on quality of life in 56 patients with asthma or chronic airflow limitation in comparison 
with the effects of BDP on symptoms and lung function During the first two years, patients only 
received bronchodilator therapy with salbutamol or ipratropium bromide For additional treatment 
with BDP during the third and fourth years 56 patients (28 asthma, 28 chronic airflow limitation) 
with an annual decline in FEV ι ot at least 80 ml/yr in combination with at least two exacerbations 
per year were selected 
Quality of life was assessed at the start and after two and four years by means of the Inventory 
of Subjective Health (ISH) and the Nottingham Health Profile (NHP) 
BDP did not improve the ISH score or the six dimensions of the NHP, neither in asthma, nor in 
chronic airflow limitation However, BDP significantly improved the course of lung function (the 
forced expiratory volume in one second, FEVi) (p<0 0001) BDP temporarily decreased respiratory 
symptoms during the first three months of BDP treatment in asthma (p<0 01 ) and during months 7-
12 in chronic airflow limitation (p<0 05) A weak correlation was found both cross sectionally and 
longitudinally between (change in) symptoms and quality of life on the one hand and the (change 
in) FEV) on the other 
It was concluded that BDP did not improve the general well being of patients with asthma or 
chronic airflow limitation However, BDP significantly improved the course of lung function and 
temporarily decreased the seventy of symptoms A possible explanation for these observations is 
that patients soon get used to different levels of lung function and learn to live with their disease It 
is advised that both genene and disease-specific health instruments should be used in future inter­
vention studies and also that quality of life should be measured frequently dunng the early phase of 
the intervention, e g once every month 
9.1. Introduction 
Treatment with inhaled corticosteroids has become increasingly important in asthma 
or (to a smaller degree) chronic airflow limitation (1-4) Airway inflammation is 
probably an important pathophysiologic mechanism in asthma and perhaps also in 
chronic airflow limitation (5,6) Several short-term studies dunng some months (7-
10) and a few long-term studies during one or two years (11-13) in asthma have 
shown that inhaled steroids are able to improve lung function, nonspecific bronchial 
responsiveness, symptoms, exacerbations and can reduce the need for bronchodilator 
therapy There is less unanimity about the effects of corticosteroids in patients with 
* Submitted for publication as Dompeling b, Molema J, Van Schayck CP, Rutten MPMH, Van Gransven 
PM, Akkermans R, Van Weel С The influence of inhaled beclomethasone dipropionate on quality of life 
in patients with asthma or chronic airflow limitation 
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stable chronic airflow limitation (14). However, a meta-analysis of available short-
term studies (15), a recent short-term trial (3) and a retrospective long-term study (4) 
suggested that corticosteroids are potentially beneficial in chronic airflow limitation. 
So far no studies have been published on the effects of inhaled steroids on quality of 
life in patients with asthma or chronic airflow limitation. However, improving the ex-
perienced health of these patients is also an important goal of therapeutic intervention 
(16). 
Patients with asthma and chronic airflow limitation may suffer from breathless-
ness, exercise limitation, anxiety and depression, and problems related to social acti-
vities (1,16-19). The quality of life in patients with asthma or chronic airflow limita-
tion was worse than in subjects of the general population (18,19). It is important to 
know whether treatment with inhaled corticosteroids does not only improve the clini-
cal outcome measures of asthma or chronic airflow limitation but also the general 
well-being (quality of life) of patients with these diseases. 
We studied the influence of an inhaled corticosteroid (beclomethasone dipropion-
ate, BDP) on the quality of life in 56 patients (28 asthma, 28 chronic airflow limita-
tion) in a prospective controlled study. The influence of BDP on quality of life was 
compared with the effects on symptoms and lung function. 
9.2. Methods 
Patients 
From a population of 160 patients, 56 (28 asthma, 28 chronic airflow limitation) 
were selected on the basis of a relatively unfavourable course of disease during bron-
chodilator therapy alone (an annual decline in FEVi of at least 80 ml/year in combi-
nation with at least two exacerbations/year) (20). All 160 patients had participated in 
a two-year bronchodilator intervention trial (21 ). At the start of the four-year study, 
29 general practitioners in the catchment area of the Nijmegen University selected all 
their patients aged 30 and over with symptoms of asthma and chronic airflow limita-
tion. Only those patients who showed mild to moderate airway obstruction (FEVi 
>50% of the predicted value (22)) and/or bronchial hyperresponsiveness to histamine 
(PC20 58 mg/ml) were included by the investigators. Patients with chronic heart 
failure, malignant disorders and/or patients who were dependent on corticosteroids 
were excluded. The criteria for diagnosis of asthma or chronic airflow limitation 
were based on the standards of the American Thoracic Society (17,21,23). The study 
was approved by the Medical Ethics Committee of the University of Nijmegen. All 
patients gave informed consent. 
Study design and treatment 
This study is of a self-controlled design. Outcome measures during treatment with 
bronchodilators alone (first two years) were compared with those during additional 
BDP therapy (third and fourth years of study). At the start of the four-year interven-
tion study, the patients were randomly allocated to one of the two parallel treatment 
regimens; continuous (four times daily) or on demand (only dry powder inhalations 
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during periods of complaints) bronchodilator therapy (21). The patients used dry 
powder inhalations of salbutamol 400 μg during the first year and of ipratropium bro­
mide 40 μg during the second, or vice versa. The sequence of the drugs was deter­
mined by random allocation. During the third and fourth year, the 56 patients were 
additionally treated with BDP 400 μg, two times daily. The bronchodilator inhaled 
during the second year was also used in the third and fourth years. Once every three 
months, proper inhalation technique as well as compliance with the prescribed medi­
cation were checked. 
Measurements 
• Baseline characteristics. At the start of the study, smoking behaviour, allergy, lung 
function (FEVi and FEVi/IVC), reversibility, diumal peak-flow rate index and bron­
chial responsiveness to histamine were assessed. 
Smoking history was assessed in pack years. Current smoking status (smoker/non-
smoker) and amount of cigarettes/day were measured. Allergy was assessed by spe­
cific IgE determinations for 7 common aero-allergens (RAST, Pharmacia, Sweden. 
Pollen: weeds, grasses, trees; Animals: cats and dogs; House dust mite; Aspergillus 
Fumigatus). Patients were considered allergic when at least one of the RAST was 
positive. Reversibility was assessed by the increase in FEVi, one hour after the ad­
ministration of salbutamol 400 μg and ipratropium bromide 80 μg and it was ex­
pressed as a percentage of the predicted value of FEVi. The diumal peak-flow rate 
index was determined by the absolute difference between the weekly measured eve­
ning and morning peak flow (same day and time of day) divided by the highest value 
of that day for a period of 4 weeks. Bronchial responsiveness to histamine was 
measured according to the method of Cockcroft et al. (24) and expressed as the pro­
voking concentration of histamine that produced a 20% fall in FEVi (PC20 value). 
• Outcome measures. Quality of life was measured by completing two questionnaires, 
viz. the Dutch version of the Nottingham Health Profile (NHP) (19,25-29) and the 
Inventory of Subjective Health (ISH) (19). The NHP is a generic, self-administered 
questionnaire designed to measure perceived physical, emotional and social health 
problems. The emphasis is on the respondent's subjective perception of his or her he­
alth status (19,25). The NHP focusses on feelings and emotions, not on changes in 
behaviour. It consists of two parts of which only part one is used in our study. It con­
tains 38 statements relating to 6 dimensions: physical mobility (8 statements), pain (8 
statements), social isolation (5 statements), emotional reactions (9 statements), ener­
gy (3 statements) and sleep (5 statements). The statements were taken from inter­
views with patients suffering from various acute or chronic diseases, and from other 
health questionnaires like the Sickness Impact Profile. All statements are formulated 
in such a way that they can be answered by yes or no. McKenna derived their 
weights from a sample of both patients and healthy subjects using Thurstone's me­
thod of perceived health problems (26). Separate NHP dimension scores are presen­
ted as a profile, not integrated into an overall score. Although the NHP was originally 
developed as a survey instrument to measure perceived health status in a population, 
it has been used extensively in evaluation studies and is claimed to be sensitive to 
change in disease severity (27-29). The NHP has proved to be reliable and can easily 
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be administered, with small demands on patient time and effort (25). The higher the 
score, the more physical complaints are reported. The Inventory of Subjective He­
alth, developed by Dirksen (19), is a generic, commonly used Dutch scale which con­
tains 21 questions related to subjective physical complaints like tiredness, chest and 
heart problems, gastric problems, indigestion, headache, etc. Most complaints can be 
grouped according to the organ system they referred to. The remaining ones relate to 
the overall physical condition. The ISH statements were partly taken from the Cor­
nell Medical Index, completed with statements from expert-interviews about the in­
fluence of physical stress on health. The internal consistency and reliability of the 
ISH are strong and answers do not appear to be influenced by social desirability (19). 
The overall ISH score is made up by the number of affirmative answers. The more 
physical complaints are reported, the higher the score. Assessments of the quality of 
life were repealed after two and after four years of study. 
Respiratory symptoms were assessed by means of two questionnaires. Firstly, the 
questionnaire of the Medical Research Council (MRC) (Dutch version) was used at 
the start and after two and four years of study (30). A total score (MRC-symptom 
score) of 0-8 was determined from the answers to eight different questions (20). Sec­
ondly, patients made weekly recordings of severity of cough, phlegm and dyspnoea 
on a scale of 0-4. The separate scores together made up the total symptom score (21). 
The FEV ι was assessed by means of the Microspiro HI-298 (Chest Corporation, 
Japan) (31). The best of three forced expiratory manoeuvres, with the highest sum of 
the forced vital capacity (FVC) and FEVi, was used for data analysis. Assessments of 
the FEVi were repeated at six-month intervals. Besides, the FEVi was also measured 
after one month and 13 months of study. 
Analysis 
No period or carry-over effects were present in this self-controlled trial (32). Regres-
sion-to-the-mean appeared to explain only a small, negligible part of the improve­
ments in FEVi during BDP therapy (32). So, this study met the criteria for a valid 
self-controlled trial (32,33). 
The annual decline in FEVi during bronchodilator therapy alone was estimated by 
linear regression of FEVi in the course of time. Because of a non-linear change in 
FEVi during BDP treatment, the FEVi values at the end of BDP treatment were com­
pared with those at the start. The changes in the quality of life scores before and dur­
ing BDP treatment were statistically compared by the Wilcoxon matched-pairs 
signed-ranks test (because the distribution was not normal), changes in FEVi by the 
unpaired Student's t-test. Correlations between the change in quality of life and 
MRC-score on the one hand and the change in FEVi on the other were calculated 
both before and during BDP therapy (longitudinal analysis). Besides, correlations be­
tween quality of life, symptoms and lung function were assessed cross-sectionally 
(between-patient analysis). 
Clinical characteristics of asthmatics and patients with chronic airflow limitation 
were statistically compared by the unpaired Student's t-test for normally distributed 
variables, the chi-square test for dichotomous parameters and the Mann-Whitney li­
test for continuous, not normally distributed variables. 
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9.3. Results 
Baseline characteristics 
At the start of the four-year study, asthmatics were characterized by less past and 
current smoking, a higher percentage of allergy, a higher reversibility and a more 
severe bronchial hyperresponsiveness than patients with chronic airflow limitation 
(Table 9.1). Quality of life as assessed by the ISH score was worse in chronic airflow 
limitation than in asthma (Table 9.1). 
Table 9.1 Clinical characteristics of the patients with asthma and chronic airflow 
limitation at the start of the four-year intervention study. Differences between asthma 
and chronic airflow limitation were statistically compared by the unpaired Student's 
t-test for normally distributed variables, the chi-square test for dichotomous variables 
and the Mann-Whitney U-test for continuous not-normally distributed variables. SD 
between parentheses. 
Variable 
Number 
Age (yrs) 
Sex (M/F) 
Pack years 
Smokers (+/-) 
Cigarettes/day 
Allergy (+/-)# 
FEVT %pred 
FEVi/IVC (%) 
Reversibility FEVi (% pred) 
Diurnal PEFR index (%) 
PC20 (mg/ml)## 
MRC-symptom score 
ISH 
N HP-score 
- energy 
- pain 
- emotions 
- sleep 
- social isolation 
- physical mobility 
Asthma 
28 
49 
12/16 
13 
14/14 
4 2 
14/14 
67 
57 
14 
12 
0 8 
4 9 
63 
30 2 
124 
125 
192 
137 
120 
(12) 
(14) 
(6 7) 
(17) 
(15) 
(9) 
(8) 
(1 8) 
(4 6) 
(38 7) 
(26 0) 
(193) 
(29 1) 
(27 9) 
(20 9) 
* 
* 
* « 
* * 
* « 
* 
Chronic airflow limits 
28 
52 
16/12 
23 
19/9 
100 
2/24 
70 
63 
7 
9 
62 
55 
95 
35 1 
191 
158 
27 1 
123 
128 
(10) 
(17) 
(9 2) 
(16) 
(13) 
(4) 
(5) 
(17) 
(4 6) 
(37 2) 
(28 8) 
(26 5) 
(23 9) 
(25 6) 
(13 8) 
*p<0 05, **p<0 001 
# Allergy was defined as at least one positive test out of seven RAST 
## coefficient of variation of the weekly measured morning peak-flow during a four-week period at the 
start of the study 
Of the 56 patients, 48 completed treatment with BDP. Reasons for dropping out 
were: refusal to use corticosteroids (1 asthma, 1 chronic airflow limitation), bronchial 
carcinoma (1 chronic airflow limitation), chronic heart failure (1 chronic airflow 
limitation), persistent oral candidiasis and dysphonia (2 chronic airflow limitation) 
and personal (non-medical) reasons (1 asthma, 1 chronic airflow limitation). 
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Quality of life of study population in comparison with a random sample 
of the population 
Compared with data in the general population (25), quality of life at the start of our 
study appeared to be impaired in the asthmatics and patients with chronic airflow 
limitation (Figure 9.1). With the exception of the emotional reaction score and the 
sleep score of the NHP, the quality of life scores in our patients with asthma or 
chronic airflow limitation were on average two to three times higher than in the 
general population (Figure 9.1). 
Figure 9.1 Quality-of-Hfe scores in patients with asthma and chronic airflow limitation of 
this study compared with the general population. 
Quality of life score 
Energy Pain Emotional Sleep Social Physical ISH 
reactions isolation mobility 
The influence of BDP on quality of life, symptoms and lung function 
In Table 9.2, the changes in quality of life, MRC-symptom score and FEVi during 
the two-year study period before the use of BDP and during BDP treatment are 
shown. No significant changes in the quality-of-life scores were found in asthma, 
neither before treatment with BDP nor during BDP therapy (all p-values >0.17) 
(Table 9.2). Also when the changes in quality-of-life scores before BDP treatment 
were compared with those during BDP therapy, no significant improvements were 
observed in asthma (Wilcoxon matched-pairs signed-ranks test, all p-values >0.48). 
Before BDP treatment in chronic airflow limitation, however, the MRC-symptom 
score, the emotional reaction score and the social isolation score of the NHP im-
proved significantly in spite of a substantial worsening of the FEV] (Table 9.2). Dur-
ing BDP therapy, no significant changes in quality of life were found in patients with 
chronic airflow limitation. 
In asthma, the severity of weekly recorded symptoms showed a decrease of 17% 
during the first three months of treatment with BDP compared to the period before 
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Table 9.2 Changes in quality-of-life scores, MRC-symptom scores and lung function 
before and during the use ofBDR SEM between parentheses. A negative change in 
quality-of-life and MRC-score implies an improvement, a positive sign a deterioration. 
Asthma 
ISH 
NHP 
- energy 
- pain 
- emotional reaction 
- sleep 
- social isolation 
- physical mobility 
MRC-symptom score 
FEVi (ml/yr) 
Chronic airflow limitation 
ISH 
NHP 
- energy 
- pain 
- emotional reaction 
- sleep 
- social isolation 
- physical mobility 
MRC-symptom score 
FEVi (ml/yr) 
Before I 
change in 
+0 27 
-5 5 
+ 1 5 
-1 2 
+0 10 
-2 7 
- 4 3 
-0 12 
-173 
-1 2 
- 6 8 
-2 0 
-7 3 
+2 6 
-4A 
-1 1 
-1 14 
-146 
(0 49) 
(4 0) 
(3 4) 
(4 2) 
(3 8) 
(4 1) 
(3 0) 
(0 37) 
(22) 
(0 6) 
(4 9) 
(5 1) 
(2 5) 
(4 3) 
(2 0) 
(2 4) 
(0 40) 
(36) 
BDP 
Ρ 
0 59 
0 1 8 
0 66 
0 78 
0 98 
0 51 
0 1 7 
0 75 
0 0001 
0 065 
0 1 8 
0 69 
0 01 
0 55 
0 04 
0 64 
0 009 
0 0006 
chan 
+0 68 
- 0 4 
- 0 5 
- 0 2 
+3 0 
- 0 5 
- 0 5 
-0 24 
+38 
+ 1 3 
+3 4 
+6 7 
+2 4 
+0 8 
+0 3 
+2 2 
+0 25 
-23 
During 
ge in 
(0 66) 
(4 8) 
(2 5) 
(3 1) 
(3 7) 
(3 1) 
(2 5) 
(031) 
(30) 
(0 9) 
(6 1) 
(4 7) 
(2 4) 
(7 3) 
(3 6) 
(2 4) 
(0 33) 
(35) 
BDP 
Ρ 
031 
0 94 
0 85 
0 94 
0 43 
0 87 
0 84 
0 45 
0 22 
0 1 8 
0 59 
0 1 8 
0 34 
0 91 
0 94 
0 38 
0 46 
0 52 
BDP was given (p<0.01) (Figure 9.2). During the rest of the treatment period, no sig­
nificant improvements were found for the total symptom score. In chronic airflow 
limitation, the severity of weekly recorded symptoms was only significantly reduced 
during months 7-12 of BDP treatment (13%, p<0.05) (Figure 9.2). 
Both in asthma and chronic airflow limitation, the course of lung function im­
proved by BDP treatment. The FEVi deterioration of -160(SEM 20) ml/yr before 
BDP differed from the change of +10(23) ml/yr during BDP (paired Student's t-test, 
p<0.0001). This effect was more evident in asthmatics (-173 versus +38 ml/yr) than 
in patients with chronic airflow limitation (-146 versus -23 ml/yr). 
Correlation between the change in quality of life or symptoms and 
the change in lung function 
In general, there was only a weak correlation between the change in quality-of-life or 
MRC-symptom scores on the one hand and the change in FEVi on the other, both in 
asthma and chronic airflow limitation (Table 9.3). The only statistically significant 
findings were those of the energy score of the NHP. In asthma, the change in the en­
ergy score was related to the change in FEVi during bronchodilator therapy alone 
(r=+0.44, p<0.05). In chronic airflow limitation, the change in energy score was re­
lated to the change in FEVi during additional BDP treatment (r=-0.46, p<0.05). 
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Figure 9.2 Weekly recorded symptom score at three-month intervals during the 
four-year study period. Only during the first period of BDP treatment a decrease in 
symptoms was found, not during the rest of the BDP treatment period. 
Symptom score 
An 
\ 
• · -
. · 
V 
CAL 
·--· Asthma 
ι ι ι ι ι ι ι ι ι 
Before 1-3 і-в 7-9 10-12 13-15 16-18 19-21 22-24 
Months of BDP treatment 
Correlation between quality of life, symptoms and lung function 
at cross-sectional assessments 
When the quality-of-life and MRC symptom scores were related to the FEVi at the 
start, after two and after four years of study, it appeared that no significant correla­
tions were found, neither in asthma (the absolute value of r ranged from 0.004 to 
0.39, p>0.05) nor in chronic airflow limitation (absolute value of г ranged from 0.005 
to 0.38, p>0.06). 
9.4. Discussion 
The most important observation of this study was that BDP significantly improved 
the course of lung function, but not the quality of life in patients with asthma or 
chronic airflow limitation. BDP diminished the severity of symptoms only signifi­
cantly for some months during the first year of BDP treatment. During the rest of the 
treatment period, no influence on symptoms was found, neither in the weekly re­
corded symptom score nor in the two-yearly measured MRC-symptom score. The 
substantial decline in lung function during bronchodilator therapy alone was not ac-
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Table 9.3 Correlation between the changes in quality-of-life scores, the MRC-symptom 
scores and the changes in FEVj before and during the use of BDP (within-subject 
analysis). 
Asthma 
ISH 
NHP 
- energy 
- pain 
- emotional reaction 
- sleep 
- social isolation 
- physical mobility 
MRC-symptom score 
Chronic airflow limitation 
ISH 
NHP 
- energy 
- pain 
- emotional reaction 
- sleep 
- social isolation 
- physical mobility 
MRC-symptom score 
Before 
r 
+0 11 
+0 44 
- 0 07 
+0 35 
-0 34 
+0 30 
+0 35 
-0 06 
-0 19 
-0 18 
-0 05 
+0 11 
-0 29 
-0 22 
+0 30 
-0 04 
BDP 
Ρ 
0 59 
0 023 
0 72 
0 076 
0 09 
0 1 4 
0 077 
0 75 
0 39 
0 41 
0 81 
0 63 
0 22 
0 32 
0 1 8 
0 85 
During 
r 
-0 33 
+0 11 
-0 02 
-0 34 
+0 26 
- 0 1 7 
+0 20 
+0 23 
-0 14 
-0 46 
-0 23 
-0 18 
-0 15 
+0 18 
-0 03 
+0 32 
BDP 
Ρ 
010 
0 60 
0 91 
0 096 
0 20 
0 42 
0 34 
0 25 
0 57 
0 039 
0 33 
0 44 
0 54 
0 44 
0 89 
0 14 
companied by a significant worsening of quality of life in this period. In fact, some 
of the scores even improved significantly during this part of the trial in patients with 
chronic airflow limitation. This may be explained by an 'in care' effect because of 
participation in the trial. All these findings together may suggest that patients soon 
get used to different levels of airway obstruction and leam to live with their disease. 
Their perception of the severity of their disease may be limited (16). There is no rea­
son to doubt the reliability and validity of the generic health instruments NHP and 
ISH (19,25-29). The NHP was a useful tool in assessing subjective well-being in pa­
tients with hypertension (34), myocardial infarction (35), coxarthrosis (36), stroke 
(37) and asthma (38). Perhaps we had found a positive effect of BDP on quality of 
life if we had measured this variable frequently during the first year of BDP, like for 
symptoms. It is also possible that more disease-specific quality of life scales would 
have indicated an improvement in quality of life. A disease-specific health instru­
ment possibly has the advantage of covering specific aspects of the clinical disorder 
under study which are not relevant for a generic well-being scale (39). However, 
examples of disease-specific quality-of-life scales of asthma or chronic airflow limi­
tation have only recently become available (16,40,41) and experience with these 
scales is therefore limited. If their asthma or chronic airflow limitation is really im­
portant for the patients' overall experienced subjective well-being, improvement of 
their disease should also be reflected in generic quality-of-life scales. Therefore, it is 
advisable to use both generic and disease-specific quality-of-life instruments for fu-
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ture trials in asthma and chronic airflow limitation. Quality of life must be measured 
frequently during the early phase of the intervention, i.e. once every month. 
A comparison of the ISH and NHP scores in our patients with asthma and chronic 
airflow limitation with data from the general population (25) revealed that patients 
indeed experience their disease as important for their general well-being. Quality of 
life seemed impaired in asthma and chronic airflow limitation when compared with 
the general population, although this simple comparison must be interpreted with 
caution. Most of the quality-of-life scores were two to three times higher in the pa­
tients of this study than in samples of the general population. Patients with asthma or 
chronic airflow limitation may suffer from breathlessness, exercise limitation, 
anxiety and depression, and problems related to social activities (1,16-19). Quality of 
life may be more disturbed in patients with chronic airflow limitation than in asthma­
tics (17). In our study, quality of life as assessed by the ISH was worse in chronic air­
flow limitation than in asthma. This difference was not found for the six dimensions 
of the NHP. In chronic airflow limitation, obstruction as well as respiratory com­
plaints are of a sustained, chronic character (17). In asthma, the degree of airflow 
limitation varies considerably in the course of time and symptom-free intervals may 
alternate with periods of cough, wheezing and dyspnoea (17). The ISH is particularly 
directed at chronic physical complaints (19) and it is therefore logical that patients 
with chronic airflow limitation had a higher ISH score than asthmatics. 
We investigated the correlation between the quality-of-life scores, MRC-symptom 
score and the FEV ι both cross-scctionally and longitudinally. In asthma as well as in 
chronic airflow limitation, the correlations between lung function and quality-of-life 
scores were weak with only two significant correlations for the energy score of the 
NHP. In general, correlations within subjects (longitudinal analysis) were slightly 
higher than between subjects (cross-sectional analysis). Many other studies found a 
low correlation between all kinds of quality-of-life scales and the lung function level 
(18,19,40,42,43). It has been suggested that the attitude to health or disease interferes 
with the relation between lung function and the results of psychometric tests (44). 
This general attitude towards health or disease may be the reason that a lower lung 
function level is not necessarily accompanied by a lower experienced quality of life. 
Our study is an example of a self-controlled trial in which different treatments are 
compared within patients. Crossover and self-controlled study designs can produce 
results that statistically and clinically are just as valid as the parallel study design 
provided that no period or carry over effects are present (33). Our study meets these 
criteria for a valid self-controlled trial (32). No placebo was given to our patients be­
cause we considered it unethical to treat patients with an annual decline in FEVi of 
160 ml/yr and almost two exacerbations per year with a placebo. From a methodo­
logical point of view, a placebo group was not absolutely necessary, because the 
treatment during bronchodilator therapy alone was a good control period within each 
patient. It appeared that regression-to-the-mean did not bias the results of BDP ther­
apy in this trial (32). 
We conclude that treatment with BDP (in comparison with bronchodilator treat­
ment alone) did not improve the general well-being of patients with asthma or 
chronic airflow limitation in spite of a positive influence of BDP on the course of 
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lung function and a temporary reduction in seventy of symptoms in these diseases 
Neither the substantial decline in lung function dunng bronchodilator therapy alone 
nor the improvement in the course of lung function dunng BDP therapy were accom-
panied by corresponding changes in the genene quality-of-life scores An explanation 
for these findings may be that patients soon get used to different levels of lung func-
tion and learn to live with their disease We recommend that quality of life in future 
intervention studies should be measured by genene as well as disease-specific health 
instruments Dunng the early phase of the intervention, quality of life must be 
measured frequently, e g once every month 
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10. Treatment with inhaled steroids in asthma and 
chronic bronchitis; long-term compliance and 
inhaler technique* 
Abstract 
We investigated compliance and inhaler technique in 50 patients with airway obstruction (26 as­
thma, 24 chronic bronchitis) being treated with an inhaled steroid (BDP, beclomethasone dipro-
pionate) via a dry powder inhaler (dry powder device Rotahaler). Patients had already participated 
for one year in a two-year trial of BDP in general practice. They were treated daily with two dry 
powder inhalations of 400 μg BDP in combination with a bronchodilator (salbutamol or ipratro­
pium bromide) Compliance with BDP was measured by counting capsules (single-blind) at the end 
of a four-month penod and through a questionnaire. 
Counting capsules revealed that patients used on average 82(SD=30)% of the prescribed 
amount of BDP. Non-compliance (defined as a compliance rate below 80% or above 120%) to BDP 
was present in 46% of the patients. The questionnaire suggested that only 7 % of the patients was 
non-compliant. Individual compliance rates were not related to age, sex, diagnosis or side-effects of 
BDP. In chronic bronchitis, but not in asthma, compliance was related to the outcome parameters of 
steroid treatment (pulmonary symptoms, the change in lung function and nonspecific bronchial re­
sponsiveness). The inhaler technique was judged insufficient in 27% of the patients 
This study stresses the importance of regular instruction in inhaler technique and proper infor­
mation about prophylactic steroid treatment by the general practitioner during the treatment of as­
thma and chronic bronchitis 
10.1. Introduction 
Asthma and chronic bronchitis are considered to be progressive diseases (1,2), which 
should be treated at an early stage. Since chronic inflammation of the airways seems 
to play an important role in the pathophysiology of airway obstruction (3), anti-in­
flammatory drugs, such as inhaled corticosteroids are increasingly being prescribed 
for prolonged periods (4-6) by GPs Jfowever, the efficacy of such prophylactic ther­
apy not only depends on adequate prescription, but also on a good patient compliance 
(7,8) and a proper inhaler technique (9). In two short-term controlled studies in as­
thma, compliance with inhaled steroids were 76 and 85%, respectively (7,8). Al­
though inhaled steroids are mostly described on a long-term basis, no studies have 
assessed the compliance with long-term inhaled steroid treatment. Dry powder inha­
lers are being used more frequently in the treatment of airway obstruction: they are 
easier to handle than the aerosol inhaler, because hand-lung coordination is not 
necessary in its use (10). In addition, dry powder inhalers do not contain chlorofluo-
rocarbon propellants, and therefore are ozone-friendly devices (10,11). In the few 
* Ongmalh published as: Dompeling E, Van Grunsven PM, Van Schayck CP, Folgenng H, Molema J. 
Van Weel С Treatment with inhaled steroids in asthma and chronic bronchitis; long-term compliance and 
inhaler technique. Fam Pract 1992,9(2) 161-166. 
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studies in which the inhaler technique of dry powder devices was assessed, an incor-
rect inhaler technique was demonstrated in 4-54% of the patients (12-14), dependent 
on the type of inhaler device and the method of measuring. 
The aim of our study was to assess the long-term compliance with beclometha-
sone dipropionate (BDP) in moderate asthma and chronic bronchitis and the inhaler 
technique. Relations between patient compliance on the one hand, and clinical char-
acteristics (age, sex, diagnosis) and outcome parameters of treatment with BDP 
(symptoms, side-effects, exacerbations, lung function, nonspecific bronchial respon-
siveness) on the other were also assessed. 
10.2. Methods 
Patients and study design 
Fifty patients with moderate airway obstruction (26 with asthma, 24 with chronic 
bronchitis), selected from general practice entered this study (Table ¡0.1). They had 
already participated for one year in a two-year intervention study with BDP: an ex-
tensive description of the patients and study design of the BDP trial are given else-
where (15-17). In summary: 56 patients were selected for a two-year trial with BDP 
and were treated daily with two dry powder inhalations (d.p.i.) of BDP 400 μg in 
combination with four d.p.i. of a bronchodilator, salbutamol 400 μg or ipratropium 
bromide 40 μg. BDP was inhaled by the Rotahaler (Glaxo, Netherlands). At the start 
of the trial with BDP, extensive instructions how to use the Rotahaler had been given 
by the principle investigator. Lung function (forced expiratory volume in one second, 
FEV|) and bronchial responsiveness to histamine (the minimal concentration of his­
tamine in mg/ml, necessary to induce a 20% fall in FEVi, the PCio-hislamine) were 
assessed under standardized circumstances by two laboratory technicians every six 
months. During these visits any possible problems with the trial medication was dis­
cussed and a fixed amount of new medication was provided. Patients had to consult 
their general practitioner in case of exacerbations (15), and were instructed to keep a 
Table 10.1 Patient characteristics. Standard deviations or ranges are given in 
parentheses. Differences between asthma and chronic bronchitis were tested by means 
of the chi-square test for dichotomous variables, by means of the unpaired Student's 
t-test for continuously distributed variables. 
Asthma Chronic Bronchitis 
Number 
Age (years) 
Sex (M/F) 
Smoker (+/-) 
Pack years (number) 
Allergy (+/-) 
FEVi (%pred) 
PC20 (mg/ml)# 
26 
52 (32-73) 
10/16 
10/16 
12 (14) 
13/13 
65 (22) 
0.07 
24 
55 
14/10 
16/8 
23 
1/23 
63 
(39-71) 
(17) 
(18) 
6 7 
*p<0 05, **p<0 005. * '*p<0 0005 
# geometric mean PC20-values are given 
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weekly report of peak-flow measurements, the severity of pulmonary symptoms 
(cough, phlegm, dyspnoea) and side-effects of BDP (dysphonia, oropharyngeal irrita-
tion, oral candidiasis). The trial was approved by the Ethics Committee of the 
University of Nijmegen and all patients gave informed consent. 
Assessment of compliance and inhaler technique 
In the second year of the two-year trial with BDP, compliance to inhaled BDP was 
measured by counting capsules at the end of a four-month period: Patients were una-
ware of this. This objective method was considered as the 'golden standard' of 
measuring compliance. Capsules of salbutamol and ipratropium bromide were also 
counted. Individual compliance rates with BDP, salbutamol and ipratropium bromide 
were determined by expressing the number of capsules taken (number of capsules 
provided minus number of capsules left) as a percentage of the amount prescribed. In 
addition a standard (anonymous) questionnaire was filled in by the patients at the end 
of the four-month period. The questionnaire asked: 'Did you miss or overuse more 
than 10 doses of BDP in the preceding month?' (ten doses of BDP in one month are 
equivalent to 20% of the amount of BDP prescribed for one month). In order to allow 
comparisons between both methods of measuring compliance, patients were con-
sidered compliant within the arbitrary range of 80-120% of the prescribed amount of 
BDP (18-19). The questionnaire also contained the following questions: 'Did you 
take BDP at fixed times of the day?' 'Do you think BDP is able to improve the long-
term state of the lungs?' 
At the end of the four-month period, an assessment of the inhaler technique was 
carried out by two medical doctors. The scoring system was based on Hilton (12) and 
consisted of an evaluation of the following four steps, which are considered to be es-
sential for a proper inhalation (and which are also recommended by the instruction 
manuals accompanying the Rotahaler): 1) initial expiration, 2) upright head position, 
3) deep and powerful inspiration, and 4) breath-holding after inspiration. Each step 
counted for 0, 0.5 or 1 point to the total score of the inhaler technique, in case of in-
correct, doubtful or correct performance respectively. A total inhaler score below 2 
was judged as 'insufficient', a score between 2 and 3 as 'adequate' and a score above 
3 as 'good'. The agreement between both observers of each step of the Rotahaler in-
haler technique was corrected for 'chance agreement' by means of the kappa-coeffi-
cient (20); when kappa values (range 0.00-1.00) are higher than 0.60, the agreement 
is judged sufficient to good. Six of the 50 patients used BDP with a pressurized dose 
inhaler and spacer device because of severe throat complaints. During the study, one 
patient died because of a myocardial infarction, two stopped with BDP because of 
severe throat complaints. Therefore the results of 41 patients were analysed in this 
study. 
Analysis 
Prior to analysis PC2o-values were log: transformed. Individual compliance rates to 
BDP, measured by counting capsules, were regarded as a continuous variable in the 
analyses. In order to compare these compliance rates with the presence or absence of 
compliance to BDP measured by the questionnaire (chi-square lest), individual com-
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pliance rates were also categorized (<80%, 80-120%, >120%). In all the analyses, the 
individual compliance rates were related to continuous parameters by means of Pear­
son's correlations, to ordinal parameters by means of Spearman correlations. Corre­
lates of individual compliance rates to BDP with dichotomous parameters were 
tested by the unpaired Student's t-test. In asthma and chronic bronchitis separately, 
relations between the compliance to BDP and the main outcome variables of treat­
ment with BDP (pulmonary symptoms, exacerbations, change in lung function, 
change in PC20) were investigated by multiple analysis of variance, correcting for in­
itial lung function and compliance to the additional bronchodilator. The Rotahaler in­
haler technique was considered as a dichotomous (insufficient/ sufficient) or as an or­
dinal variable (individual inhaler score). 
NU. Results 
Compliance with BDP 
The mean study period was 118 (range 33 to 158) days. Individual compliance rates 
with BDP were on average 82(SD 30)% of the prescribed amount of BDP (range 8-
126%). According to our definition of compliance (compliance rate between 80-
120%), 19 out of 41 patients (46%) were non-compliant (Figure W.J). Underuse 
(less than 80% of the prescribed dose) was far more common than overuse (above 
Figure 10.1 Individual compliance rates to BDP (counting capsules): the number of 
capsules taken, as a percentage of the prescribed dose. 
Percentage of patients (%) 
50 π 
ί,Ο-
30-
20-
10-
0-19 20-39 40-59 60-79 80-99 100-119 120-139 
Compliance to BDP (% prescribed) 
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120% of the prescribed dose), in 34 and 12% of the patients respectively (Figure 
10.1). However, the questionnaire, which was completed and returned by all patients 
suggested that only 7% of the patients were non-compliant to BDP. A relationship 
was found between the individual compliance rates with BDP and the individual 
compliance rates with the additional bronchodilator (r=0.32, p=0.049). Nevertheless, 
the average compliance rate to BDP was lower than that for the additional bronchodi­
lator (82%(SD=30))and 98(SD=29)% respectively, p=0.018). Compliance with BDP 
was not related to age, sex, diagnosis, inhaler technique, exacerbations or side-effects 
of BDP. In patients with chronic bronchitis, but not in asthma, compliance with BDP 
was related to the pulmonary symptoms (r=0.57, p=0.036), the change in FEV ι 
(r=0.60, p=0.10) and the change in PC20 (r=0.72, p=0.031) during steroid treatment. 
Compliance with BDP was not greater in patients who took their medication at fixed 
times of the day or who were convinced that BDP is able to improve the long-term 
state of the lungs (p=0.24 and 0.55, respectively). 
Rotahaler inhaler technique 
There was an acceptable agreement between the two observers on all steps of the Ro­
tahaler inhaler technique, corrected for chance agreement. Kappa was on average 
0.63 (range 0.35-1.00). The mean Rotahaler inhaler score was 2.2 (range 0.5-3.5). 
The Rotahaler inhaler technique was judged 'insufficient' (score of less than 2) in 11 
of the 41 patients (27%). Twenty-eight (68%) of the patients had an 'adequate' per­
formance (score 2-3). Only 2 (5%) of the subjects had a 'good' Rotahaler inhaler 
technique (score 3.5 or 4, Figure 10.2). 
Figure 10.2 Rotahaler inhaler technique. Percentages of patients are given. 
'insufficient' a score below 2, 'adequate' a score between 2 and 3, 'good' a score above 3 (at most 4) 
When all steps of the inhaler technique were considered separately (Table /0.2), only 
three of the 41 patients (7%) expired clearly prior to inspiration. Twenty-two (54%) 
of the subjects did not hold breath after inspiration. 
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Table 10.2 Rotahaler inhaler technique, all steps separately. Numbers of patients are 
given. 
Pressing capsule into hole 
Keeping Rotahaler horizontally 
Maximal rotation 
Initial expiration* 
Upward head position* 
Deep and powerful inspiration* 
Breath-holding* 
Not correct 
0 
16 
0 
34 
3 
1 
22 
Doubtful 
0 
5 
0 
4 
4 
11 
9 
Correct 
41 
20 
41 
3 
34 
29 
10 
Each marked step (#) represents one of the four basic steps of the Rotahaler inhaler technique 
10.4. Discussion 
Most patients asthma and chronic bronchitis are treated in general practice (21). Sev-
eral studies in the past reported underdiagnosis and undertreatmcnt of asthma in 
general practice (22-24). Various factors on both doctor and patient level may be re-
sponsible for this situation (21,23,25), of which non-compliance is one (21). In the 
last few years, new evidence for the long-term efficacy of (inhaled) steroids was 
found (26) whereas doubts emerged about the long-term benefits of continuous bron-
chodilator therapy, in particular with the beta2-agonists. This has led to the advice 
that inhaled steroids should be introduced at an early stage (28), which is particularly 
important for general practice. From this study, it appeared that both non-compliance 
with inhaled steroids and incorrect inhaler technique are common in the long-term 
treatment of asthma and chronic bronchitis, even in a controlled trial situation. This 
stressed the important role of the general practitioner in an adequate prescription of 
inhaled steroids, regular instruction of inhaler technique and proper information 
about this prophylactic therapy to patients with asthma and chronic bronchitis. 
The mean compliance rate with BDP in this study was 82% of the prescribed dose, 
a figure comparable with compliance rates to inhaled steroids in two short-term trials 
(76 and 85% respectively) (7,8). However, individual compliance rates varied from 8 
to 126%, with underuse more frequent than overuse. Kruse et al. (29) stated that drug 
therapy in chronic conditions, even if controlled, is often characterized by a wide 
range of compliance rates, with underuse predominating. In our study of compliance 
in asthmatic and chronic bronchitic patients, in whom the likelihood of compliant be-
haviour (assumed by the GP) was one of the inclusion criteria of the intervention 
study (15), a comparable pattern was observed. Under uncontrolled and unselected 
conditions compliance with prescribed drugs in asthma and chronic bronchitis is ex-
pected to be much lower (30). 
The questionnaire over-estimated compliance to a large extent, when counting 
capsules was considered as the gold standard. This over-estimation of compliance by 
asking patients is a well-known phenomenon in clinical practice (18,31). A possible 
explanation for this result of our study could be that patients did not want to disap-
point the investigator after participating in the intervention study for a long period. 
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We minimized this possibility by asking patients to return the questionnaire anony­
mously. Another possibility of denying possible non-compliance may be that the as­
sessment of compliance by questionnaire was retrospectively, while capsule counting 
was prospective. In order to avoid memory bias as much as possible, we only asked 
for use of medication in the preceding month. Still, counting capsules is known to 
over-estimate true compliance rates, when compared to even more objective, direct 
methods such as blood and urine tests (31). This may indicate that the true com­
pliance rates may have been even lower than was found by simply counting capsules. 
In general, there are many possible determinants of compliance (32). In this study, 
we related a number of clinical characteristics but not psychosocial or economic 
determinants, to compliance. It has been suggested that compliance to steroids should 
be lower than to bronchodilators, because of the lack of direct symptom-relieving ef­
fect of the steroids (9). Indeed, compliance rates to BDP in this study were lower 
than with bronchodilators. More importantly however, a relationship was observed 
between the compliance with BDP and the compliance with the additional bronchodi-
lator. In other words, compliance seemed to be patient-dependent rather than drug-
dependent. Nevertheless, there is no convincing evidence in literature that patient 
characteristics (for example age, sex, race, economic status) predict non-compliance 
to steroids (32). In our study, compliance to BDP was not related to sex, age, and di­
agnosis. 
Compliance with BDP was not related to the patients' assessment of the ability of 
the drug to improve the long-term state of the lungs, or to taking BDP at fixed times 
of the day. With regard to the latter, Haynes found that compliance can be improved 
by negotiating specific times to take medications (for example during mealtimes) 
(34). No other studies in which this relation was assessed were found. 
It has been proposed that the efficacy of inhaled steroid therapy depends to a large 
extent on compliance and a proper inhaler technique (9), which was confirmed in two 
short-term steroid trials (7,8). In the chronic bronchitic patients in this study, the 
compliance with BDP was related to pulmonary symptoms and the change in lung 
function and PC20 during steroid treatment. Surprisingly, these relationships were not 
found in asthma. A possible explanation for this difference may be that in asthma 
doses between 400 and 800 μg per day already give a maximum treatment effect. 
Side-effects of steroids may compromise patient compliance (33). In our study, the 
absence of a relation between compliance to BDP and side-effects of this drug may 
be caused by the exclusion of six patients who used BDP with a spacer device be­
cause of severe throat complaints. 
Our cross-sectional assessment showed that one year after extensive inhalation in­
structions 27% of the patients had an insufficient Rotahaler inhaler technique. In two 
other reports about the Rotahaler inhaler technique (one in asthmatic children (13) 
and one in asthmatics of all ages (14), a wrong technique was demonstrated in 56% 
and 20% of the subjects, respectively. Moreover, it appeared from our study that the 
majority of patients either did not expire prior to inhalation or did not hold breath 
after inspiration. Pedersen et al. studied 39 asthmatic children and found that 62% of 
them did not exhale before a Rotahaler inhalation and 49% of the children did not 
hold breath for at least seven seconds (13). Although the Rotahaler may be relatively 
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easy to use, regular instructions of the inhaler technique, with special regard to initial 
expiration and holding breath afterwards, seem to be essential 
We conclude that non-compliance with inhaled steroids and poor inhaler tech­
nique often occur in the long-term treatment of asthma and chronic bronchitis, even 
in a controlled situation Regular instruction in the inhaler technique and proper in­
formation about steroid treatment by the general practitioner is important 
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11. Treatment of mild asthma and chronic 
bronchitis with inhaled corticosteroids: 
is discontinuation of therapy possible?* 
Abstract 
Inhaled corticosteroids are becoming increasingly important for treatment of asthma and chronic 
bronchitis in general practice The aim of this study was to investigate if long term therapy with in­
haled corticosteroids could be discontinued in mild asthma and chronic bronchitis when patients 
are in a clinically stable phase of disease The study population consisted of 223 patients who en 
tered a two-year randomised controlled bronchodilator intervention study in general practice The 
experimental group consisted of 39 patients, who had used inhaled corticosteroids daily during at 
least the year preceding this study and stopped using these drugs because of participation in the 
bronchodilator intervention study The control group consisted of the remaining 184 patients, who 
had not used corticosteroids in the year preceding the study At the start ol the study, the patients of 
the two groups were completely comparable with respect to all relevant characteristics During the 
study, patients were only treated with a bronchodilator (salbutamol or ipratropium bromide) Out­
come measures were exacerbations, symptoms, yearly decline in forced expiratory volume in one 
second (FEVi) and yearly change in nonspecific bronchial responsiveness (PC20 histamine) An 
important outcome measure and also endpoint in this study was the need for additional corticoste­
roid therapy because of signs and symptoms of increased airway obstruction (advice of responsible 
GP, insufficient study medication, too severe or too many exacerbations) Treatment with inhaled 
corticosteroids was discontinued under close observation during an eight week wash-out period 
just before the start of the trial 
In the experimental group, 22 of the 39 patients (56%) dropped out during the two year study 
penod because of a deterioration of their clinical condition and need for additional (inhaled) corti­
costeroid treatment In the control group, only 16 patients dropped out for this reason (9%) This 
difference was statistically significant (Chi-square=48 5, p<:0 0001) In the patients of the ex­
perimental group, who could continue without steroids for at least one year, the yearly FEVi de­
cline was much larger than in the control subjects 
It was concluded that stopping maintenance treatment with inhaled corticosteroids in patients 
with mild asthma and chronic bronchitis is troublesome Instead of stopping or interrupting treat­
ment, GPs are therefore advised to try to find out the minimal effective daily dose of inhaled corti­
costeroids within each patient which provides adequate control of the disease 
11.1. Introduction 
The current understanding that inflammation is a major pathophysiologic mechanism 
of asthma (1) and maybe also of chronic bronchitis (2), has resulted in a shift in treat­
ment policy towards the early introduction of inhaled corticosteroids (3,4) This tend­
ency is strengthened by the similar finding in two independent studies that continu­
ous therapy with bronchodilators had adverse effects on the control of asthma (5) and 
* Submitted for publication as Dompeling b, Van Grunsven PM, Van Schayck CP, Molema J, Akker-
mans R, Folgenng H, Van Weel С Treatment of mild asthma and chronic bronchitis with inhaled corti­
costeroids is discontinuation of therapy possible7 
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on the progression of asthma and chronic bronchitis (6). Two retrospective, uncon­
trolled studies (7,8) and some recent prospective ones (9-11) suggested that (inhaled) 
corticosteroids can improve the long-term course of asthma or chronic bronchitis. As 
continuous therapy with bronchodilators may have the opposite effect, treatment with 
inhaled corticosteroids is probably the only therapy available at the moment which is 
able to improve the long-term course of asthma and chronic bronchitis. 
Since the majority of patients with asthma or chronic bronchitis are treated in 
general practice (12-13), GPs will have to prescribe this kind of therapy for a grow­
ing number of patients. An important question for both GPs and patients is: can treat­
ment with inhaled corticosteroids be interrupted or stopped when patients are in a 
stable phase of disease? A large proportion of patients in general practice do not re­
ally need inhaled steroids for an adequate control of their disease, at least not on a 
permanent basis. Since inhaled steroids do not have a direct symptom-relieving ef­
fect, patient compliance with this medication is a large problem (14). Therefore, pa­
tients may ask their GP to stop maintenance treatment with inhaled steroids. Al­
though in general inhaled steroids have relatively mild side-effects, oral candidiasis, 
hoarseness and irritation of the oropharynx may occur (15,16). Moreover, systemic 
effects may develop in an increasing number of subjects when doses of 800 μg and 
over are used (15,16). All these aspects make the above question very relevant. 
When corticosteroids 'cure' the underlying mechanisms of asthma and chronic 
bronchitis to some extent, treatment can probably be interrupted. If they only sup­
press inflammation temporarily, stopping might be difficult. There is very little do­
cumented material about the effects of stopping treatment with inhaled corticoste­
roids. 
The aim of this study was to assess the effects of stopping treatment with (inhaled) 
corticosteroids on the long-term control and progression of asthma and chronic bron­
chitis in general practice. For this purpose, data of 223 patients with asthma or 
chronic bronchitis from a large intervention study in general practice were analyzed 
(6). 
11.2. Methods 
Patients 
The study population consisted of 223 patients who entered a two-year randomised 
controlled bronchodilator intervention study in general practice (6,17). The primary 
goal of this study was to compare the effects of continuous bronchodilator therapy 
with those of treatment on demand. Patient selection, and in- and exclusion criteria of 
the intervention study have been described in detail elsewhere (6). In short: 29 GPs 
were asked to select all their patients aged 30 and over with symptoms of asthma or 
chronic bronchitis. Only patients with a mild to moderate airway obstruction (FEVi 
or FEVi/EVC at least two standard deviations below their predicted value (18) but 
more than 50% of the predicted value) and/or bronchial hyperresponsiveness to 
histamine (provoking concentration of histamine that produces a 20% fall in FEVj 
(PC20) <8mg/ml) were included by the investigators. Exclusion criteria were: depen-
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dency on corticosteroids, chronic heart failure, malignant disorders or other life-
threatening diseases. The experimental group consisted of 39 patients who had con­
tinuously used (inhaled) corticosteroids daily during at least one year preceding the 
study and had stopped because of participation in the bronchodilator intervention 
study. Patients had been permitted by their responsible physician to stop corticoste­
roids, and they entered an eight-week wash-out period before the start of the study 
during which inhaled corticosteroid treatment (and other pulmonary medication) was 
stopped. During this period, only inhaled salbutamol or ipratropium bromide were 
prescribed. When patients had an exacerbation or aggravating symptoms during this 
period, they were considered to be steroid dependent and therefore excluded from the 
intervention study. The control group consisted of the remaining 184 patients who 
had not used (inhaled) corticosteroids in the year preceding the study. Clinical char­
acteristics of the experimental group and the control group are given in Tables 11.1 
and 11.2. At the start of the study, there were no significant differences between the 
two groups. The study was approved by the Medical Ethics Committee of the 
University of Nijmegen. All patients gave informed consent. The criteria for the 
diagnosis of asthma or chronic bronchitis were based on the standards of the Ameri­
can Thoracic Society (19). Asthma was defined as the combination of (6,17): 1. re­
versible obstruction (FEVi increased by more than 15% of the baseline value, 60 
minutes after the administration of ipratropium bromide 80 μg and salbutamol 400 
μg; 2. bronchial hyperresponsiveness to histamine (PC20 ^ 8 mg/ml); 3. dyspnoea; 4. 
allergy and/or wheezing. Chronic bronchitis was defined as the combination 
of (5,17): 1. chronic cough or chronic sputum production for at least three months 
during at least two consecutive years; 2. continuous bronchus obstruction (FEVi 
<85% of the predicted value). 
Table 11.1 Patient characteristics of the 39 patients of the experimental group (continu­
ous use of inhaled corticosteroids during the year preceding the study), and the 184 
patients of the control group (no use of corticosteroids during the pre-study period). 
Standard deviations or ranges are given in brackets. Differences in dichotomous 
variables are statistically compared by means of the chi-square test, in normally 
distributed variables by means of the unpaired Student's t-test. No statistically signifi­
cant differences were present. 
Variable Experimental group Control group 
Number 
Age (yrs) 
Sex (M/F) 
Symptom score 
Pack years 
Smokers (+/-) 
Allergy (+/-)# 
FEVi %pred 
FEV1/IVC (%) 
Reversibility FEVi (% pred) 
PC20 (mg/ml)## 
39 
52 (12) 
19/20 
4 9 (17) 
14 (12) 
9/15 
7/20 
71 (17) 
62 (15) 
14 (10) 
2 5 
184 
53 
107/77 
4 8 
17 
87/77 
44/123 
75 
63 
10 
4 6 
(13) 
(18) 
(17) 
(19) 
(14) 
(10) 
# Allergy was defined as at least one positive test out of seven RAST 
## geometric mean PC20 is given 
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Table 11.2 The patient characteristics of the group who participated for at least one year 
in the two-year randomised controlled study. Standard deviations or ranges are given in 
brackets. Differences in dichotomous variables are statistically compared by means of 
the chi-square test, in normally distributed variables by means of the unpaired Student's 
t-test. No statistically significant differences were present. Patients of the experimental 
group had used an average daily dose of 450 μg (range 150-800 μρ) of an inhaled 
corticosteroid (budesonide or beclomethasone dipropionate). 
Asthma Chronic bronchitis 
Variable 
Number 
Age (years) 
Sex (M/F) 
Pack years (no ) 
Smokers (+/-) 
Allergy (+/-)# 
FEVi (%pred) 
PC20 (mg/ml)## 
Reversibility### 
Experimental 
10 
54 (34-72) 
3/7 
10 
2/8 
5/5 
72 (23) 
0 9 (0 8) 
17 (11) 
Control 
62 
50 (27-74) 
30/32 
12 
27/35 
24/37 
74 (21) 
2 7 (19) 
15 (11) 
Experimental 
13 
49 (31-68) 
7/6 
14 
6/7 
2/11 
73 (15) 
17 6 (1 6) 
10 (6) 
Coi 
99 
54 
62/37 
19 
60/39 
20/77 
78 
135 
7 
# presence of allergy was defined as at least one positive test out of the 7-RAST tests 
## geometric mean PC20 values are given 
### reversibility of airway obstruction, measured on the basis of the increase in FEVi and expressed as a 
percentage of the predicted value 
Outcome measures 
Under standard bronchodilator treatment the experimental group and the control 
group were followed during two years. Outcome measures during this period were: 
the number of exacerbations, severity of symptoms, annual decline in forced expira­
tory volume in one second (FEVi) and annual change in nonspecific bronchial re­
sponsiveness (PC2o-histamine). An important outcome measure and also endpoint in 
this study was the need for additional corticosteroid therapy because of signs and 
symptoms of increasing airway obstruction (advice of responsible GP, insufficient 
study medication, too severe or too many exacerbations). 
Measurements 
• Respiratory symptoms. The severity of respiratory symptoms (cough, phlegm, 
dyspnoea) was assessed weekly on a scale of 0-4 and recorded in a diary. 
• Exacerbations. Exacerbations were defined according to Fletcher et al. (20) with 
modifications of Boman et al. (21). In case of an exacerbation, a ten-day course of 
oral prednisone was given: 5-5,4-4, 3-3, 2-2, 1-1. 
• FEVi, PC2o-histamine and reversibility of airway obstruction. No bronchodilating 
medication was taken during at least eight hours before the assessments. Measure­
ments of FEVi were performed with the Microspiro HI-298 (Chest Corporation, Ja­
pan) (22) by two qualified laboratory technicians. On all occasions patients had to 
perform three satisfactory forced vital capacity (FVC) manoeuvres. Data were taken 
from the curve with the highest sum of FVC and FEVi. Then the bronchial responsi­
veness to histamine was measured according to the method described by Cockcroft et 
al. (23), and expressed as the PC2o-histamine value (concentration of histamine in 
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mg/ml producing a 20% fall in FEVi). After the FEVi had returned to baseline value, 
the increase in FEVi 60 minutes after the inhalation of both salbutamol 400 μg and 
ipratropium bromide 80 μg was assessed. 
• Smoking behaviour. The number of cigarettes per day were recorded by the patients 
in a weekly report. The smoking history was retrospectively assessed in pack years. 
Treatment during two-year follow-up 
All patients were randomly allocated to one of the two parallel treatment regimens: 
1. continuous use of salbutamol 400 μg or ipratropium bromide 40 μg, four times 
daily (dry powder inhalations); 
2. use of salbutamol 400 μg or ipratropium 40 μg (dry powder inhalations) on de­
mand (6). 
The number of dry powder inhalations used was recorded by the patients in their 
weekly report. All patients who had used salbutamol during the first year crossed 
over to ipratropium bromide during the second year and vice versa. The sequence of 
the drugs was determined by random allocation. 
Analysis 
The score of cough, phlegm and dyspnoea was combined in the total symptom score. 
The annual FEVi decline was determined by linear regression of FEVi in the course 
of time (maximum of 7 measurements). PC20 values were 2log transformed prior to 
analysis. The annual changes of PC20 were estimated by linear regression of 2logPC2o 
in the course of time (maximum of 5 measurements). The influence of stopping treat­
ment with inhaled corticosteroids on the outcome variables was assessed by multiple 
analysis of variance (MANOVA), controlling for age, sex, height, smoking, pack 
years, allergy, initial PC20 and FEVi, reversibility of obstruction and treatment 
regimen (24). The relation between clinical characteristics and the annual FEVi de­
cline after stopping treatment with steroids in the experimental group was also inves­
tigated by means of MANOVA. 
11.3. Results 
In the experimental group, 22 of the 39 patients (56%) dropped out during the two-
year study period because of a deterioration of their clinical condition and need for 
additional (inhaled) corticosteroid treatment (Figure 11.1). In the control group, only 
16 patients dropped out for the same reason (9%). This difference was significant 
(Chi-square=48.5, p<0.0001) (Figure 11.1). Of the 22 dropouts from the experimen­
tal group 13 already needed additional corticosteroids during the first six months of 
the bronchodilator trial. 
When the patients who could continue bronchodilator therapy alone during at least 
one year were analyzed, the following data were found (Table 11.3). In asthma, the 
annual FEVi decline was larger in the experimental group (165 ml/yr) than in the 
control group (40 ml/yr) (p=0.022. Table 11.3). No differences between experimental 
and control group were found with respect to symptoms, exacerbations and the year-
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Figure 11.1 The percentage of patients in the experimental and control group that 
dropped-out during the two-year study period because of the need for additional 
corticosteroid therapy. 
Patients needing • 
corticosteroids (%>) 
100-1 
80-
60-
40-
20-
• chi-square =48 5, 
p<0 0001 
Experimental group Control group 
ly change in PC20. For chronic bronchitis, there was no significant difference in the 
decline in FEV] between the experimental group and the control group (95 and 65 
ml/yr respectively, Table 11.3) or in the other outcome measures. 
In the 10 asthmatic patients of the experimental group, it was only allergy that was 
to some extent related to a larger annual decline in FEVi after stopping treatment 
with corticosteroids (estimate ß=131 ml/yr, p=0.114). In the chronic bronchitis pa-
tients of the experimental group, less smoking in the past (a lower number of pack 
years) was significantly associated with a more rapid annual decline in FEVi after 
stopping treatment with corticosteroids (estimate ß=7.23 ml/yr, p=0.047). 
In the whole group of 72 asthmatic patients, an interaction was observed between 
stopping treatment with corticosteroids and the reversibility of obstruction at the start 
of the study (p<0.05). A high reversibility at the start of the study was related to a 
faster annual FEVi decline in the experimental group but to a lower decline in the 
control group (Figure 11.2). 
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Table 11.3 The effect of stopping treatment with corticosteroids on symptoms, 
exacerbations, the annual decline in FEVj and PC20 in patients with mild asthma and 
chronic bronchitis. Standard errors of the mean between parentheses. Differences were 
tested by means of the unpaired Student's t-test. 
Asthma 
FEVi decline (ml/yr) 
PC20 decline (doubl dose/yr)# 
Exacerbations (no /yr) 
Symptom score 
Chronic bronchitis 
FEVi decline (ml/yr) 
PC20 decline (doubl dose/yr)# 
Exacerbations (no /yr) 
Symptom score 
Experimental 
(n=10) 
165 (50) 
0 33 (0 62) 
11 (0 3) 
2 0 (0 5) 
Experimental 
(n=13) 
95 (40) 
0 55 (0 54) 
0 9 (0 4) 
2 3 (0 5) 
Control 
(n=62) 
40 (20) 
0 33 (0 22) 
0 8 (0 1) 
2 2 (0 3) 
Control 
(n=99) 
65 (15) 
0 60 (0 20) 
0 6 (0 2) 
2 2 (0 2) 
p-value 
0 022 
1 000 
0216 
0 697 
p-value 
0 446 
0 922 
0315 
0 836 
# the annual decline m PC20 is given in doubling doses per year 
11.4. Discussion 
Long-term treatment with inhaled corticosteroids in asthma and chronic bronchitis is 
becoming increasingly important for general practice. Two recent guidelines about 
the therapeutic management of asthma have advocated the early introduction of in-
haled corticosteroids in subjects with asthma (3,4). There is increasing evidence for 
the efficacy of inhaled corticosteroids in patients with chronic bronchitis (11,25), al-
though the effects on average are lower than in asthma. Since most patients with as-
thma or chronic bronchitis are treated in primary care (12,13) and indications for the 
use of inhaled corticosteroids are increasing, GPs will have to prescribe this kind of 
therapy for a growing number of patients. 
For GPs an important therapeutic question about treatment with inhaled corticos-
teroids is if maintenance therapy with these drugs can be discontinued when steroids 
are not (or no longer) essential for an adequate control of the disease. This question 
has not been addressed yet in a long-term follow-up study. Therefore, it seemed ap-
propriate to stop steroid therapy under close observation, as we did in this study. 
We tried to answer the above question by investigating the progression and control 
of asthma or chronic bronchitis in 223 patients who were treated in a two-year ran-
domised controlled bronchodilator intervention study in general practice (6). Of the 
223 patients 40 had continuously used (inhaled) corticosteroids during the year 
preceding the intervention study. Only those patients were selected who had mild de-
grees of airway obstruction (FEVi was 75% of the predicted value) and mild symp-
toms and who -in the opinion of the responsible GP- could stop the use of inhaled 
corticosteroid therapy. There were no differences in characteristics at the start of the 
study between the patients who had used inhaled corticosteroids and those who had 
not. After selection, inhaled corticosteroid treatment was stopped in an eight-week 
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Figure 11.2 The relationship between the reversibility of obstruction at the start of the 
study and the annual FEVi decline in the experimental and control group of asthma. The 
difference in slopes was statistically compared by means of the unpaired Student's t-test. 
Regression lines (x=Reversibility <%initial FEVi, y=Change FEVi (ml/yr): 
FEV |-change (ml/yr) 
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- ) Experimental group y = -2 80 χ -90, г = 0 52 
- ) Control group у = +1 80 χ - 75, г = 0 23 
wash-out period before the start of the study. During this period, we observed 
whether the symptoms were well controlled by bronchodilators alone and if no 
exacerbations or signs of increasing airway obstruction developed. If patients did not 
respond well to this bronchodilating therapy alone, they were excluded from the 
study. 
The present study shows that it is difficult to stop treatment with inhaled corticos­
teroids in patients with mild asthma and chronic bronchitis. Of the 39 patients 32 
needed additional corticosteroids during the two-year period (=56%), a large part of 
them already during the first six months after stopping. This percentage was much 
higher than in the control group (only 9%). In the asthmatic patients who were able 
to continue treatment with bronchodilators alone for at least one year, the annual de­
cline in ventilatory function was much higher than in the control group. In chronic 
bronchitis, stopping treatment with inhaled corticosteroids was accompanied by an 
increased annual FEVi decline in the patients who smoked relatively little (small 
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number of pack years). It is probable that the patients with a small number of pack 
years, have less irreversible damage to the airways (26) and therefore respond better 
to inhaled corticosteroids. As a consequence, stopping treatment with corticosteroids 
in these patients will also give an increased annual decline in ventilatory function. 
The first aim of our randomised controlled study was to compare the effects of 
continuous bronchodilator therapy with those of treatment on demand on the progres­
sion and control of asthma and chronic bronchitis in general practice (6). However, 
we had a reasonably good design for addressing the question of stopping treatment 
with inhaled corticosteroids. All patients were closely observed under prospective 
controlled trial conditions, with a standardized treatment and standardized measure­
ments of symptoms, exacerbations and ventilatory function so that the effects of 
stopping could be assessed perfectly. Patients who had used inhaled corticosteroids 
before the start of the study did probably not have a more severe degree of asthma or 
chronic bronchitis than those who had not. No differences in characteristics were 
found between the patients of the experimental and control group. In an earlier re­
port, we did not find a relation between the severity of asthma or chronic bronchitis 
and the use of corticosteroids before the start of the study in the same patient popula­
tion (27). The use of corticosteroids appeared to be determined by the differences in 
prescription behaviour of GPs and pulmonary physicians rather than by the severity 
of the disease (27). The pulmonary physician prescribed almost six times more in­
haled steroids than GPs in the same type of patient. We also have data of a few years 
before the start of the present study about the course of lung function in the patients 
who were also treated by a pulmonary physician during the pre-study period (and 
mostly also used inhaled corticosteroids). It appeared that the ventilatory function 
had hardly deteriorated during the pre-study period. These data suggest that the rapid 
decline in ventilatory function in the patients of the experimental group must have 
been caused by stopping treatment with inhaled steroids. The results of this study 
were not confounded by the bronchodilator intervention, because as all treatment 
groups were equally represented in the experimental and the control group. More­
over, the bronchodilator treatment was incorporated as a covariate in the multiple 
analysis of variance (MANOVA) of the annual FEVi decline. 
The results of this study have several implications for the treatment with inhaled 
corticosteroids in general practice. It is difficult to interrupt or stop long-term treat­
ment with inhaled corticosteroids because of an increase in the number or severity of 
exacerbations, an increase in the symptoms of airway obstruction and a rapid fall in 
ventilatory function. Instead of stopping treatment with inhaled corticosteroids, it 
might be better to lower the daily dose of inhaled corticosteroids under close moni­
toring of daily functioning, respiratory symptoms and peakflow rate (3). In this way, 
the GP can find out the minimal daily dose necessary to provide adequate control of 
the disease. 
The high percentage of patients who needed (additional) corticosteroid therapy 
and the large decline of FEV ι in the patients stopping treatment with steroids suggest 
that inhaled steroids do not cure but only suppress underlying disease processes. It 
even suggests the existence of a 'rebound increase' in airway inflammation and a 
consequent excessive increase in airway obstruction after the withdrawal of steroids. 
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Short-terms studies in asthma demonstrated a decline in FEVi (28-30) and an in­
crease in nonspecific bronchial responsiveness (31) after withdrawal of inhaled ste­
roids (28,29,31) or dose reduction (30). After stopping treatment with oral steroids or 
replacement by inhaled corticosteroids, fatal asthma (32) and severe asthma relapse 
(33) may occur as late as four to eight months after discontinuation. The syndrome of 
pseudorheumatism (myalgia, arthralgia, joint swelling, etc.) in some asthmatic pa­
tients stopping treatment with oral steroids (34) might also suggest a rebound in­
crease in systemic and local inflammatory processes. 
In our study, a high reversibility (assessed at the start of the two-year study period) 
was related to a rapid yearly FEV ι decline in the asthmatics who stopped treatment 
with steroids but to a slow yearly decline in the asthmatics of the control group (Fig­
ure 11.2). A comparable interaction was found between bronchial hyperresponsive-
ness and stopping treatment with steroids. This remarkable difference needs clarifica­
tion. In general, a high reversibility of obstruction is accompanied by a better prog­
nosis (less decline in FEVi) (26,35). Therefore, the relation between reversibility and 
yearly decline in asthmatics who stopped treatment with steroids was the reverse of 
what was expected. We suggest that a better reversibility (and/or a lower bronchial 
hyperresponsiveness) in the asthmatics of the experimental group was caused by a 
higher efficacy of steroids. Stopping treatment with steroids in these asthmatics re­
sults in a higher decline in lung function than in the asthmatics with a lower revers­
ibility (or more bronchial hyperresponsiveness). It has been suggested by Josephs et 
al. that assessments of bronchial hyperresponsiveness in asthma may be of help in 
the decision to stop corticosteroids (36). However, our study suggests that this is dif­
ficult. A less severe degree of bronchial hyperresponsiveness in asthmatics using in­
haled corticosteroids might be the consequence of a good response to these drugs. 
When steroids are discontinued in these patients, a rapid decline in lung function may 
occur. 
We conclude that stopping maintenance treatment with inhaled corticosteroids in 
patients with mild asthma and chronic bronchitis is not advisable. After discontinua­
tion, about 60% of the patients needed additional inhaled corticosteroids, most of 
them already during the first six months after stopping. In the patients who could 
continue without corticosteroids during one or two years, the annual decline in venti­
latory function was much larger than in the control subjects. Instead of stopping, GPs 
are therefore advised to try to find out the minimal effective daily dose of inhaled 
corticosteroids which provides adequate control of the disease in individual patients. 
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Summary 
Chapter J gives a general introduction and describes the objectives of the studies re-
ported in this thesis. The main study in this thesis is a follow-up to our previously 
published trial in which the effects of bronchodilators on the course of asthma and 
COPD was assessed in 223 patients from general practice. This previous trial re-
vealed two important aspects of the treatment of asthma and COPD with bronchodi-
lators alone: 
a. A relatively large group of 56 patients had an unexpectedly rapid progression of 
their asthma or COPD (in terms of annual decline in lung function and frequency 
of exacerbations). 
b. The use of a bronchodilator (salbutamol or ipratropiym bromide) four times 
daily was accompanied by a more rapid annual decline in lung function than 
treatment on demand; 
The main questions of this follow-up study and this thesis are: 
1 ) How can we identify patients with a rapid progression of asthma or COPD? 
2) Does treatment with inhaled corticosteroids decelerate this rapid progression of 
asthma or COPD? 
These questions are very much related to the early diagnosis and early treatment of 
patients with asthma or COPD in general practice. Underdiagnosis and undertreat-
ment of asthma and COPD have been reported in general practice. Most patients with 
asthma or COPD in the Netherlands and several other countries are treated in general 
practice, which stresses the importance of the subject. 
Simple spirometers for use in general practice are nowadays available. However, the 
reliability is often unclear. In Chapter 2 the accuracy, precision and linearity of the 
integrating Microspiro HI-298 flow meter (Chest Corporation, Japan) was assessed 
by using a Fleisch no. 4 pneumotachograph as a standard. A healthy subject per-
formed forced vital capacity manoeuvres at different levels of lung inflation. 
The results showed that the linearity of the Microspiro was good except for the 
peak expiratory flow rate (PEFR) and the maximal expiratory flow at 25% of the ex-
pired volume (MEF75). The random error (measure of precision) of all flow-volume 
(F-V) indices was lower than 5%. The systematic error (measure of accuracy) was 
low for the forced expiratory volume in one second (FEVi) and the FVC (1.0% and 
4.6% respectively) but much higher for the instantaneous expiratory flows (PEFR 
11%; MEF75 7.0%; MEF50 8.5%; MEF25 11.4%). Only the total error in FEVi com-
plied with the tolerance of 4% of the European Coal and Steel Community (ECSC). 
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When the measured values were adjusted according to the regression equations of 
this study, all F-V indices were accurate and precise within 5%. It can be concluded 
that the portable Microspiro HI-298 is a useful instrument for bedside, work-site spi-
rometry and for use in general practice. As the accuracy of the instantaneous expira-
tory flows (PEFR, and MEF-values) is moderate, it is advised to adjust these values 
with the regression equations of this study. The instrument is relatively expensive. 
For the future, there is (still) a need for cheap but reliable flow-volume meters for use 
in general practice. 
The bronchodilating response (reversibility) after administration of a bronchodilator 
is not only a usefull test for separating asthmatics from patients with COPD, but 
probably also has prognostic value. Different ways of expressing reversibility are 
used. It is unclear how reversibility is best expressed. Chapter 3 compares six differ-
ent ways of expressing the bronchodilating response with respect to: a) the inde-
pendence of the prebronchodilator FEVi, and b) the reproducibility of the bronchodi-
lating response. With respect to a), linear regression analysis was applied to the 
cross-sectional and longitudinal data. With respect to b), coefficients of variation 
(CV) of the 6 bronchodilating responses during two years of bronchodilator therapy 
alone were calculated and compared by analysis of variance (ANOVA). 
It appeared that no index was independent of the prebronchodilator FEVi. How-
ever, some indices were significantly less dependent on the prebronchodilator lung 
function and therefore more reproducible than others. The index '% initial' (change 
as a percentage of the prebronchodilator value) was most dependent on the prebron-
chodilator lung function and had the worst reproducibility (coefficient of variation 
ranged from 50-61%). The indices '% possible' (change as a percentage of the pre-
dicted minus prebronchodilator value) and '% achievable' (change as a percentage of 
the maximal postbronchodilator minus prebronchodilator value) were least depend-
ent on the prebronchodilator value and therefore had the highest reproducibility 
(coefficient of variation ranging from 34-53%). 
The way bronchodilating responses should be expressed depends on which index 
is most informative for the purpose of the test. However, the index '% initial' was 
most dependent on the prebronchodilator FEVi and had the worst reproducibility, 
whereas for the indices '% possible' or '% achievable' the opposite was found. In 
bronchodilator studies, the latter expression indices may increase the possibility of 
detecting changes or differences in bronchodilating efficacy between different drugs. 
To distinguish between asthmatics and patients with COPD on the basis of revers-
ibility, bronchodilating responses are probably best expressed as '% predicted'. 
Early detection of patients with an unfavourable course of asthma or COPD in 
general practice can be important for the prevention of early morbidity and mortality. 
Chapter 4 deals with the early detection of patients with fast progressive asthma or 
chronic bronchitis in general practice on the basis of a single cross-sectional assess-
ment of symptoms, smoking behaviour, quality of life, physical signs of the chest, al-
lergy and lung function. 56 Patients showed fast progressive disease (FPD, a rapid 
annual decline in FEVi in combination with a high exacerbation rate). Measurements 
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at the start of the study were used in a logistic regression analysis in order to detect 
the patients at risk (those with FPD). 
The results showed that a lower maximal expiratory flow at 50% of expired vol­
ume (MEF50) was related to an increased risk of FPD in both asthma and chronic 
bronchitis (relative risks of 16.8 and 8.0 respectively, p<0.05). Most lung function in­
dices, but also quality of life and pack years were significant predictors of FPD in 
chronic bronchitis (p<0.05). However, with these predictors separately or even with 
the combination of several relevant clinical variables, it was not possible to detect 
FPD reliably: 18% of the patients with chronic bronchitis and 22% of those with as­
thma were still misclassified. 
Probably more than one measurement in time (monitoring) is necessary to detect 
the patients at risk. Monitoring should include assessments of objective ventilatory 
function indices (PEFR, FEVi or MEF50). 
Chapter 5 studies the hypothesis that the degree of bronchial hyperresponsiveness 
(BHR) is a risk factor for the progression of airway obstruction in asthma, while in 
COPD it reflects the existing airway obstruction. The relationships between the (an­
nual change in) PCao-histamine and the (annual change in) FEVi were investigated in 
the two-year randomized controlled bronchodilator intervention study. Patients used 
bronchodilator therapy alone. No steroids were permitted during the study. The re­
sults demonstrated that the PC20 at the start of the study was related to the subsequent 
annual decline of FEVi in asthma (r=0.32, p<0.05), but not in COPD (r=-0.10, 
p=0.885). Asthmatic patients with a РСго- аІие <2 mg/ml had an average decline of 
118 ml/yr, those with a РСзо- аІие >2 mg/ml of 27 ml/yr. The change of PC2o-his-
tamine during the two-year study period was related to the annual change of FEV 1 in 
COPD (r=0.45, p<0.05), but not in asthma (r=0.06, p=0.898). The disturbing in­
fluence of possible confounders was investigated and if necessary controlled for (age, 
sex, height, past and current smoking, allergy, FEVi, bronchodilator response, PC20, 
exacerbations and the bronchodilator treatment during the study). 
BHR as assessed with the PCzo-histamine, was involved in the progression of air­
way obstruction in asthma. In COPD, the degree of BHR only reflected the degree of 
existing airway obstruction. Therefore, BHR is a 'cause' of airway obstruction in as­
thma, but a 'consequence' of airway obstruction in COPD. 
An unexpectedly high number of 56 patients with asthma or COPD appeared to have 
an unfavourable course of their disease during bronchodilator therapy alone. In 
Chapters 6 and 7, the effects of treatment with inhaled beclomethasonc dipropionate 
(BDP) of 800 μg daily during one and two years respectively on the course of asthma 
and COPD were assessed. 
The results showed that a large initial increase in prebronchodilator FEVi of 
+458(SEM 115) ml/yr during the first six months of BDP treatment (p<0.0001) was 
followed by a decrease of -102(23) ml/yr during months 7-24 in the group as a 
whole (both asthma and COPD). However, the annual decline in FEVi during BDP 
treatment was less than the decline of-160(20) ml/yr before BDP (p<0.05). During 
the whole treatment period with BDP in asthmatics, the peak expiratory flow rate 
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(PEFR) significantly improved compared to the value at the start of BDP treatment 
with a maximal increase of 0.7(0.2) 1/s during months 13-15 of BDP treatment 
(p=0.0006). In patients with COPD, the PEFR increased by 0.21(0.09) 1/s compared 
to the value at the start of steroid treatment during months 4-9 of BDP treatment 
(p<0.05). Only in asthma, the bronchial hyperresponsiveness (assessed by the pro­
voking concentration of histamine that induces a 20% fall in FEVi, PC20) improved 
by BDP treatment. The decrease in PC20 of -0.4 doubling dose/year before BDP was 
different from the improvement of +1.1 doubling dose/year during BDP treatment 
(p<0.05). The number of exacerbations decreased during BDP treatment in both as­
thma and COPD (p<0.05). Besides, beneficial effects of BDP were found on the diur­
nal variation of the weekly measured PEFR and the severity of symptoms in both as­
thma and COPD. Only in asthmatics did BDP improve the forced inspiratory volume 
in one second (FIVi) and the static lung function indices of residual volume (RV), 
ratio residual volume/total lung capacity (RV/TLC) and inspiratory vital capacity 
(IVC). 
Additional treatment with BDP of 800 μg daily in the 56 patients with asthma or 
COPD improved an unfavourable course of disease during bronchodilator therapy 
alone. This effect was more evident in asthmatics than in patients with COPD. 
It is important to identify those patients who will particularly benefit from inhaled 
corticosteroids, because it will increase our understanding of the effects of steroid ac­
tion and it may refine the treatment policy of asthma and COPD. Chapter 8 deals 
with the relationships between the two-year response to inhaled corticosteroids in as­
thma or COPD and the clinical characteristics at the start of treatment (sex, age, 
smoking habits, symptoms, quality of life, allergy, static and dynamic spirometry, 
bronchodilating response, bronchial responsiveness to histamine). 
In asthmatics, the average increase in FEVi during BDP therapy was larger in pa­
tients with a better bronchodilating response (FEVi-pre: r=0.62, p<0.0001), a higher 
diumal peak-flow rate index (FEVi-post: r^0.42, p<0.05), a severer degree of bron­
chial hyperresponsiveness (FEVi-pre: r=-0.64, p=0.066), a higher transfer coefficient 
(FEVi-pre: r=0.76, p<0.01), a larger annual FEVi decline during bronchodilator ther­
apy alone (FEVi-post: r=-0.62, p<0.001) and a lower FIV, (FEVi-post: r=-QA2, 
p<0.05). It was not possible to predict the improvement in bronchial hyperrespon­
siveness to BDP from these clinical characteristics. In COPD, the average increase in 
FEVi during BDP treatment was larger in patients with a better bronchodilating re­
sponse (FEVi-pre: r=0.89, p<0.0001), a lower FEVi/IVC (FEVi-pre: r=-0.54, 
p<0.05), and a larger decline in FEVi during bronchodilator therapy alone (FEVi-
pre: r=-0.77, p<0.0001). No variables were significantly related to the change in 
postbronchodilator FEVi during BDP therapy in COPD. 
In asthmatics or patients with COPD, the two-year response in FEVi to inhaled 
BDP 400 μg two times daily was larger in patients with more reversibility, more in­
itial airway obstruction and a larger annual FEVi decline during bronchodilator ther­
apy alone. Only in asthmatics was the response to inhaled BDP more pronounced in 
patients with a larger degree of bronchial hyperresponsiveness, more diumal vari­
ations in peak-flow rate and a higher transfer coefficient. 
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Improving the quality of life of patients with asthma or COPD is one of the goals of 
therapy. Chapter 9 describes the effects of BDP on quality of life in asthma or 
COPD. Quality of life was assessed by means of the Inventory of Subjective Health 
(ISH) and the Nottingham Health Profile (NHP). 
Two-year treatment with BDP did not improve the ISH score or the six dimen-
sions of the NHP, neither in asthma nor in COPD. However, BDP significantly im-
proved the course of lung function (the forced expiratory volume in one second, 
FEVi) (p<0.0001). BDP temporarily decreased respiratory symptoms during the first 
three months of BDP treatment in asthma (p<0.01) and during months 7-12 in COPD 
(p<0.05). Only a weak cross-sectional and longitudinal correlation was found be-
tween (change in) symptoms and quality of life on the one hand and the (change in) 
FEVi on the other. 
Although BDP clearly improved the course of lung function and other parameters 
in asthma and COPD, no improvement in generic quality of life was found in the pa-
tients of this study. The data may indicate that patients soon get used to different le-
vels of lung function. In future trials in asthma and COPD, it is advised that both 
generic and disease-specific health instruments are used and also that quality of life 
is measured frequently during the early phase of the intervention, e.g. once every 
month. 
The compliance of patients with inhaled corticosteroids and the inhalation technique 
can be important problems for the long-term effectiveness of this kind of treatment. 
In Chapter 10 the compliance with and the inhaler technique (dry powder device Ro-
tahaler) of beclomethasone dipropionate (BDP) were investigated. Compliance with 
BDP was measured by counting capsules single-blind over a four-month period, and 
also by answering a questionnaire. 
The average compliance rate was 82(SD 30)% of the prescribed amount of BDP. 
Counting capsules revealed non-compliance with BDP in 46% of the patients when 
compliance was defined as using 80 to 120% of the prescribed amount of BDP. The 
questionnaire suggested that only 7 % of the patients was non-compliant. Individual 
compliance rates were not related to age, sex, type of disease and side-effects of 
BDP. In chronic bronchitis, but not in asthma, the rates of compliance rates with BDP 
were related to the pulmonary symptoms, the change in lung function and the change 
in nonspecific bronchial responsiveness. The inhaler technique was judged insuffi-
cient in 27% of the patients. 
Both non-compliance with and a wrong inhaler technique of inhaled steroids often 
occur in the long-term treatment of asthma and chronic bronchitis, even in a control-
led trial situation. This stresses the importance of regular instruction in inhaler tech-
nique and proper information about prophylactic steroid treatment by the physician 
during the treatment of asthma or chronic bronchitis. 
An important questions to patients with asthma or COPD and their responsible physi-
cian is if treatment with inhaled corticosteroids can be discontinued when patients are 
(again) in a clinically stable phase of their disease. In Chapter lì, the course of mild 
asthma and COPD after discontinuation of treatment with inhaled corticosteroids was 
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studied in clinically stable patients. 223 Patients from general practice entered our 
two-year randomised controlled bronchodilator intervention study. The experimental 
group consisted of 39 patients, who had used inhaled corticosteroids daily during at 
least the year preceding this study and had stopped using these drugs because of par-
ticipation in the bronchodilator intervention study. The subjects were judged as non-
steroid-dependent by their physician. Treatment with inhaled corticosteroids was dis-
continued under close observation during an eight-week wash-out period just before 
the start of the trial. 
The control group consisted of the remaining 184 patients, who had not used cor-
ticosteroids in the year preceding the study. At the start of the study, the patients of 
the two groups were completely comparable with respect to all relevant charac-
teristics. 
In the experimental group, 22 of the 39 patients (56%) dropped out during the 
two-year study period because of a deterioration of their clinical condition and need 
for additional (inhaled) corticosteroid treatment. In the control group, only 16 pa-
tients dropped out for this reason (9%). This difference was statistically significant 
(Chi-square= 48.5, p<0.0001). In the patients of the experimental group, who could 
continue without steroids for at least one year, the annual decline in FEVi was much 
larger than in the control subjects. 
In general, stopping maintenance treatment with inhaled corticosteroids in patients 
with mild asthma and chronic bronchitis is not to be recommended. Instead of stop-
ping or interrupting treatment, GPs are therefore advised to try to find out what is the 
minimal effective daily dose of inhaled corticosteroids within each patient that still 
provides adequate control of symptoms, exacerbations and lung function. 
Conclusions and recommendations 
1. The Microspiro HI-298 is a useful instrument for use in general practice. The ap-
paratus complies with the international requirements for spirometry as far as the 
FEVi is concerned. However, it is relatively expensive. There is still a need for 
cheap but reliable flow-volume meters for use in general practice. 
2. The detection in general practice of patients with asthma or COPD at risk (with 
rapidly progressive disease) is only possible in a reliable way by monitoring the 
course of disease. Even an extensive cross-sectional assessment of all kinds of 
relevant characteristics is insufficient to detect the patients at risk. Monitoring of 
asthma and COPD should imply assessing lung function. 
3. The choice of an index to express reversibility depends on which index is most 
informative for the purpose of the test. However, the most frequently used 
method of expressing the bronchodilating response as a percentage of the pre-
bronchodilator lung function value is most dependent on the prebronchodilator 
lung function and therefore least reproducible in the course of time. 
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4. In bronchodilator studies, the use of the expression indices '% possible' (change 
as a percentage of the predicted minus prebronchodilator lung function value) 
and '% achievable' (change as a percentage of the maximal postbronchodilator 
minus prebronchodilator value) increase the possibility of detecting differences 
in bronchodilating efficacy of different bronchodilator drugs within patients with 
asthma or COPD. This is the case because these expression indices are least de-
pendent on the prebronchodilator lung function and are most reproducible. 
5. Nonspecific bronchial hyperresponsiveness is a 'cause' of airflow obstruction in 
asthma but a 'consequence' of airflow obstruction in patients with COPD. 
6. Additional treatment with an inhaled corticosteroid (BDP, beclomethasone di-
propionate) improves an unfavourable course of asthma or COPD during bron-
chodilator therapy alone. 
7. BDP diminishes symptoms and exacerbations and decelerates the annual decline 
in lung function in both asthma and COPD. Only in patients with asthma did the 
inhaled steroid improve bronchial hyperresponsiveness. 
8. In both asthma and COPD, the two-year response (in lung function) to inhaled 
BDP was larger in patients with more reversibility on a bronchodilator, a faster 
annual decline in lung function during bronchodilator therapy alone and more 
airway obstruction. Only in asthmatics were more severe bronchial hyperrespon-
siveness, larger diurnal variations in peak flow and a higher transfer coefficient 
related to a better two-year response to the inhaled steroid. 
9. No influence of two-year treatment with inhaled BDP was found on quality of 
life in asthma and COPD as assessed by the generic quality of life instruments 
'Inventory of Subjective Health (ISH)' or the 'Nottingham Health Profile 
(NHP)'. As patients may get rapidly used to different levels of lung function, the 
quality of life should be measured frequently during the early phase of the inter-
vention (e.g. once every month). In future trials in asthma and COPD, it is ad-
vised that both generic and disease-specific health instruments are used. 
10. Both patient compliance with and inhaler technique of corticosteroids are a prob-
lem for the long-term treatment of asthma and COPD with this type of drugs. 
Regular instruction in inhaler technique and proper information about prophylac-
tic steroid treatment by the physician during the treatment of asthma or chronic 
bronchitis may improve these aspects of treatment. 
11. Stopping maintenance treatment with inhaled corticosteroids in patients with 
mild to moderate asthma or chronic bronchitis is not to be recommended. Instead 
of stopping or interrupting treatment, GPs are therefore advised to try to find out 
what is the minimal effective daily dose of inhaled corticosteroids within each 
patient that still provides adequate control of the disease. 
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Samenvatting 
Hoofdstuk I geeft een algemene introductie en beschrijft de onderzoeksvragen van de 
studies in dit proefschrift. De meeste patiënten met astma en COPD in Nederland en 
verschillende andere landen worden in de eerste lijn behandeld. Er zijn regelmatig 
publikaties verschenen over onderdiagnostiek en onderbehandeling van astma en 
COPD in de huisartsenpraktijk. De hoofdstudie in dit proefschrift is een vervolg op 
ons reeds eerder gepubliceerde onderzoek waarin de effecten van bronchusverwijders 
op het beloop van astma en COPD werden onderzocht bij 223 patiënten uit de huis-
artsenpraktijk. Dit onderzoek liet twee belangrijke aspecten van de behandeling van 
astma en COPD met alleen bronchusverwijders zien: 
a. Bij een relatief grote groep van 56 patiënten met astma of COPD trad een onver-
wacht snelle progressie op in hun ziekte (in termen van jaarlijkse longfunctieda-
ling en frequentie van exacerbaties). 
b. Het gebruik van een bronchusverwijder (salbutamol of ipratropium bromide) 
vier maal daags ging gepaard met een snellere daling in longfunctie dan het 'zo 
nodig' gebruik; 
De hoofddoelen van deze vervolgstudie en van dit proefschrift zijn: 
1) Hoe kunnen patiënten met een snelle progressie van astma of COPD worden op-
gespoord? 
2) Kan behandeling met inhalatiecorticosteroïden de/e snelle progressie van astma 
of COPD afremmen? 
Deze onderzoeksvragen zijn sterk gerelateerd aan de vroege opsporing en behande-
ling van patiënten met astma en COED in de huisartsenpraktijk. 
Eenvoudige spirometers voor gebruik in de huisartsenpraktijk zijn tegenwoordig 
voorhanden. De betrouwbaarheid van deze instrumenten is echter vaak onduidelijk. 
In hoofdstuk 2 werden de nauwkeurigheid, de zuiverheid en de lineariteit van de 
flow-volume meter Microspiro HI-298 (Chest Corporation, Japan) onderzocht door 
een Fleisch no. 4 pneumotachograaf als standaard te gebruiken. Een gezonde proef-
persoon voerde geforceerde expiraties uit bij verschillende longinflatieniveaus. 
De resultaten lieten zien dat de lineariteit van de Microspiro goed was behalve 
voor de pcakflowwaarde (PEFR) en de maximale expiratoire flow bij 25% van het 
geëxpireerde volume (MEF75). De toevallige fout (maat voor de zuiverheid) van alle 
flow-volume (F-V) parameters was lager dan 5%. De systematische fout (maat voor 
de nauwkeurigheid) was laag voor het geforceerde expiratoire volume in één seconde 
(FEVi) en de geforceerde vitale capaciteit (FVC) (respectievelijk 1,0% en 4,6%), 
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maar veel groter voor de direct gemeten expiratoire flows (PEFR 11,0%; 
MEF75 7,0%; MEF50 8,5%; MEF25 11,4%). Alleen de totale fout in de FEVi voldeed 
aan het tolerantiecriterium van 4% van de Europese Gemeenschap voor Kolen en 
Staal (EGKS). Wanneer de gemeten waarden werden aangepast volgens de regressie-
vergelijkingen in deze studie waren alle F-V indices tot op 5% nauwkeurig en zuiver. 
De conclusie was dat de draagbare Microspiro HI-298 een geschikt instrument is 
voor spirometrie aan het bed, op de werkplek en voor gebruik in de huisartsenprak-
tijk. Aangezien de nauwkeurigheid van de direct gemeten expiratoire flows (PEFR, 
en MEF-waarden) matig is, is het aan te bevelen om deze waarden aan te passen vol-
gens de regressievergelijkingen in deze studie. Het instrument is relatief duur. In de 
toekomst is er behoefte aan goedkopere maar betrouwbare flow-volume meters voor 
gebruik in de huisartsenpraktijk. 
De directe reactie na toediening van een bronchusverwijder (reversibiliteit) is niet al-
leen van belang om een onderscheid te kunnen maken tussen patiënten met astma of 
COPD maar heeft tevens prognostische betekenis. Er zijn verschillende methoden in 
gebruik om de reversibiliteit uit te drukken. Het is onduidelijk welke methode het be-
ste is. In hoofdstuk 3 worden zes verschillende methoden om de bronchusverwijden-
de reactie uit te drukken vergeleken met betrekking tot: a) de mate van onafhanke-
lijkheid van de FEVi waarde vóór bronchusverwijding (prebronchodilatoire FEVi), 
en b) de reproduceerbaarheid van de directe reactie op bronchusverwijders. Met be-
trekking tot a), werd lineaire regressieanalyse toegepast op de cross-sectionele en de 
longitudinale waarden. Met betrekking tot b), werden de variatiecoëfficiënten (VC) 
van de zes bronchodilatoire reacties gedurende de twee-jarige behandeling met alleen 
bronchusverwijders berekend en vergeleken met behulp van variantieanalyse (ANO-
VA). 
De resultaten gaven aan dat geen enkele uitdrukkingsmethode onafhankelijk was 
van de prebronchodilatoire FEVi. Echter, sommige indices waren significant minder 
afhankelijk van de prebronchodilatoire longfunctie en daardoor meer reproduceer-
baar dan anderen. De index '% initial' (toename als percentage van de FEVi waarde 
vóór bronchusverwijding) was het meest afhankelijk van de prebronchodilatoire 
longfunctie en had de slechtste reproduceerbaarheid (de variatiecoëfficiënten varieer-
den van 50-61%). De indices '% possible' (toename als percentage van de voorspel-
de minus de prebronchodilatoire waarde) en '% achievable' (toename als percentage 
van de maximale postbronchodilatoire minus prebronchodilatoire waarde) waren het 
minst afhankelijk van de prebronchodilatoire waarden en hadden daarom de hoogste 
reproduceerbaarheid (de variatiecoëfficiënten varieerden van 34-53%). 
De manier waarop de directe reactie op een bronchusverwijder moet worden uit-
gedrukt hangt af van de vraag welke methode de meeste informatie geeft over het 
doel van de test. De index '% initial' was het meest afhankelijk van de prebronchodi-
latoire FEVi en had de slechtste reproduceerbaarheid, terwijl voor de indices '% pos-
sible' en '% achievable' het omgekeerde gevonden werd. In onderzoeken naar de di-
recte reactie op bronchusverwijders kunnen de laatste uitdrukkingsmethoden de mo-
gelijkheid vergroten om veranderingen of verschillen in directe reacties tussen ver-
schillende bronchusverwijders op te sporen. Voor het onderscheid tussen patiënten 
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met astma en CORD op basis van de reactie op bronchusverwijders kan deze waar-
schijnlijk het best uitgedrukt worden als '% predicted'. 
Vroege opsporing van patiënten met ongunstig beloop van astma of COPD in de 
huisartsenpraktijk is van belang voor de preventie van vroege morbiditeit en mortali-
teit. In hoofdstuk 4 wordt onderzocht of een vroege opsporing van patiënten met een 
snel progressieve vorm van astma of chronische bronchitis mogelijk is in de huisart-
senpraktijk aan de hand van een eenmalige cross-sectionele meting van symptomen, 
rookgedrag, fysische diagnostiek, allergie en longfunctie. Van de 162 patiënten had-
den er 56 een snel progressieve ziekte (FPD (fast progressive disease), een snelle 
longfunctiedaling in combinatie met een hoog aantal exacerbaties). Metingen aan het 
begin van het onderzoek werden in een logistische regressieanalyse gebruikt voor het 
opsporen van de risicopatiënten (met een snel progressieve vorm van astma of chro-
nische bronchitis). 
Uit het onderzoek bleek dat een lagere maximale expiratoire flow bij 50% van het 
geëxpireerde volume (MEF50) gerelateerd was aan een toegenomen risico op FPD 
zowel bij astma als bij chronische bronchitis (relatieve risico's van respectievelijk 
16,8 and 8,0, p<0,05). Niet alleen de meeste longfunctieparameters maar ook kwali-
teit van het leven en pack years waren significante voorspellers van FPD bij chroni-
sche bronchitis (p<0,05). Echter, met deze voorspellers afzonderlijk of zelfs met de 
combinatie van verschillende, klinisch relevante parameters was het niet mogelijk 
om op een individueel niveau FPD op betrouwbare wijze te voorspellen: 18% van de 
patiënten met chronische bronchitis en 22% van de patiënten met astma werden nog 
verkeerd ingedeeld. 
Meer dan één meting (monitoring) van o.a. longfunctie is nodig om risicopatiën-
ten betrouwbaar op te sporen. 
Hoofdstuk 5 bestudeert de hypothese dat bij patiënten met astma de bronchiale hyper-
reactiviteit (BHR) een risicofactor is voor de progressie van luchtwegobstructie ter-
wijl bij patiënten met COPD de mate van BHR vooral bepaald wordt door de ernst 
van de chronische luchtwegobstructie. De relaties tussen de (jaarlijkse verandering 
in) PC2o-histamine en de (jaarlijkse^verandering in) FEVi werden onderzocht in het 
twee jaar durende gerandomiseerde en gecontroleerde interventieonderzoek met 
bronchusverwijders. Het gebruik van Steroiden tijdens het onderzoek was niet toege-
staan (behalve tijdens exacerbaties). 
De resultaten lieten zien dat de PC20 aan het begin van het onderzoek gerelateerd 
was aan de daaropvolgende jaarlijkse daling in FEVi bij astma (r=0,32, p<0,05) maar 
niet in COPD (r=-0,10, p=0,885). Bij astmapatiënten met een PC2<)-waarde <2 mg/ml 
was de gemiddelde daling 118 ml/jaar, bij astmatici met een PC20-waarde >2 mg/ml 
27 ml/jaar. De verandering in PC2o-histamine gedurende de twee jaar durende onder-
zoeksperiode was gerelateerd aan de jaarlijkse verandering in FEVi bij patiënten met 
COPD (r= 0,45, p<0,05), maar niet in astma (r= 0,06, p= 0,898). De invloed van mo-
gelijke storende variabelen werd onderzocht en zo nodig werd hiervoor gecorrigeerd 
(leeftijd, geslacht, lengte, rookgedrag vroeger en nu, allergie, FEV], reversibiliteit, 
PC20, exacerbaties en het type bronchusverwijdende therapie tijdens de studie). 
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BHR gemeten met de histamine provocatietest, is een risicofactor voor de progressie 
van luchtwegobstructie bij patiënten met astma. Bij patiënten met COPD gaf de mate 
van BHR voornamelijk de emst van de reeds bestaande luchtwegobstructie aan. BHR 
is daarmee een 'oorzaak' van luchtwegobstructie bij astma, maar een 'gevolg' van 
luchtwegobstructie bij COPD. 
Een onverwacht groot aantal van 56 patiënten met astma of COPD bleek gedurende 
behandeling met alleen bronchusverwijders een ongunstig ziektebeloop te vertonen. 
In de hoofdstukken 6 en 7 wordt onderzocht of deze snelle progressie van astma of 
COPD vertraagd kan worden door aanvullende behandeling met een inhalatiecorti-
costeroïd (BDP, beclometason dipropionaat) in een dosering van 800 μg per dag ge­
durende respectievelijk één en twee jaar. 
De resultaten lieten zien dat een grote initiële stijging van de prebronchodilatoire 
FEVi van +458(SEM 115) ml/jaar gedurende de eerste zes maanden van de behande-
ling met BDP (p<0,0001) gevolgd werd door een afname van -102(23) ml/jaar gedu-
rende de maanden 7-24 in de groep als geheel (zowel astma als COPD). Echter, de 
jaarlijkse daling in FEVi gedurende het gebruik van BDP was minder dan de daling 
van -160(20) ml/jaar voor het gebruik van BDP (p<0,05). Gedurende de gehele be-
handelingsperiode met BDP bij patiënten met astma was de peakflowwaarde (PEFR) 
significant toegenomen in vergelijking met de waarde aan het begin van de BDP be-
handeling. De maximale toename was 0,7(0,2) l/s, welke gedurende de maanden IS-
IS van de BDP behandeling optrad (p=0,0006). Bij patiënten met COPD nam de 
PEFR toe met 0,2(0,1) l/s gedurende de maanden 4-9 van de behandeling met BDP in 
vergelijking met de waarde aan het begin van de behandeling met Steroiden (p<0,05). 
De bronchiale hyperreactiviteit (gemeten aan de hand van de histamineconcentratie 
die een 20% daling van de FEVi geeft, de PC20) verbeterde alleen bij patiënten met 
astma. De afname in PC20 van -0,4 verdubbelingsdosering/jaar voor het gebruik van 
BDP verschilde van de verbetering van +1,1 verdubbelingsdosering/jaar gedurende 
het gebruik van BDP (p<0,05). Het aantal exacerbaties verminderde gedurende BDP 
behandeling bij zowel astma als COPD (p<0,05). Daarnaast werden gunstige effecten 
van BDP gevonden op de variaties in de wekelijks gemeten PEFR over de dag en de 
emst van de symptomen in zowel astma als COPD. Alleen bij astmapatiënten verbe-
terde BDP het maximaal geïnspireerde volume in één seconde (FIVi) en de statische 
longfunctieindices residuaal volume (RV), ratio residuaal volume/totale long capaci-
teit (RV/TLC) and inspiratoire vitale capaciteit (IVC). 
Additionele behandeling met BDP in een dosering van 800 μg per dag bij de 56 
patiënten met astma of COPD in deze studie verbeterde het ongunstige beloop van de 
ziekte gedurende behandeling met alleen bronchusverwijders. Dit effect was duidelij-
ker aanwezig bij patiënten met astma dan bij COPD. 
Het is belangrijk om patiënten te kunnen identificeren die met name op een inhalatie-
corticosteroïd zullen reageren, omdat het ons inzicht in de effecten van Steroiden kan 
vergroten en mogelijk het behandelingsbeleid ten aanzien van astma of COPD kan 
nuanceren. In hoofdstuk 8 worden de relaties tussen de effecten van behandeling met 
een inhalatiecorticosteroïd (BDP) gedurende twee jaar en de klinische karakteristie-
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ken aan het begin van de behandeling (geslacht, leeftijd, rookgedrag, symptomen, 
kwaliteit van leven, allergie, statistische en dynamische spirometrie, directe reactie 
op bronchusverwijders, bronchiale hypeireactiviteit) bij patiënten met astma of 
COPD onderzocht. 
De gemiddelde toename in FEVi gedurende het gebruik van BDP bij astma was 
groter bij patiënten met een grotere directe reactie op bronchusverwijders (FEVi-pre: 
τ=0,62, p<0,0001), een hogere diurnale PEFR index (FEV ι-post: M),42, p<0,05), 
een grotere bronchiale hypeireactiviteit (FEV ι-pre: r=-0,64, p=0,066), een hogere 
transfer coëfficiënt (FEV ι-pre: r=0,76, p<0,01), een grotere jaarlijkse FEV] daling 
gedurende monotherapie met bronchusverwijders (FEV ι-post: r=-0,62, p<0,001) en 
een lagere FIVi (FEVi-post: r=-0,42, p<0,05). Het was niet mogelijk om de verbete­
ring in bronchiale hypeireactiviteit gedurende BDP behandeling te voorspellen vanuit 
deze afzonderlijke klinische karakteristieken. Bij COPD was de gemiddelde toename 
in FEVi groter bij patiënten met een grotere directe reactie op bronchusverwijders 
(FEVi-pre: r=0,89, p<0,0001), een lagere РЕ іЛ С (FEV,-pre: r=-0,54, p<0,05), en 
een grotere daling in FEVi gedurende monotherapie met bronchusverwijders (FEVi-
pre: p=-0,77, p<0,0001). Geen enkele variabele was significant gerelateerd aan de 
verandering in postbronchodilatoire FEVi gedurende BDP gebruik bij COPD. 
De effecten op de FEVi door behandeling met geïnhaleerd BDP gedurende twee 
jaar bij patiënten met astma of COPD is groter bij patiënten met meer reversibuiteit, 
meer initiële luchtwegobstructie en een grotere longfunctiedaling gedurende behan-
deling met alleen bronchusverwijders. Alleen bij patiënten met astma was de reactie 
op geïnhaleerd BDP ook meer uitgesproken bij patiënten met meer bronchiale hyper-
reactiviteit, een hogere diurnale PEFR index en een grotere transfer coëfficiënt. 
Verbetering van kwaliteit van leven bij patiënten met astma of COPD is ondermeer 
één van de doelen van therapie. Hoofdstuk 9 beschrijft de effecten van BDP op de 
kwaliteit van het leven bij patiënten met astma of COPD. De kwaliteit van het leven 
werd gemeten aan de hand van de Inventory of Subjective Health (ISH) en de Not-
tingham Health Profile (NHP). 
De twee jaar durende behandeling met BDP verbeterde de ISH score of de score 
van de zes dimensies van de NHP niet, noch bij astma, noch bij COPD. Echter, BDP 
verbeterde het beloop van longfunctie (het geforceerde expiratoire volume in één se-
conde, de FEV]) significant (p<0,0001). BDP verminderde de ernst van de sympto-
men tijdelijk gedurende de eerste drie maanden van de BDP behandeling bij astma 
(p<0,01) en gedurende de maanden 7-12 bij COPD (p<0,05). Er werd zowel cross-
sectioneel als longitudinaal slechts een zwakke correlatie gevonden tussen de (veran-
dering in) symptomen en kwaliteit van het leven aan de ene kant en de (verandering 
in) FEVi aan de andere kant. 
Hoewel BDP duidelijk het beloop van longfunctie en andere parameters bij astma 
en COPD verbeterde, werd geen verbetering in kwaliteit van het leven gevonden bij 
de patiënten in deze studie. Deze gegevens kunnen er op wijzen dat patiënten snel 
wennen aan wisselende longfunctieniveaus. In toekomstige onderzoeken naar astma 
en COPD wordt aangeraden dat zowel algemene als ziektespecifieke kwaliteit-van-
leven instrumenten worden gebruikt en tevens dat kwaliteit van het leven frequent 
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gemeten wordt gedurende de vroege fase van de interventie, bijv. één keer per 
maand. 
De therapietrouw van patiënten voor inhalatiecorticosteroïden en de inhalatietechniek 
kunnen een probleem zijn voor de effectiviteit van een lange-termijns behandeling 
met deze middelen. Hoofdstuk 10 onderzoekt de therapietrouw (compliantie) voor en 
de inhalatietechniek (droge poeder Inhalator Rotahaler) van beclometason dipropio-
naat (BDP). De therapietrouw voor BDP werd gemeten door het tellen van capsules 
over een periode van vier maanden en door het invullen van een vragenlijst. 
Het gemiddelde gebruik bedroeg 82(SD 30)% van de voorgeschreven hoeveelheid 
BDP. Het tellen van capsules toonde non-compliantie aan bij 46% van de patiënten 
wanneer compliantie werd gedefinieerd als het gebruik van 80 tot 120% van de voor-
geschreven dosis van BDP. De vragenlijst suggereerde non-compliantie bij slechts 
7% van de patiënten. De individuele compliantieratio's waren niet gerelateerd aan 
leeftijd, geslacht, diagnose en bijwerkingen van BDP. De therapietrouw voor BDP 
was wel gerelateerd aan een beter beloop van symptomen, longfunctie en bronchiale 
hyperreactiviteit gedurende BDP gebruik bij patiënten met chronische bronchitis 
maar niet bij patiënten met astma. De inhalatietechniek werd bij 27% van de patiën-
ten als onvoldoende beoordeeld. 
Zowel non-compliantie voor als een verkeerde inhalatietechniek van inhalatieste-
roïden kunnen vaak voorkomen gedurende de lange-termijns behandeling van astma 
en chronische bronchitis, zelfs in gecontroleerde onderzoeksomstandigheden. Dit be-
nadrukt het belang van regelmatige instructie van de inhalatietechniek en duidelijke 
informatie over de profylactische behandeling met Steroiden door de behandelend 
arts gedurende de behandeling van patiënten met astma en chronische bronchitis. 
Een belangrijke vraag voor patiënten met astma of COPD en hun behandelend arts is 
of behandeling met inhalatiecorticosteroïden gestopt kan worden wanneer patiënten 
weer in een klinisch stabiele toestand zijn. In hoofdstuk 11 werd het beloop van een 
milde vorm van astma en COPD bestudeerd bij klinisch stabiele patiënten, nadat de 
behandeling met inhalatiecorticosteroïden was gestopt. De onderzoekspopulatie was 
samengesteld uit 223 patiënten die meededen aan ons gerandomiseerd, gecontroleerd 
interventieonderzoek in de huisartsenpraktijk. De experimentele groep bestond uit 39 
patiënten die dagelijks inhalatiesteroïden hadden gebruikt gedurende het jaar vóór het 
onderzoek en die stopten met het gebruik hiervan vanwege deelname aan het inter-
ventieonderzoek met bronchusverwijders. De mensen werden als niet-steroïdafhan-
kelijk beoordeeld door hun behandelend arts. De behandeling met inhalatiecorticoste-
roïden werd gestopt onder nauwlettende observatie gedurende een acht weken duren-
de wash-out periode net voor aanvang van het onderzoek. De controlegroep bestond 
uit de andere 184 patiënten die geen inhalatiecorticosteroïden hadden gebruikt in het 
jaar voorafgaande aan de studie. Aan het begin van de studie waren de patiënten van 
de twee groepen wat betreft alle relevante kenmerken volledig vergelijkbaar. 
In de experimentele groep vielen 22 van de 39 patiënten uit gedurende de twee 
jaar durende onderzoeksperiode (=56%) vanwege een verslechtering van hun klini-
sche toestand en de behoefte aan (inhalatie)corticosteroïden. In de controlegroep vie-
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len slechts 16 patiënten om deze reden uit (=9%). Dit verschil was statistisch signifi-
cant (Chi-kwadraat= 48,5, p<0,0001). Bij de patiënten van de experimentele groep 
die tenminste een jaar zonder inhalatiecorticosteroïden konden was de jaarlijkse da-
ling in FEV ι veel groter dan bij de personen uit de controlegroep. 
In het algemeen is het stoppen van de onderhoudsbehandeling met inhalatiecorti­
costeroïden bij patiënten met een milde vorm van astma en chronische bronchitis niet 
aan te bevelen. In plaats van de behandeling te stoppen of te onderbreken wordt ge-
adviseerd om de minimale effectieve dosis inhalatiecorticosteroïden uit te vinden die 
nog een goede controle van symptomen, exacerbaties en longfunctie geeft bij elke in-
dividuele patiënt. 
Conclusies en aanbevelingen 
1. De Microspiro HI-298 is een geschikt instrument voor gebruik in de huisartsen-
praktijk. Het apparaat voldoet aan de internationale criteria voor spirometrie 
voor zover het de FEVi betreft. Het is echter relatief duur. Er is nog steeds be-
hoefte aan goedkope maar betrouwbare flow-volume meters voor gebruik in de 
huisartsenpraktijk. 
2. De opsporing van patiënten met snel progressief astma of COPD in de huisart-
senpraktijk is alleen op een betrouwbare manier mogelijk door monitoring van 
het ziektebeloop, т.п. door het meten van longfunctie. Zelfs een uitgebreide 
cross-sectionele meting van allerlei klinisch relevante karakteristieken is onvol­
doende om de risico-patiënten op te sporen. 
3. De meest gebruikte methode om de directe reactie op bronchusverwijders als een 
percentage van de waarde voor bronchusverwijding (prebronchodilatoire long-
functiewaarde) uit te drukken is het meest afhankelijk van deze prebronchodila-
toire longfunctie en daarom het minst reproduceerbaar in de loop van de tijd. 
4. In onderzoeken naar de directe reacties op bronchusverwijders kan het gebruik 
van de uitdrukkingsmethoden '%possible' (toename als percentage van de voor-
spelde minus de prebronchodilatoire waarde) en '% achievable' (toename als 
percentage van de maximale postbronchodilatoire minus de prebronchodilatoire 
waarde) bij patiënten met astma of COPD de mogelijkheid vergroten om ver-
schillen in directe reacties tussen verschillende bronchusverwijders aan te tonen. 
5. Niet-specifieke bronchiale hyperreactiviteit is een 'oorzaak' van luchtwegob-
structie bij astma maar een 'gevolg' van luchtwegobstructie bij patiënten met 
COPD. 
6. Additionele behandeling met een inhalatiecorticosteroïd (BDP, beclometason di-
propionaat) verbetert een ongunstig beloop van astma en COPD gedurende be-
handeling met alleen bronchusverwijders. 
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7. BDP vermindert de ernst van symptomen, de frequentie en duur van exacerbaties 
en vertraagt de jaarlijkse longfunctiedaling bij patiënten met astma of COPD. De 
bronchiale hyperreactiviteit verbetert alleen bij patiënten met astma. 
8. Zowel bij patiënten met astma als bij COPD zijn de tweejarige effecten (in long-
functie) gedurende behandeling met BDP groter bij patiënten met meer revers-
ibiliteit, een snellere daling in longfunctie gedurende behandeling met alleen 
bronchusverwijders en meer luchtwegobstructie. Alleen bij astma gaan meer 
bronchiale hyperreactiviteit, een grotere diurnale PEFR index en een hogere 
transfercoëfficiënt gepaard met grotere effecten van het inhalatiesteroïd. 
9. De twee jaar durende behandeling met BDP had geen invloed op kwaliteit van 
het leven bij astma en COPD gemeten aan de hand van de algemene kwaliteit 
van leven instrumenten 'Inventory of Subjective Health (ISH)' en de 'Notting-
ham Health Profile (NHP)'. Aangezien patiënten mogelijk snel wennen aan een 
ander longfunctieniveau, verdient het aanbeveling dat kwaliteit van het leven 
voldoende vaak gemeten wordt gedurende de eerste fase van de interventie (bij-
voorbeeld eens per maand). In toekomstige onderzoeken naar astma en COPD 
wordt geadviseerd om zowel algemene alsook ziekte-specifieke instrumenten te 
gebruiken. 
10. Zowel de therapietrouw van patiënten voor inhalatiecorticosteroïden als de inha-
latietechniek vormen een probleem voor de lange-termijns behandeling van ast-
ma en COPD met dit type medicijn. Regelmatige instructie van de inhalatietech-
niek en duidelijke informatie over de achtergronden van profylactische behande-
ling met Steroiden door de behandelend arts kunnen mogelijk tot verbetering lei-
den. 
11. In het algemeen is het stoppen van een onderhoudsbehandehng met inhalatiecor-
ticosteroïden bij patiënten met een milde vorm van astma of chronische bronchi-
tis niet aan te bevelen. In plaats van de behandeling met inhalatiecorticosteroïden 
te stoppen of te onderbreken kunnen artsen beter proberen de minimale effectie-
ve dosis te vinden die nog een goede controle van symptomen, exacerbaties en 
longfunctie geeft. 
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Appendix. The calculation of the effect of 
regression-to-the-mean in the BDP trial 
For the BDP trial, 56 out of 160 patients with asthma or COPD were selected on the 
basis of a relatively fast annual decline in lung function. Because of this selection, 
some degree of spontaneous improvement (on the basis of regression-to-the-mean) 
can be expected in the subsequent two-year period of treatment with BDP, which is 
not really attributable to BDP. In this way, regression-to-the-mean can introduce bias 
in the BDP trial by overestimating the effect of BDP. Therefore, an important ques­
tion is how large the disturbing influence of regression-to-the-mean is. It is probably 
small because regression-to-the-mean mainly plays a part with one measurement and 
decreases rapidly with two or more assessments (1). The main outcome measure of 
the BDP trial was the annual decline in FEVi, which was estimated by seven meas­
urements of the FEVi during a period of two years. A quantification of the effect of 
regression-to-the-mean is possible by using the statistical models of Gardner et al., 
Das et al., and Davis (1-3). 
Let a continuous random variable X be measured twice on the subjects of a popu­
lation. Both measurements Xi and X2 are assumed to be normally distributed in the 
stationary population of subjects with the same μ, the same variance σ2 and correla­
tion coefficient г (0<г<1) due to within-subject error. The mathematical expectation 
of the difference X1-X2, given Xi=x, then becomes: Ε(Χι-Χ2\Χι=χ) = (Ι-Γ).(χ-μ) = 
R(x) in which R(x) is the regression-to-the-mean effect of x. The correlation coeffi­
cient г of Xi and X2 equals the proportion of the total variance σ2 of X attributable to 
the between-patient variance: гЦс^-б^/ст2 in which δ2 is the variance due to within-
patient error. In our situation, the annual decline in FEVi appeared to be a normally 
distributed variable with a mean μ of 56.9 ml/yr and a standard deviation σ of 150.7 
ml/yr. The regression-to-the-mean effect of a patient i, selected for steroid treatment 
with an annual decline in FEVi of Xi is given by R(x,) = (Ι-Γ).(χί-μ). The average re­
gression-to-the-mean R(x) in the whole population of η patients selected for steroid 
treatment is given by: 
i=n 
R(x) = n- | .XR(x 1) 
1=1 
тк · .A (150.7)2-(93.2):! __. 
The r in our study was -* ¿ ^^ —— = 0.72 
(150.7)2 
We calculated the treatment effect of BDP during the first six months before and 
after adjusting for the effect of regression-to-the-mean. The following data were 
found: 
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Treatment effect during the first six months of BDP treatment 
Disease 
Asthma 
CORD 
Before adjusting 
Change FEVi (ml/yr) 
+562 (148) 
+323 (183) 
p-value 
0 0002 
0 041 
After adjusting 
Change FEVi (ml/yr) p-value 
+530 (150) 0 003 
+299 (191) 0 049 
The treatment effect and the corresponding p-values hardly changed when the values 
were adjusted for regression-to-the-mean. A significant treatment effect remained in 
both asthma and COPD. 
We made a comparable analysis for the effect of BDP during two years. We calcu-
lated the gain in FEVi caused by two-year additional treatment with BDP. This was 
done by comparing the end-point of FEVi after the two-year treatment with BDP 
with the extrapolated end-point when bronchodilator therapy alone had been conti-
nued during the third and fourth year. The gain in FEVi was calculated before and 
after adjusting for the influence of regression-to-the-mean. 
Gain in FEVi after two-year BDP therapy 
Disease 
Total 
Asthma 
CORD 
Before adjusting 
Gam in FEVi (I) 
+0 34 (0 08) 
+0 42 (0 08) 
+0 25 (0 13) 
p-value 
0 0001 
0 0001 
0 073 
After adjusting 
Gain in FEVi ID 
+0 28 (0 05) 
+0 36 (0 08) 
+0 20 (0 11) 
p-value 
0 0001 
0 0002 
0 096 
Also in this analysis, it appeared that the results did not change, neither in the group 
as a whole nor in asthma and COPD separately. From these data, it can be concluded 
that regression-to-the-mean explained a negligible part of the increase in FEVi dur-
ing steroid treatment. As the patients were selected on the combination of both a fast 
annual decline in FEVi and a high exacerbation rate, regression-to-the-mean will 
even be lower because the rapid fall in lung function is more likely to be a real reflec-
tion of their worsening disease. 
The observed changes in FEVi and other parameters during BDP treatment are the 
consequence of a real treatment effect and not of regression-to-the-mean. 
References 
1 Gardner MJ, Heady JA. Some effects of within-person variability in epidemiological 
studies. J Chron Dis 1973;26:781-795. 
2 Das P, Mulder PGH. Regression to the mode. Statistica Neerlandica 1983;37:15-20. 
3 Davis CE. The effect of regression to the mean in epidemiologic and clinical studies. Am 
J Epidemiol 1976;104:493-498. 
151 

Dankwoord 
Graag wil ik iedereen van harte bedanken die op enigerlei wijze heeft bijgedragen 
aan de totstandkoming van dit onderzoek en dit proefschrift. 
In de eerste plaats wil ik Chris van Weel, Onno van Schayck en Johan Molema 
hartelijk danken voor hun onontbeerlijke steun en hulp tijdens de afgelopen jaren. Ik 
heb de samenwerking met jullie als heel vruchtbaar en als kameraadschappelijk er-
varen. Mijn kamergenoot Onno wil ik bedanken voor alle ruggespraak die wij in fi-
guurlijke en letterlijke zin konden houden. Mijn dank gaat tevens uit naar Cees van 
Herwaarden, Hans Folgering en Pierre van Grunsven die bij de opzet en/of uitvoer-
ing en verslaglegging van het onderzoek een cruciale rol hebben gespeeld. 
De statistische adviezen en analyses van Reinier Akkermans en Henk van den 
Hoogen zijn essentieel geweest voor het succes van het onderzoek. Zeer waardevol 
was ook de bijdrage van onze longfunctieassistentes Lilian Bierman en Agnes Raay-
makers. Bedankt, Agnes en Lilian voor het uitvoeren van de vele longfunctiemeting-
en bij onze grote patiëntengroep en het onvermoeibaar motiveren van patiënten om 
door te gaan. Een bijzonder woord van lof gaat uit naar alle patiënten die de lange 
periode van vier jaar bereid waren om naar Dekkerswald te gaan, weekrapporten in te 
vullen en hun medicatie volgens protocol te gebruiken. Ook alle 29 huisartsen die 
aan het onderzoek hebben deelgenomen hebben een belangrijke rol gespeeld bij de 
motivatie van patiënten om aan het onderzoek te blijven deelnemen. Hartelijk dank 
voor de tijd die jullie aan het onderzoek besteed hebben. 
Dit onderzoek was alleen mogelijk dankzij de financiële ondersteuning van het 
Nederlands Astma Fonds, de firma Boehringer Ingelheim en de firma Glaxo. Hans 
Tamminga van Glaxo wil ik bedanken voor zijn adviezen en steun aan het onderzoek. 
Alle instanties die het drukken van het proefschrift financieel mogelijk hebben ge-
maakt ben ik zeer erkentelijk. 
André Verbeek wil ik hartelijk bedanken voor zijn hulp bij het onderzoek in het al-
gemeen en bij de analyse van hoofdstuk 4 in het bijzonder. Paul Mulder van de afde-
ling Epidemiologie en Biostatistiek van de Erasmus Universiteit ben ik zeer erkente-
lijk voor zijn hulp bij analyses rond 'regressie-naar-het-gemiddelde effecten' en 
'variantieanalyse met herhaalde metingen'. De stagiaires José de Jongh van Hoof en 
Gineke Putters wil ik bedanken voor hun bijdrage. Onze medewerker Paul van de 
Broek wil ik bedanken voor zijn hulp bij congressen en voordrachten in de vorm van 
prachtige posters en dia's, inhoudelijke adviezen en ook morele steun. 
Johan Lummen en Sharmalee Elkerbout-Tirimanna hebben de Engelse tekst ge-
corrigeerd. Hartelijk dank voor jullie goede adviezen en deskundige hulp. 
Lea Peters wil ik bedanken voor haar medewerking bij het aanpassen van manu-
scripten en het ontwerpen van posters. 
153 
Alle medewerkers van de vakgroep huisartsgeneeskunde in het algemeen en van de 
CARA onderzoeksgroep in het bijzonder wil ik bedanken voor de goede sfeer op het 
instituut die mijn onderzoek zeer zeker ten goede gekomen is. 
Onmisbaar was de bemoediging, aandacht en steun van mijn ouders, niet alleen de 
afgelopen periode van mijn promotieonderzoek maar ook in vele jaren daarvoor. Har-
telijk dank wat jullie voor mij hebben gedaan en nog steeds doen. 
Ook jou, Anneke wil ik bedanken voor je vele (indirecte) hulp bij de totstandkom-
ing van het proefschrift. Nelleke en Bas wil ik bedanken voor het verschaffen van de 
nodige afleiding voor hun papa. 
Ik wil afsluiten met Degene te bedanken aan wie ik alles te danken heb. Zonder 
hulp van mijn hemelse Vader zou dit proefschrift nooit geschreven zijn. 
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De auteur van dit proefschrift werd geboren op 12 april 1963 te Leersum. Hij volgde 
zijn middelbare schoolopleiding Atheneum В aan het CLV (Christelijk Lyceum 
Veenendaal) te Veenendaal. In 1981 behaalde hij het examen N-propedeuse aan de 
Landbouw Universiteit in Wageningen. Daarna begon hij zijn studie geneeskunde 
aan de Katholieke Universiteit te Nijmegen. Het doctoraalexamen geneeskunde be­
haalde hij op 23 februari 1987. Op 1 januari 1989 startte hij met het promotie-onder­
zoek op de afdeling huisartsgeneeskunde van de Katholieke Universiteit te 
Nijmegen. Hij is getrouwd met Anneke Dompeling-Schouten. Zij hebben twee kin­
deren: Nelleke en Bas. 
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Stellingen 
1 Anti-inflammatoire therapie bij de lange-termijns behandeling van pa-
tiënten met astma is onontbeerlijk (dit proefschrift). 
2 Introductie van eenvoudige maar betrouwbare flow-volume meters in de 
huisartsenpraktijk is essentieel voor de verbetering van diagnostiek en 
behandeling van patiënten met astma en COPD (dit proefschrift). 
3 Een eenmalige bepaling van respiratoire klachten, rookgedrag, fysisch-
diagnostische bevindingen, kwaliteit van leven, allergie, longfunctie, re-
versibiliteit en bronchiale hyperreactiviteit is onvoldoende om betrouw-
baar te kunnen voorspellen welke patiënten een snelle of welke een trage 
progressie van astma en COPD zullen vertonen (dit proefschrift). 
4 Bronchiale hyperreactiviteit (gemeten aan de hand van de PC2o-his-
tamine) gaat bij patiënten met astma vooraf aan (de progressie van) 
luchtwegobstructie terwijl bij patiënten met COPD deze functionele 
stoornis voornamelijk optreed als gevolg van (de progressie van) lucht-
wegobstructie (dit proefschrift). 
5 De methode om de directe reactie op een bronchusverwijder (revers-
ibiliteit) uit te drukken als percentage van de voorspelde FEVi discri-
mineert weliswaar het beste tussen patiënten met astma en COPD maar 
is niet onafhankelijk van de longfunctiewaarde vóór bronchusverwijding 
en heeft ook niet de beste reproduceerbaarheid in vergelijking met an-
dere uitdrukkingsmethoden (dit proefschrift). 
6 Bij COPD patiënten met een ongunstig ziektebeloop gedurende 
monotherapie met bronchusverwijders, een relatief grote reversibiliteit 
en meer initiële luchtwegobstructie mag een gunstig effekt van behande-
ling met inhalatiecorticosteroïden verwacht worden (dit proefschrift). 
7 Het is van belang om de ernst van astma bv. tijdens een astma-aanval 
niet alleen te evalueren aan de hand van 'klassieke' parameters als 
symptomen, longfunctie en bronchiale hyperreactiviteit maar hierin ook 
het dagelijks functioneren van patiënten met astma te betrekken (D. 
Wong-Chung, N Mateijsen, R West, L Ravell, С van Weel, Fam Pract 
1992;8(4):404-408). 
8 De therapietrouw en inhalatietechniek van patiënten voor inhalatiecorti-
costeroïden kunnen dè beperkende factoren zijn voor het slagen van een 
lange-termijns behandeling met dit type middelen (dit proefschrift). 
9 Het staken van een onderhoudsbehandeling met inhalatiecorticosteroïden 
bij patiënten met astma en COPD kan allerlei ongewenste effekten heb-
ben: een snelle verslechtering van longfunctie, een toename in ernst en 
duur van exacerbaties en symptomen. Deze verschijnselen treden veelal 
in het eerste jaar na het stoppen op (dit proefschrift). 
10 De functie van het proefschrift als kastvulling voor academici wordt 
zwaar onderschat. 
11 De mens maakt zich eeuwig-en-altijd druk over tijdelijke dingen maar 
maakt zich meestal slechts tijdelijk druk over eeuwige dingen. 
12 De geschiedenis van de mens in heden en verleden laat zien hoe mense-
lijk falen de harmonie verstoort tussen de mens en zichzelf, de mens en 
het milieu, de mens en zijn medemens en ook de mens en God. 
13 Een wereld zonder zonde zou niet zonde zijn. 
14 Het dwingend principe van economische groei belemmert de werkelijke 
groei en bloei van hele samenlevingen en bevordert juist dat rijk en arm 
verder uit elkaar groeien. 
15 Er zijn er die meer uitdelen dan nodig is en toch nog overhouden terwijl 
anderen meer inhouden dan goed is en toch tekort komen (Spreuken 
11:24). 
16 Een geruchtmakend Nijmeegs spreekwoord zegt: Als het regent in mei, 
is april gewis voorbij. 
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